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1 Introduction 
 
1.1 Innate immunity and pattern recognition receptors 
All multicellular organisms are permanently challenged by pathogens, such as bacteria, viruses, 
fungi and protozoans. Therefore it is of  crucial importance for the organism to be able to detect 
harmful agents and to launch a potent defence response for its own protection. All animals and 
plants possess an innate immune system that relies on germline encoded invariant pathogen 
receptors and is characterised by an instantaneous reaction. Vertebrates and jawed fish have 
additionally evolved an adaptive (or acquired) immune system that relies on somatic recombina-
tion of  genes and clonal expansion of  B- and T-lymphocytes. The adaptive immune system 
provides an unlimited number of  receptors against all possible types of  pathogens and is char-
acterised by a delayed response.  
   The receptors of  the evolutionary older innate immune system are invariant; they detect a 
limited number of  conserved and mostly invariant patterns of  the pathogens that are not prone 
to structural changes provoked by mutations, referred to as PATHOGEN-ASSOCIATED 
MOLECULAR PATTERNS (PAMPs) (reviewed in Medzhitov and Janeway, 1997). These patterns, 
also referred to as “microbial non-self ”, such as bacterial cell wall components like peptidogly-
can, flagellin, lipopolysaccharide (LPS) or nucleic acids, are recognised by specialised PATTERN 
RECOGNITION RECEPTORS (PRRs) (reviewed in Akira et al., 2006) that are situated on the surface 
of  or within the host cell. Additionally, the innate immune system surveys the integrity of  cells 
and tissues, as it also reacts to DANGER-ASSOCIATED MOLECULAR PATTERNS (DAMPs). These 
are endogenous substances that are normally spatially confined from PRRs, such as cellular 
DNA, ATP or uric acid, or substances that are produced upon injury, such as reactive oxygen 
species (ROS). Upon cellular rupture, DAMPs are released and cause an innate immune reaction 
mediated by PRRs (Medzhitov, 2007). 
   PRRs are highly expressed in innate immune cells like macrophages and dendritic cells (DCs), 
but they are also abundant in a variety of  non-professional immune cells like epithelial cells or 
fibroblasts and mediate the onset of  immune responses (reviewed in Takeuchi and Akira, 2010).  
   PRRs are compartmentalised; there are specialised receptors that monitor the extracellular 
milieu, the vesicular compartment and the intracellular milieu. Transmembrane receptors detect 
extracellular pathogens and pathogens that enter the vesicular compartment. There are also 
PRRs that are secreted into the extracelluar milieu (reviewed in Litvack and Palaniyar, 2010). 
Invasive pathogens that avoid detection by surface receptors can be detected by intracellular 
PRRs that monitor the cytoplasm. 
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   PRRs are evolutionary conserved. Toll-like receptors (TLRs), for example, are found in many 
organisms, including insects, fish and humans (reviewed in Aderem and Ulevitch, 2000). An-
other striking example of  the conservation of  PRRs among different organisms are the resis-
tance proteins (R-proteins) of  the nucleotide-binding site leucine-rich repeat (NBS-LRR) class 
found in plants that share high structural similarities with mammalian nucleotide binding and 
oligomerisation domain (NOD)-like receptors (NLRs) (reviewed in Maekawa et al., 2011) (Fig. 1).  
   In most cases, activated PRRs trigger signalling cascades that culminate in inflammatory re-
sponses, mainly mediated by activation of  the transcription factor nuclear factor B (NF-B) 
and of  mitogen-activated protein kinases (MAPKs). That in turn leads to the onset of  antim-
icrobial responses, such as phagocytosis, autophagy, production of  reactive oxygen species 
(ROS), degranulation or secretion of  antimicrobial peptides, which have direct antimicrobial 
effects. Furthermore, activation of  PRRs leads to secretion of  inflammatory chemokines and 
cytokines that mediate inflammation and recruit immune cells, such as macrophages or neutro-
phils, to the site of  infection. Some PRRs also induce antiviral responses by triggering type I 
interferon (IFN) expression (reviewed in Takeuchi and Akira, 2010). Additionally, this first de-
fence reaction mediated by the innate immune system is essential to trigger and to direct a full 
adaptive immune response (Fritz et al., 2007; Dabbagh and Lewis, 2003).  
   There are at least four classes of  PRRs: TLRs and the C-type lectin receptors (CLRs), which 
are membrane-bound and RIG-I-like receptors (RLRs) and NLRs, which are localised in the 
cytoplasm. The most extensively studied PRRs are the TLRs. Receptors of  that family are exclu-
sively membrane-bound and either face the extracellular milieu or the vesicular compartment. 
Pattern recognition is mediated by leucine-rich repeats (LRRs) pointing to the extracellular mi-
lieu, whereas the intracellular Toll/IL-1R homology (TIR) domain serves intracellular down-
stream signalling. In humans, there are 10 TLRs known so far, conferring protection against a 
wide variety of  bacteria and viruses. They display a very broad substrate specificity reaching 
from cell wall components, such as lipopolysaccharide (LPS), lipoproteins or flagellin to nucleic 
acids, such as CpG DNA, double-stranded RNA (dsRNA) and single stranded RNA (ssRNA). 
Upon activation, TLRs trigger NF-B- and MAPK-mediated expression of  pro-inflammatory 
cytokines and interferon response factor (IRF) 3/IRF7-mediated expression of  type I IFNs via 
the adaptor proteins MyD88 (myeloid differentiation primary response gene 88) and TRIF 
(Toll/IL-1R domain containing adaptor inducing IFN-β), respectively (reviewed in Akira and 
Takeda, 2004).  
   Similar to the TLRs, CLRs are also membrane-bound. They sense carbohydrates present on 
fungi, viruses and bacteria through a carbohydrate-binding domain and trigger MAPK-, NF-B- 
and NF-AT (nuclear factor of  activated T-cells)-mediated expression of  pro-inflammatory cyto-
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kines upon activation. CLRs also seem to be involved in the regulation of  TLR-mediated re-
sponses (reviewed in Geijtenbeek and Gringhuis, 2009). 
   RLRs, in contrast, are localised in the cytoplasm. They contain one or two N-terminal caspase 
activation and recruitment (CARD) domains, a central DEAD box helicase/ATPase domain 
and a C-terminal regulatory domain. Thus far, there are three known members: RIG-I (retinoic 
acid inducible gene I), MDA5 (melanoma-differentiation associated gene 5) and LGP2 (labora-
tory of  genetics and physiology 2). RIG-I and MDA5 confer protection to viruses through rec-
ognition of  viral nucleic acids via their C-terminal domains. LGP2, in contrast, might not rec-
ognise nucleic acids directly, but was shown to negatively regulate RIG-I and MDA5 signalling. 
Activation of  RIG-I and MDA5 triggers IRF3/IRF7-dependent type I IFN production and 
expression of  inflammatory cytokines (reviewed in Takeuchi and Akira, 2010). 
   Recently, a novel class of  PRRs has been discovered. The pyrin and HIN200 (hematopoietic 
interferon-inducible nuclear antigens with 200 amino acid repeats) domain containing proteins 
absent in melanoma 2 (AIM-2) and interferon--inducible protein 16 (IFI-16) have been shown 
to be sensors for cytoplasmic foreign DNA. Engagement of  these receptors triggers inflamma-
tory responses, such as pro-IL-1 processing and IFN signalling through formation of  multi-
protein complexes termed INFLAMMASOMES (Unterholzner et al., 2010; Burckstummer et al., 
2009).  
 
 
1.2 NLRs 
In humans, there are 23 NLR members identified so far; many of  these act as cytoplasmic PRRs. 
They are expressed in various cell types, including myeloid and epithelial cells. Characteristic for 
NLRs is a tripartite domain structure similar to the structure of  the apoptotic protease-
activating factor 1 (APAF-1) (Fig. 1). The C-termini of  NLRs consist of  leucine-rich-repeats 
(LRRs), whereas APAF-1 contains C-terminal WD40 repeats. The LRRs are thought to mediate 
recognition of  elicitors. Furthermore, all members contain a central oligomerisation domain 
referred to as present in NAIP, CIITA, HET-E and TP-1 (NACHT). NLRs are divided into 
sub-groups based on their N-terminal domains that consist of  pyrin (PYD), baculovirus inhibi-
tory repeat (BIR) or CARD domains (reviewed in Wilmanski et al., 2008) (Fig. 1). These motifs 
have in common that they mediate protein-protein interactions.  
   NLRs can be roughly divided into two functional groups: INFLAMMASOME and NODOSOME 
NLRs. Some PYD-containing NLRs, such as NLRP3 and NLRP1, but also BIR-containing 
NLRs, such as NLRC4, are referred to as inflammasome NLRs. Upon activation, these proteins 
interact with the adaptor protein ASC (apoptosis-associated speck-like protein containing a 
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CARD), leading to formation of  large multimeric protein complexes that contain NLR proteins, 
ASC and pro-caspase-1. The induced proximity leads to auto-activation of  caspase-1, which in 
turn mediates processing and secretion of  the pro-inflammatory cytokines IL-1β and IL-18. 
This inflammatory response consists of  a two-step process: Expression of  pro-caspase-1, pro-
IL-1β and pro-IL-18 is triggered by detection of  microbial substances by TLRs, but a second 
signal, provided by the inflammasome, is required for maturation and secretion of  the cytokines. 
Inflammasome NLRs display very broad substrate specificities. They can be activated by nu-
merous bacteria and bacterial toxins and by a variety of  DAMPs, but also by crystalline aggre-
gates, such as asbestos, urea crystals or cholesterol crystals (reviewed in  Schroder and Tschopp, 
2010). For most cases, there is no proof  for direct interactions of  NLRs with their elicitors 
available, suggesting that their activation occurs via intermediate factors, and may not rely on 
direct ligand binding, analogous to the example of  TOLL in Drosophila that recognises the 
ligand Spaetzle, which is proteolytically cleaved by upstream cascades upon PAMP recognition 
(reviewed in Valanne et al., 2011). 
 
NOD1
NOD2
NLRC4 (IPAF)
NAIP (BIRC1)
NLRP3
APAF-1
(apoptosis)
NACHTCARD
CARD CARD NACHT
CARD NACHT
NACHT
NACHT
NACHTCARD
BIR
PYD
BIR BIR
LRR
LRR
LRR
LRR
LRR
WD40
NACHT LRRTIRRPS-4
(plant R-protein)
NLR proteins
Homologues
 
 
Figure 1. Domain architecture of several NLR proteins and homologues. The NLR family is characterised by 
a tripartite domain composition similar to that of the pro-apoptotic factor APAF-1.  The C-termini consist of 
lecine-rich repeats (LRRs) involved in detection of pathogens, the central parts contain so-called present in 
NAIP, CIITA, HET-E and TP1 (NACHT) domains that mediate oligomerisation. The N-termini consist of effec-
tor domains, such as caspase activation and recruitment (CARD), pyrin (PYD) or baculovirus inhibitory re-
peat (BIR) domains. NLR proteins share close homology with plant NBS-LRR R-proteins, such as RPS-4 (based 
on Fritz et al., 2006; Meylan et al., 2006). 
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   A sub-group of  CARD domain containing NLRs, namely NOD1 and NOD2, are referred to 
as nodosome NLRs. NOD1 and NOD2 detect bacterial peptidoglycan (PGN) fragments with 
different substrate specificities, upon activation they trigger signalling cascades that culminate in 
activation of  NF-B and MAPKs. This mediates expression of  pro-inflammatory cytokines, 
chemokines and anti-microbial peptides (Fig. 2) (reviewed in Kufer, 2008). 
 
 
 
1.3 NOD1 and NOD2 
 
1.3.1 Signalling pathways and regulation 
Human NOD1 is encoded by the CARD4 gene (Bertin et al., 1999), NOD2 by the CARD15 
gene (Ogura et al., 2001). NOD1 and NOD2 share the typical tripartite domain structure com-
mon to all NLR proteins consisting of  C-terminal LRRs, a central NACHT domain and N-
terminal effector domains consisting of  one or two CARD domains, respectively (Fig. 1). 
   NOD1 and NOD2 show a  predominantly cytoplasmic localisation, however, recent reports 
indicate that they also localise to the plasma membrane upon activation (Zurek et al., 2012; Tra-
vassos et al., 2010; Kufer et al., 2008; Barnich et al., 2005a; McDonald et al., 2005). The exact role 
of  this membrane-association still remains elusive, however, it seems to be dependent on actin 
and actin remodelling enzymes, such as RAC1 (ras-related C3 botulinum toxin substrate 1) (Eitel 
et al., 2008; Legrand-Poels et al., 2007). 
   NOD1 and NOD2 were the first NLR proteins that were described to detect microbial 
PAMPs. In recent years, a multitude of  publications elucidated the main signalling cascades em-
ployed by these proteins. Recognition of  PGN by NOD1 and NOD2 is thought to occur 
through the LRRs, as mutants lacking this domain proved to be incapable of  PGN-sensing 
(Girardin et al., 2005; Tanabe et al., 2004). However, there is no solid evidence for a direct inter-
action of  the LRRs with PGN so far. There is also the possibility that NOD1 and NOD2 might 
act as downstream adaptors of  so far unidentified PRRs, as this is the case for NLRC4 that acts 
downstream of  the actual PRR NAIP (Kofoed and Vance, 2011; Zhao et al., 2011). A similar 
mechanism has been proposed for NLRP3, as there is evidence that NLRP3-mediated re-
sponses to PGN require upstream activation of  NOD2 (Pan et al., 2007). However, this impor-
tant issue still needs clarification. 
   Under normal conditions, NOD1 and NOD2 are thought to be kept in an inactive state. Fol-
lowing recognition of  PGN, these molecules likely undergo conformational changes that render 
them active by exposing the NACHT-domains that mediate homo-oligomerisation of  the mole-
cules. The exact nature of  such conformational changes has not been worked out so far; the 
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presumed model is based on structural information on the activation of  APAF-1 (reviewed in 
Riedl and Salvesen, 2007), which is closely related to NLRs (Fig. 1). Oligomerisation leads to re-
cruitment and activation of  the serine-threonine kinase RIP2 (Receptor interacting protein 2) 
via homophilic CARD-CARD interactions (Inohara et al., 2000). This creates a molecular signal-
ling platform. RIP2 thereby acts as a molecular scaffold for the recruitment of  downstream 
components. The kinase activity of  RIP2 itself  is not essential for this function, but it is re-
quired to stabilise the protein (Hasegawa et al., 2008; Windheim et al., 2007). NOD1- as well as 
NOD2-mediated recruitment of  RIP2 promotes conjugation of  RIP2 with K63-linked ubiq-
uitin within the kinase domain at lysine 209. In contrast to K48-linked ubiquitination, K63-
linked ubiquitination does not target proteins for proteasomal degradation, but serves as a regu-
latory mechanism, especially in NF-B signalling (reviewed in Chen, 2005). K63-linked ubiquitin 
chains on RIP2, possibly attached by the E3 ligases TRAF2, TRAF5 (TNF receptor associated 
factor) and ITCH (itchy E3 ubiquitin ligase homolog (mouse)) (Tao et al., 2009; Hasegawa et al., 
2008), serve as docking sites for TAK1 (transforming growth factor- activated kinase 1) 
(Hasegawa et al., 2008). Recruitment of  TAK1 is mediated by the ubiquitin-binding proteins 
TAB1 (TAK binding protein) and TAB2 that form a complex with TAK1 (Hasegawa et al., 
2008; Abbott et al., 2007). Polyubiquitinated RIP2 also serves as a docking site for the IKK-
complex by direct interaction with the regulatory subunit IKK (NEMO, NF-B essential 
modifier). In NOD2 signalling, IKK itself  gets conjugated with K63-linked ubiquitin chains at 
lysine 399 in a RIP2-dependent manner (Abbott et al., 2004). The interactions of  RIP2 with 
IKK and TAK1 establish a close proximity between the IKK complex and the TAB/TAK 
complex, thus mediating TAK1-dependent activation of  IKKα and IKK. The activated IKK 
complex phosphorylates the NF-B inhibitory protein inhibitor of  B (IB) that sequesters 
NF-B in the cytoplasm. Phosphorylation of  IB triggers its proteasomal degradation, causing 
NF-B to translocate to the nucleus and activate its target genes (reviewed in Hayden and 
Ghosh, 2008). Additionally, there is evidence that NOD2 can also activate the alternative NF-
B pathway by interaction with the NF-B-inducing kinase (NIK) in a RIP2-independent man-
ner (Pan et al., 2006). 
   Interestingly, the TLR pathways leading to NF-B activation utilise partly the same ubiquitina-
tion mechanisms as the NOD1/2 pathway, for example, ubiquitination of  IKK at the same site 
is essentially involved (reviewed in Akira and Takeda, 2004). NOD1- and NOD2-dependent 
activation of  TAK1 via RIP2 also induces c-Jun N-terminal kinase (JNK) and p38 MAPK-
pathways (da Silva Correia et al., 2007; Windheim et al., 2007; Opitz et al., 2006; Girardin et al., 
2001). The molecular mechanisms of  NOD-mediated MAPK activation are not well under-
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stood, but there is evidence that the protein CARD9 is essentially involved at least in NOD2-
mediated p38 activation (Hsu et al., 2007) (Fig. 2).  
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Figure 2. Uptake of PGN triggers NOD1- and NOD2-dependent signalling cascades. Bacterial PGN can gain 
access to the cytoplasm by invasion of bacteria, by injection via bacterial secretion systems, by pH-
dependent endocytotic events and by the transmembrane translocators hPepT1 and hPepT2. Intracellular 
PGN fragments trigger NOD1 and NOD2 signalling cascades that involve RIP2 and TAK1, leading to expres-
sion of pro-inflammatory cytokines, chemokines and antimicrobial peptides. Factors that are known to 
regulate NOD signalling are indicated. For further information please refer to the main text (based on Le 
Bourhis et al., 2007). 
   
 
   Overwhelming inflammatory responses can be detrimental to the host, therefore the NOD1 
and NOD2 signalling cascades have to be tightly controlled. Even though NOD1 and NOD2 
share the same core signalling cascade, they appear to be partly differentially regulated by asse-
sory proteins (Fig. 2).  
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   A common factor that dampens NF-B activation in NOD1 and NOD2 signalling, but also in 
TLR signalling, is the de-ubiquitinating enzyme A20 (also known as TNFAIP3; tumor necrosis 
factor, alpha-induced protein 3), which reverses K63-linked ubiquitination of  RIP2 (Hasegawa et 
al., 2008; Hitotsumatsu et al., 2008). NOD2-specific K63-linked ubiquitination of  IKK can also 
be reversed by A20 and the deubiquitinating enzyme CYLD (cylindromatosis (turban tumor 
syndrome)) (Zhang et al., 2006; Boone et al., 2004). There are more examples of  factors that 
uniquely regulate NOD2 signalling. For instance, it has been shown that MEKK-4 (mitogen-
activated protein kinase kinase kinase 4) and caspase-12 down-regulate NOD2-mediated re-
sponses by interfering with the NOD2/RIP2 interaction (Clark et al., 2008; LeBlanc et al., 2008). 
Furthermore, it was reported that the protein Erbin (erbb2 interacting protein) binds NOD2 
and exerts a negative regulatory function on NOD2 signalling (Kufer et al., 2006; McDonald et 
al., 2005). Recently, we discovered that the angio-associated migratory cell protein (AAMP) also 
interacts with NOD2 and negatively influences NOD2-mediated NF-B activation (Bielig et al., 
2009). GRIM19 (gene associated with retinoid-IFN-induced mortality-19), in contrast, has been 
described to positively contribute to NOD2-mediated NF-B activation (Barnich et al., 2005b).  
   The regulation and fine-tuning of  NOD1 signalling, in contrast, is less well characterised. 
Thus far, it has only been shown that the GTPase-activating protein centaurin- 1 (CENTB1) 
negatively regulates NOD1 and also NOD2 signalling. (Yamamoto-Furusho et al., 2006). Fur-
thermore, CARD6 exerts positive effects on NOD1-mediated NF-B activation by interaction 
with RIP2. However, these effects are not very strong and CARD6 also seems to act on NF-B 
pathways triggered by other stimuli (Dufner et al., 2006).  
   The regulatory networks that control positive- and negative-regulation of  NOD1 and NOD2 
are still very poorly defined. For Erbin and CENT1B there is evidence that they serve as feed-
back inhibitors, as their expression is up-regulated following NOD1 and NOD2 stimulation 
(Kufer et al., 2006; Yamamoto-Furusho et al., 2006). Given the potentially dangerous effects of  
overwhelming inflammation, it can be assumed that NOD signalling is tightly regulated, as this 
is the case for TLR signalling (reviewed in Akira and Takeda, 2004). However, to date it is still 
not known how detection of  elicitors occurs, or how NOD-mediated inflammatory responses 
are terminated, for example.  
 
 
1.3.2 Bacterial sensing and physiological relevance of NOD1 and NOD2 
Peptidoglycan (PGN) is present in the cell wall of  nearly all bacteria and is essential for con-
structing the cell shape. PGN is constantly remodeled during cell-growth and -division (re-
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viewed in Park and Uehara, 2008). There are recycling mechanisms, but at least some PGN and 
degradation products are shed by growing bacteria (reviewed in Boneca, 2005).  
NOD1 specifically recognises diaminopimelic acid (DAP)-containing PGN fragments that are 
produced as breakdown-products during growth of  Gram-negative bacteria. The minimal struc-
tural motif  required for NOD1-activation was identified to be γ-D-glutamyl-meso-diaminopimelic 
acid (ie-DAP), a dipeptide that serves to crosslink the carbohydrate-backbones of  Gram-
negative PGN (Chamaillard et al., 2003; Girardin et al., 2003c). Human NOD1 preferentially 
recognises L-Ala-D-Glu-meso-DAP (Tri-DAP) containing PGNs. Of  note, murine NOD1 has a 
different substrate specificity as it is activated better by L-Ala-D-Glu-meso-DAP-D-Ala (Tetra-
DAP) than by ie-DAP (Girardin et al., 2003a). Thus NOD1 should provide protection primarily 
against Gram-negative bacteria. Consistently, it has been shown that NOD1 detects the invasive 
Gram-negative pathogens Shigella flexneri (Girardin et al., 2001), enteroinvasive Escherichia coli 
(Kim et al., 2004) and Chlamydia spp. (Welter-Stahl et al., 2006; Opitz et al., 2005), among others. It 
has also been shown that NOD1-deficient mice have a higher bacterial burden after infection 
with the Gram-negative pathogen H. pylori compared to WT mice (Viala et al., 2004). In addition, 
NOD1 also recognises some Gram-positive bacteria that contain DAP-type PGNs, such as Ba-
cillus spp. or Listeria monocytogenes (Hasegawa et al., 2006; Opitz et al., 2006).  
   NOD2, in contrast, recognises the PGN-moiety MurNac-L-Ala-D-isoGln (MDP, for muramyl 
dipeptide), the minimal motif  common to all PGNs that is conserved in Gram-negative as well 
as in Gram-positive bacteria (Girardin et al., 2003b; Inohara et al., 2003). Due to its ability to 
sense MDP, NOD2 should be able to detect a very broad spectrum of  bacteria. Indeed, it has 
been shown that NOD2 detects a variety of  Gram-positive and Gram-negative bacteria, such as 
Streptococcus pneumoniae, Salmonella typhimurium and Mycobacterium tuberculosis (Ferwerda et al., 2005; 
Opitz et al., 2004; Hisamatsu et al., 2003). NOD2 also detects a huge variety of  PGNs of  heat 
killed bacteria in vitro (Hasegawa et al., 2006). Furthermore, it has been shown that NOD2 is 
essentially involved in protection against L. monocytogenes in the intestine of  mice (Kobayashi et al., 
2005).  
 
Bacterial pathogens can be roughly divided into two groups: Extracellular bacteria, which evade 
phagocytic uptake and/or subsequent lysosomal degradation and invasive bacteria, which ac-
tively enter host cells. The latter either reside freely within the cytosol or stay entrapped and 
replicate within altered compartments of  the host’s endocytic pathway (so-called “pathogen-
containing vacuoles”) (reviewed in Raupach and Kaufmann, 2001).  
   Due to their cytoplasmic localisation, NOD1 and NOD2 are able to detect invasive bacteria, 
such as S. flexneri or L. monocytogenes that invade host cells and reside freely within the cytosol. It 
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has been shown that PGN fragments derived from invasive Shigella activate NOD1-signalling in 
epithelial cells (Nigro et al., 2008). Furthermore, MDP can potentially be generated by secreted 
bacterial autolysins in cells infected with L. monocytogenes (Lenz et al., 2003). There is also evi-
dence that NOD1 and NOD2 detect bacteria that normally reside within intracellular vacuoles, 
such as Legionella pneumophila (Berrington et al., 2010; Frutuoso et al., 2010), S. typhimurium (Le 
Bourhis et al., 2009) or Mycobacterium tuberculosis (Brooks et al., 2011; Pandey et al., 2009). However, 
it is not well understood how in general PGN is translocated from the vesicular compartment to 
the cytosol where it is sensed by NOD1 and NOD2, although translocation via pore-forming 
toxins and peptide transporters is involved in some cases (see below). 
   Initially, it has been presumed that only bacteria colonising intracellular niches are recognised 
by intracellular PRRs and that extracellular bacteria are detected by cell surface receptors, for 
example by TLRs. Nowadays there is increasing evidence that extracellular bacteria can also be 
detected by intracellular PRRs. This raises the question how the hydrophilic PGN fragments 
shed by extracellular bacteria are delivered into the host cells. One possibility is delivery via bac-
terial secretion systems, as it has been shown that H. pylori can deliver PGN fragments into the 
cytosol of  host cells via its type IV secretion system encoded by the cag pathogenicity island 
(Viala et al., 2004). It is also possible that pore-forming toxins secreted by some bacteria facili-
tate entry of  PGN to host cells, as it has been observed that NOD1 activation by PGN derived 
from Haemophilus influenzae required the pore-forming toxin pneumolysin from S. pneumoniae. 
Similar effects were observed for pore-forming toxins from Bacillus anthracis and Staphylococcus 
aureus  (Ratner et al., 2007). 
   Host cell factors might contribute to uptake of  PGN as well, as it has been shown that 
clathrin- and dynamin-dependent pathways mediate an active uptake of  PGN to the cytosol in a 
pH-dependent manner (Lee et al., 2009; Marina-Garcia et al., 2009). Moreover, the NOD2-
elicitor MDP can specifically be taken up into the cytosol via the plasma membrane-located 
peptide transporter hPepT1 (human peptide transporter 1), whereas NOD1-elicitors can be 
taken up by hPepT2 (Swaan et al., 2008; Ismair et al., 2006; Vavricka et al., 2004) (Fig. 2). However, 
these mechanisms are still not fully worked out and there are very likely further mechanisms that 
contribute to PGN uptake.  
 
Whereas NOD1 is widely expressed in many tissues of the stromal and haematopoetic com-
partments, NOD2 shows the highest expression in immune cells like macrophages and dendritic 
cells and in paneth cells in the intestinal crypts, but it is also expressed in epithelial cells of the 
intestine and the lung (Hitotsumatsu et al., 2008; Uehara et al., 2007; Tada et al., 2005; Ogura et al., 
2003; Ogura et al., 2001; Inohara et al., 1999). NOD1 and NOD2 are indispensable for intestinal 
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homeostasis and pathogen recognition. As there are myriads of commensals in the gut, expres-
sion of TLRs in the adult is restricted in intestinal epithelial cells to prevent constant inflamma-
tion (Abreu et al., 2001). Moreover, TLR signalling can be rendered anergic due to constant ex-
posure to PAMPs (Shahin et al., 1987). This prevents harmful overwhelming immune reactions 
to commensals. Pathogens rupturing the epithelial barrier or invading the host cells are subse-
quently recognised by cytoplamic NLRs. There is a close cross-talk between NLRs and TLRs 
ensuring a proper distinction between commensals and pathogens. NOD1 and NOD2 are es-
sential to trigger anti-microbial responses in cells that are anergic for TLR signalling in vivo (Kim 
et al., 2008). Furthermore, there are strong synergistic effects between NOD1 and NOD2 elici-
tors and agonists of various TLRs (Fritz et al., 2005; Uehara et al., 2005; van Heel et al., 2005; 
Traub et al., 2004). 
   Activation of NOD1 and NOD2 in epithelial and endothelial cells by bacteria induces expres-
sion of pro-inflammatory cytokines and chemokines, such as IL-8 (CXCL-8), a chemokine that 
mediates the recruitment of neutrophils (Opitz et al., 2006; Kim et al., 2004; Viala et al., 2004). 
Furthermore, activation of NOD1 and NOD2 in macrophages and dendritic cells induces the 
release of IL-8 and the cytokines IL-6, IL-1β and TNF-α (reviewed in Fritz et al., 2006). The 
important chemo-attractant RANTES (regulated upon activation, normal T-cell expressed and 
secreted/CCL5) is secreted by primary murine macrophages in vivo following stimulation with 
NOD agonists, underlining the importance of NOD signalling in co-ordinating innate immune 
responses (Werts et al., 2007). Importantly, stimulation of NOD1 and NOD2 additionally leads 
to secretion of anti-microbial peptides (AMPs) in the gut. AMPs are secreted short peptides that 
kill bacteria by forming pores in bacterial cell membranes; they are the key effectors in cell 
autonomous immunity, i.e. defence mechanisms that are executed by the attacked cell itself that 
do not rely on the recruitment of immune cells. They are not only produced by professional 
immune cells, but also by epithelial cells. Secretion of AMPs is important to control the num-
bers of commensal bacteria and is thus essential for maintaining intestinal homeostasis (re-
viewed in Auvynet and Rosenstein, 2009; Selsted and Ouellette, 2005). Especially in intestinal 
crypts, a compartment that is likely kept sterile, NOD2 seems to play a pivotal role in the pro-
tection against pathogens. NOD2 is highly expressed in the AMP-secreting paneth cells in the 
crypts and it triggers secretion of AMPs upon pathogen intrusion (Petnicki-Ocwieja et al., 2009; 
Kobayashi et al., 2005). Furthermore, NOD2 controls the expression of the AMP human -
defensin in epithelial cells (Voss et al., 2006). 
   NOD1 as well is crucial for the regulation of intestinal homeostasis. It is required for produc-
tion of human and murine -defensins in response to H. pylori infection (Boughan et al., 2006; 
Hamanaka et al., 2001) and has been shown to mediate lymphoid tissue genesis induced by com-
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mensals in the intestine of mice. Formation of intestinal B-cell containing isolated lymphoid 
follicles (ILFs) is essentially regulated by recognition of Gram-negative bacteria by NOD1 
(Bouskra et al., 2008). 
   Of  note, NOD1 and NOD2 have also been shown to contribute to autophagy by recruiting 
ATG16L1 (ATG16 autophagy related 16-like 1 (S. cerevisiae)) to the plasma membrane. Auto-
phagy is a process that serves to maintain cellular homeostasis and mediates degradation of  
intracellular pathogens (reviewed in Ramjeet et al., 2010).  
   Within the last years, it became clear that NOD1 and NOD2 also contribute to the induction 
of adaptive immune responses. NOD1 and NOD2 elicitors, in particular in synergy with TLR 
agonists, have been shown to induce Th1- and Th2-type immune responses (Fritz et al., 2007; 
Kobayashi et al., 2005; Tada et al., 2005). Furthermore, it has been demonstrated that administra-
tion of  NOD1 elicitors restored neutrophil function in mice depleted in intestinal microbiota. 
Consistently, NOD1 deficient mice proved to be more susceptible to early pneumococcal sepsis 
due to unefficient neutrophil activation (Clarke et al., 2010).  
   Taken together, innate immune mechanisms involving NOD1 and NOD2 counter-act bacte-
rial infections by the release of anti-microbial factors, recruitment of phagocytes and by mediat-
ing the onset of adaptive immune responses. Furthermore, NOD1 and NOD2 are crucial for 
the regulation of the intestinal homeostasis by mediating interactions with the commensal mi-
crobiota.  
   Consistently, mutations in the CARD4 and CARD15 genes are linked to a variety of  inflam-
matory disorders. Polymorphisms in the NOD1 gene CARD4 have been associated to the onset 
of  inflammatory bowel disease (McGovern et al., 2005). A different polymorphism in CARD4 
seems to increase the susceptibility to asthma and allergy (Eder et al., 2006; Hysi et al., 2005). 
Frameshift mutations in the NOD2 gene CARD15 strongly increase the susceptibility to 
Crohn’s disease (CD), which is a severe form of  chronic inflammatory bowel disease (reviewed 
in Hruz and Eckmann, 2010). Other mutations in CARD15 are associated with the chronic in-
flammatory barrier diseases Blau syndrome and early onset sarcoidosis (reviewed in Rosenstiel et 
al., 2007). 
   Of  note, NOD1 has also been linked to events leading to cell death. In the first description of  
NOD1 it was reported that NOD1 binds several caspases and specifically activates caspase-9-
mediated apoptosis (Inohara et al., 1999). Later, it has been shown that NOD1 induces apop-
tosis by RIP2-dependent activation of  caspase-8 as well, contributing to the control of  tumour 
growth (da Silva Correia et al., 2007; da Silva Correia et al., 2006). However, the putative func-
tions of  NOD1 in apoptosis are far from being understood.  
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1.4 Apoptosis: Programmed cell death 
Apoptosis, often referred to as programmed cell death, is an evolutionary conserved process in 
which proteolytic cascades lead to the degradation of  cells in a controlled manner. In contrast to 
necrotic cell death, a toxic process induced by extrinsic factors or injury, apoptosis does not 
cause an immune reaction. Apoptosis is required for many processes, such as normal cell turn-
over, embryonic development and for a proper function of  the immune system.  
   The hallmarks of  apoptosis are cell shrinkage, nuclear fragmentation, protein-crosslinking, 
and chromatin condensation and degradation. The degraded cellular material is engulfed in ve-
sicular structures consisting of  intact cellular membranes, whereby mitochondria and other or-
ganelles stay intact within the apoptotic vesicles. The vesicles are quickly phagocytosed by 
macrophages and other surrounding cells. As cell membrane integrity is not affected, there is no 
release of  cellular constituents into the extracellular milieu and no immune response following 
apoptotic cell death (reviewed in Elmore, 2007).  
   Cellular events that lead to the aforementioned biochemical changes are mediated by a family 
of  aspartate-specific cysteine proteases termed caspases (cysteine-dependent aspartate-directed 
proteases) (Alnemri et al., 1996). Caspases are ubiquitously expressed as inactive pro-forms and 
get activated by various apoptotic stimuli. This leads to proteolytic cascades that amplify the 
initial signals and ensure a rapid degradation of  cells by selective cleavage of  hundreds of  target 
proteins (Nicholson, 1999). 
   There are two major pathways that trigger apoptosis: The extrinsic pathway and the intrinsic 
pathway. The extrinsic pathway relies on activation of  tumor necrosis factor receptor (TNFR) 
family transmembrane receptors by extracellular ligands. Ligand binding induces formation of  a 
multimeric protein complex termed DEATH-INDUCED SIGNALLING COMPLEX (DISC) that re-
cruits pro-caspase-8. The induced proximity leads to trans-autoactivation of  caspase-8, trigger-
ing proteolytic cascades by activating effector caspases (Muzio et al., 1998; Kischkel et al., 1995).  
   The intrinsic pathway is activated by numerous non-receptor stimuli, such as deprivation of  
growth factors or cytokines, or by intrinsic cues like DNA damage, endoplasmatic reticulum 
(ER) stress, free radicals, radiation, UV light, viral infection or toxins. This leads to 
MITOCHONDRIAL OUTER-MEMBRANE PERMEABILISATION (MOMP) and subsequent release of  
pro-apoptotic factors into the cytosol. This process is tightly regulated by complex interactions 
between pro- and anti-apoptotic members of  the B cell lymphoma 2 (BCL-2) protein family 
(reviewed in Cory and Adams, 2002). MOMP leads to secretion of  the pro-apoptotic molecules 
cytochrome c, second mitochondria-derived activator of  caspase (SMAC) and high temperature 
requirement protein A2 (HtrA2). SMAC and HtrA2 inhibit anti-apoptotic factors of  the BIRC-
family. Cytochrome c, in contrast, triggers the activation of  APAF-1. Activated APAF-1 forms a 
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heptameric complex termed APOPTOSOME that mediates activation of  caspase-9, which in turn 
cleaves and activates effector caspases, thereby initiating the proteolytic cascades that finally lead 
to cell death (reviewed in Yuan et al., 2011; Riedl and Salvesen, 2007).  
 
 
1.5 The BIRC-family: Functions beyond inhibition of apoptosis 
Members of  the BIRC-family (baculovirus IAP repeat containing; also termed IAPs, for inhibi-
tors of  apoptosis) have mainly been investigated in respect of  their roles in counter-acting 
apoptosis. BIRC proteins were initially found in baculoviruses and are highly conserved from 
viruses to yeast, nematodes and insects to humans (Uren et al., 1998). In humans there are eight 
members, BIRC1 (NAIP), BIRC2 (c-IAP1), BIRC3 (c-IAP2), BIRC4 (XIAP, ILP-1), BIRC5 
(Survivin), BIRC6 (Bruce, Apollon), BIRC7 (Livin, ML-IAP) and BIRC8 (ILP-2). Members of  
the BIRC family are characterised by the presence of  1-3 tandem baculovirus inhibitory repeat 
(BIR) domains (Fig. 3) (reviewed in Gyrd-Hansen and Meier, 2010). The BIR domain is a zinc-
binding fold containing ~70 amino acid residues that is known to promote protein-protein in-
teractions. Most members also contain a really interesting new gene (RING) finger motif  that 
has E3 ubiquitin ligase function (Vaux and Silke, 2005). BIRC2 and BIRC3 additionally contain 
a CARD domain of  yet unknown function.  
   BIRC proteins are known to inhibit apoptosis either by direct binding of  active caspases 
(Riedl et al., 2001; Deveraux et al., 1997), or by indirect means. Initially, it was thought that all 
BIRCs inhibit caspases by direct binding, as overexpression of  BIRCs effectively protects cells 
against apoptotic stimuli. Nonetheless, recent studies indicate that only XIAP (BIRC4) is able to 
inhibit caspases by direct binding under physiological conditions (Eckelman and Salvesen, 2006; 
Eckelman et al., 2006). BIRC8 shows a close homology to XIAP, but lacks the first two BIR-
domains. In spite of  its putative caspase-9 interaction domain, it is only a weak caspase-9 inhibi-
tor on its own (Shin et al., 2005). However, it has been shown that over-expression of  BIRC8 
potently inhibits BAX-induced apoptosis (Richter et al., 2001).  
   Indirect means to inhibit apoptosis are thought to include mono- and polyubiquitination of  
caspases (Morizane et al., 2005; Hao et al., 2004; Suzuki et al., 2001; Huang et al., 2000), or of  the 
pro-apoptotic factor SMAC (Ma et al., 2006; Morizane et al., 2005; Hao et al., 2004; Hu and Yang, 
2003; MacFarlane et al., 2002), leading to proteasomal degradation of  these factors. Other re-
ports indicate that BIRC7 and BIRC8 might exert their anti-apoptotic effects by binding and 
neutralising SMAC, rather than by direct inhibition of  caspases (Shin et al., 2005; Vucic et al., 
2005).  
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Figure 3.  Domain architecture of the eight members of the BIRC family. The BIRC family is characterised by 
1-3 N-terminal baculoviral inhibitory repeat (BIR) domains. Several members also contain caspase activation 
and recruitment (CARD) domains and/or really interesting new gene (RING) domains. For further details 
please refer to the main text (based on Salvesen and Duckett, 2002). 
 
 
   BIRC proteins are regulated by pro-apoptotic IAP-binding proteins, such as the mitochondrial 
proteins SMAC and HtrA2. SMAC has been shown to inhibit the association of  XIAP with 
caspases and mediate the release of  caspases to execute their downstream apoptotic functions. 
This may also be the case for other BIRCs (Liu et al., 2000; Wu et al., 2000; Deveraux et al., 1997; 
Roy et al., 1997), as SMAC also targets BIRC2 and BIRC3 for proteasomal degradation by ubiq-
uitination (Yang and Du, 2004). Furthermore, HtrA2 has an intrinsic protease activity and can 
directly cleave BIRC proteins (Srinivasula et al., 2003; Yang et al., 2003; Hegde et al., 2002; Mar-
tins et al., 2002; Verhagen et al., 2002). 
   Recent reports indicate that BIRC family members also have important functions in other 
cellular processes. Some members are involved in the regulation of  cell division (Verhagen et al., 
2001), cellular signalling (Salvesen and Duckett, 2002) and in immune detection of  bacterial 
products. BIRC1, for example, which also belongs to the NLR family (Fig. 1, Fig. 3), acts as PRR 
itself; it directly recognises bacterial flagellin and components ot the bacterial type III secretion 
apparatus to mediate caspase-1 activation and IL-1β processing via formation of  a NLRC4- and 
ASC-dependent inflammasome (Kofoed and Vance, 2011; Zhao et al., 2011). BIRC5 is involved 
in the segregation of  chromosomes in the G2/S-phase of  the cell cycle (Skoufias et al., 2000; 
Uren et al., 2000), and BIRC6 plays a role in cytokinesis (Pohl and Jentsch, 2008).  
   Importantly, recent studies indicate that some members of  the BIRC family exert important 
functions in innate immunity and pro-survival signalling. BIRC2 and BIRC3 are implicated as 
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key players in the TNFR1 (tumor necrosis factor receptor 1) signalling pathway. They were 
found to be associated with the TNFR signalling complex (Rothe et al., 1995) where they act as 
K63 E3 ubiquitin ligases mediating TNFR1-dependent NF-B activation and preventing 
TNFR1-mediated apoptosis (Bertrand et al., 2008). A recent study revealed that BIRC2 and 
BIRC3 play similar roles in NOD1 and NOD2 signalling (Bertrand et al., 2009). Furthermore, 
BIRC2 and BIRC3 also seem to positively regulate MyD88-dependent TLR signalling by medi-
ating K48-linked ubiquitionation of  TRAF3 (Tseng et al., 2010). 
   XIAP was also found to be implicated in pro-survival signalling events. Through interactions 
of  its BIR1 domain with the TAB1/TAK1 complex it participates in activation of  MAPKs and 
NF-B (Lu et al., 2007; Sanna et al., 2002; Sanna et al., 1998). Moreover, XIAP is essential for 
NOD2-mediated immune responses against the invasive pathogen L. monocytogenes (Bauler et al., 
2008), indicating a role in innate immunity. This raises the questions how exactly the mentioned 
BIRC proteins are involved in the regulation of  innate immune responses, and if  also other 
BIRC family members contribute to innate immunity. 
 
 
1.6 RNAi and systematic screening approaches 
The principle of  RNA-interference (RNAi)-mediated gene-silencing is widely used in research 
to determine the function of  genes in certain biological processes by loss-of-function studies. In 
this work, we conducted an RNAi-based high-throughput screen (HTS) to identify novel factors 
involved in the regulation of  the NOD1 signalling cascade. 
   RNAi is a conserved mechanism common to eukaryotic cells. It serves to regulate gene ex-
pression by post-transcriptional gene silencing and provides protection against foreign nucleic 
acids, such as transposons and viruses. The first RNAi-based processes, described in the early 
1990s, were gene silencing in plants (Jorgensen, 1990) and quelling in the fungus Neurospora 
crassa (Romano and Macino, 1992). Evidence for the exinstance of  RNAi in animals was then 
provided by Fire and colleagues in 1998. They demonstrated that injection of  long dsRNA into 
the nematode Caenorhabditis elegans triggers the degradation of  complementary mRNA (Fire et al., 
1998). Only later it became evident that RNAi also occurs in mammalian cells (Elbashir et al., 
2001). Recently, a related RNA-based defence mechanism was also described for bacteria and 
archea (Horvath and Barrangou, 2010), underlining the ubiquitous importance of  RNA-based 
mechanisms as protection systems against viruses and mobile genetic elements. Today, RNAi-
based methods are widely used as standard methods for reverse genetics, and also therapeutic 
applications are being investigated.  
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Figure 4. The molecular mechanism of RNAi. Long dsRNA is cleaved into short interfering RNAs (siRNAs) by 
Dicer protein complexes. Alternatively, siRNAs can directly be inserted into cells. The siRNA duplexes are 
unwound starting at the 5’ end. The guide strand is taken up into the RNA-induced silencing complex (RISC) 
mediated by argonaute proteins, whereas the other strand is degraded (pre-RISC). The guide strand directs 
the endonuclease activity of the activated RISC (holo-RISC) to cleave homologous mRNA. For further details 
please refer to the main text (based on Dykxhoorn and Lieberman, 2005).  
    
 
   Many of  the underlying mechanisms were discovered in Drosophila, but the involved proteins 
and regulatory mechanisms are believed to be very similar in mammalian cells. Degradation of  
mRNA by RNAi is guided by small 23-25 nucleotide dsRNA, termed small interfering RNA 
(siRNA). These small RNAs are produced by cleavage of  long dsRNA molecules by members 
of  the highly conserved Dicer enzyme family that possess RNase III-like properties (Myers et al., 
2003; Zamore et al., 2000). The siRNA is subsequently passed on to the argonaute (AGO) pro-
teins contained in a ribonucleoprotein complex (RNP) termed RNA-INDUCED SILENCING 
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COMPLEX (RISC), where it is unwound and cleaved, whereby the leading strand (guide strand) 
remains bound to the complex and the other strand gets degraded (Leuschner et al., 2006; Ma-
tranga et al., 2005; Liu et al., 2004). The leading strand subsequently guides recognition of  com-
plimentary mRNA trough base-pairing, which in turn leads to incorporation of  the mRNA into 
the RISC. The bound mRNA gets degraded by the endonuclease activity of  the contained argo-
naute proteins. This in turn leads to silencing of  the corresponding gene (reviewed in Ender and 
Meister, 2010) (Fig. 4). 
   Large-scale HTS approaches based on RNAi, often on a genome-wide scale, proved to be a 
very powerful tool in functional genomics (for example Sharma et al., 2011; Karlas et al., 2010; 
Muller et al., 2005)). The major advantage of  these automated approaches is that the functions 
of  many thousand genes in a specific biological process can be monitored by systematic gene-
by-gene knock-downs in one single screening approach under controlled conditions.  
 
 
1.7 Aim of the study 
The intracellular NLR-type PRR NOD1 is critically involved in innate immune responses 
against Gram-negative bacteria by detection of  PGN fragments. Even though the main events 
leading to NF-B activation are established, the regulation and fine-tuning of  this potentially 
harmful inflammatory signalling pathway remains largely elusive. The aim of  this study was to 
gain a better understanding of  the NOD1 signalling cascade by conducting an unbiased high-
throughput siRNA screen to identify novel components of  the NOD1 pathway. 
 
Another event in NOD1 and NOD2 signalling that is still not fully understood is the uptake of  
PGN into the cytosol of  host cells. Recent studies indicate that multiple different mechanisms 
in the host cell facilitate PGN translocation from the extracellular and vesicular milieu into the 
cytosol. Recently, it was shown that also pathogens possess factors that enable PGN uptake. 
Pore-forming toxins and the type IV secrtion sytem were shown to be involved in this by ena-
beling PGN translocation across the plasma membrane of  host cells (Ratner et al., 2007; Viala et 
al., 2004). Intriguingly, many Gram negative bacteria secrete large amounts of  outer-membrane 
vesicles (OMVs) that contain proteins from the periplasmic space and PAMPs (Kulp and Kuehn, 
2010). It has been shown that OMVs purified from Pseudomonas aeruginosa can induce IL-8 re-
sponses in host cells (Bauman and Kuehn, 2006) and that OMVs can trigger NOD1 responses 
(Kaparakis et al., 2009). The second part of  this project aims at elucidating a possible role of  
OMVs as carriers of  PGN fragments that might trigger NOD1 and NOD2 signalling. 
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2 Materials and Methods 
 
 
2.1 Materials 
 
2.1.1 Cell lines and bacteria 
 
 
HEK293T cells  
HEK293 (human embryonic kindney) cells are adherent human epithelial cells transformed with 
sheared adenovirus 5 DNA (Graham et al., 1977). The derivative HEK293T is highly transfect-
ible and additionally contains the SV40 (simian virus 40) T-antigen that allows replication of  
plasmids containing the SV40 origin of  replication. HEK293T cells were purchased from 
ATCC (#CRL 11268, www.atcc.org/). 
 
 
HeLa cells 
HeLa cells are adherent human epithelial cells derived from a cervical carcinoma. This immor-
talised cell line is tansformed with human papilloma virus 18 (HPV18). HeLa cells were pur-
chased from ATCC (#CCL 2, www.atcc.org/). 
 
 
HeLa shRNA cell lines 
HeLa cells stably expressing shRNA (XIAP and scrambled) were provided by Hamid Kashkar 
and are described elsewhere (Kashkar et al., 2007). 
 
 
THP-1 cells 
The human monocytic cell line THP-1 was first isolated from the blood of  a one-year old boy 
with acute monocytic leukemia. During culture, THP-1 cells maintain monocytic characteristics 
for up to 14 months (Tsuchiya et al., 1980). THP-1 cells are non-adherent, but can be differenti-
ated into adherent macrophage-like cells with phorbol esters, such as phorbol 12-myristate 13-
acetate (PMA). THP-1 cells were purchased from ATCC (#TIB 202, www.atcc.org/). 
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THP1-Blue cells 
THP1-Blue cells are a derivative of  the THP-1 cell line. They have a NF-B-inducible reporter-
system stably integrated into the genome. The reporter expresses secreted embryonic alkaline 
phosphatase (SEAP) under the control of  a NF-B inducible promoter. Cells are resistant to 
zeocin and were purchased from InVivoGen (#thp-sp, www.invivogen.com).  
 
 
Escherichia coli DH5α 
Competent E. coli DH5α (F- 80lacZM15 (lacZYA-argF)U169 deoR recA1 endA1 hsdR17 (rk-, 
mk+) phoA supE44 thi-1 gyrA96 relA1 -), derived from apathogenic E. coli K12 (purchased from 
Invitrogen) were used for plasmid amplifications. 
 
 
Escherichia coli XL01-Blue 
Competent E. coli XL01-Blue (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB 
laclqZM15 Tn10 (Tetr)]) (purchased from Stratagene) were used for plasmid amplifications. 
 
 
Shigella flexneri M90T afaE+ 
S. flexneria M90T is a wild-type (WT) invasive strain of  S. flexneri serotype 5a derived from a 
clinical isolate containing the virulence plasmid pWR100. This strain additionally contains the 
pIL22-afaE (spectinomycin resinstance) plasmid encoding the afimbrial adhesion factor afaE 
from uropathogenic E. coli to enhance the capability to invade human cells (Clerc and Sansonetti, 
1987). 
 
 
Shigella flexneri BS176 afaE+ 
S. flexneri BS176 is an apathogenic mutant of  the M90T afaE+ strain which lacks the virulence 
plasmid pWR100 and cannot invade eukaryotic cells (Clerc and Sansonetti, 1987). 
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2.1.2 Chemicals, reagents and enzymes 
All chemicals were purchased from Merck, Sigma-Aldrich or Roth, if not otherwise stated. 
 
Reagent Supplier 
3 mm CHR chromatography paper Whatman 
384 well cell culture plates Corning 
ATP Sigma-Aldrich 
Agarose Sigma-Aldrich 
C12-ieDAP InVivoGen 
Cell culture plastics (10cm-, 24 well-, 96 well-plates, flasks) TRP 
dNTP mix Fermentas 
D-Luciferin Sigma-Aldrich 
Dulbecco’s modified Eagle’s medium (DMEM) Biochrom AG 
Fetal Bovine Serum (FBS) Gibco 
Fetal Calf Serum (FCS) Bio West 
FuGENE6 Roche 
GeneRuler DNA ladder, low range Fermentas 
Gentamycin Roth 
HiPerFect Qiagen 
illustra PuReTAq Ready-To-Go PCR beads  GE Healthcare 
iQTM SYBR Green Supermix Bio-Rad 
Kanamycin Roth 
LPS InVivoGen 
MAXI-Sorp ELISA plates, 96 well Nunc 
MDP InVivoGen 
M-Tri-DAP InVivoGen 
Nitrocellulose Membrane (0.2 μm) Bio-Rad 
Non-essential amino acids Biochrom AG 
ONPG Fluka 
PAGE ruler prestained protein marker Fermentas 
Penicillin/Streptomycin Biochrom AG 
PBS (1x) for cell culture Biochrom AG 
PMA Sigma-Aldrich 
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Polymyxin B Sigma-Aldrich 
QUANTI-BlueTM InVivoGen 
Recombinant Human BMP-2 R&D Systems 
Rotiphorese® Gel 30 (37.5:1) Roth 
Spectinomycin Fluka Biochemika 
Super Signal West Femto Maximum sensitivity Substrate Thermo Scientific 
Super Signal West Pico Luminol/Enhancer Solution Thermo Scientific 
Taq DNA polymerase Fermentas 
Tri-DAP InVivoGen 
Trypsin/EDTA (10x) Biochrom AG 
Tumor necrosis factor α (TNF-α) InVivoGen 
VLE RPMI1640 medium Biochrom AG 
X-tremeGENE 9 Roche 
Zeocin InVivoGen 
 
 
2.1.3 Kits 
Kit Manufacturer 
Bio Rad Dc Protein Assay Bio Rad 
Cell Proliferation Kit II (XTT) Roche 
DuoSet ELISA (human IL-6 and IL-8) R&D Systems 
First Strand cDNA Synthesis Kit  Fermentas 
NucleoBond PC500 (Plasmid preparation MAXI) Macherey-Nagel 
Qiagen Plasmid Giga Kit Qiagen 
Qiagen Plasmid Maxi Kit Qiagen 
RNeasy Mini Kit (RNA preparation) Qiagen 
 
 
2.1.4 Plasmids  
Plasmid Insert Reference 
pcDNA3.1 - Invitrogen 
pcDNA3.1-β-galactosidase - (Kufer et al., 2006) 
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pcDNA3.1-Myc-XIAP human XIAP (Seeger et al., 2010) 
pcDNA3.1-NOD1 human NOD1 Gift from G. Nuñez 
pcDNA3.1-NOD2 human NOD2 Gift from G. Nuñez 
pcDNA3.1-SMACMTS human SMACMTS (Kashkar et al., 2006) 
pGL3-IL-8-luciferase - (Bowie et al., 2000) 
NF-B-reporter-Igκ-luciferase - (Munoz et al., 1994) 
 
 
2.1.5 Primer 
Name GC [%] Length [bp] Tm [°C] Sequence 
BIRC2_fwd 45 20 55.3 GCATTTTCCCAACTGTCCAT 
BIRC2_rev 50 20 57.3 GGAAACCACTTGGCATGTTC 
BIRC3_fwd 45 20 55.3 CAGCCCGCTTTAAAACATTC 
BIRC3_rev 50 20 57.3 TGGGCTGTCTGATGTGGATA 
BIRC5_fwd 55 20 59.4 GGACCACCGCATCTCTACAT 
BIRC5_rev 60 20 61.4 GTCTGGCTCGTTCTCAGTGG 
BIRC7_fwd 55 20 59.4 TGGCCTCCTTCTATGACTGG 
BIRC7_rev 55 20 59.4 GCACCTCACCTTGTCCTGAT 
BIRC7_fwd2 55 20 59.4 CCATCAGGACAAGGTGAGGT 
BIRC7_rev2 60 20 61.4 AGCTGGGAGTGAGTCTCCTG 
BIRC8_fwd 45 20 55.3 AATCCATCCATGACGGGTTA 
BIRC8_rev 50 20 57.3 CATGCTGTTCCCAAGGATCT 
BMPR-2_fwd 48 25 63.0 CACTGAATTGCTTGACTTCTGTGGC 
BMPR-2_rev 48 25 63.0 GCTACGCATCTCCATGTTTCAGCTA 
GAPDH_5 60 23 52.2 GGTATCGTGGAAGGACTCATGAC 
GAPDH_3 60 23 56.5 ATGCCAGTGAGCTTCCCGTTCAG 
Myco fwd 47.8 23 60.6 CACCATCTGTCACTCTGTTAACC 
Myco rev 47.8 23 60.6 GGAGCAAACAGGATTAGATACCC 
NOD1_fwd 42.9 21 55.9 TCCAAAGCCAAACAGAAACTC 
NOD1_rev 52.6 19 56.7 CAGCATCCAGATGAACGTG 
NOD2_fwd 57.9 19 58.8 GAAGTACATCCGCACCGAG 
NOD2_rev 50 22 60.3 GACACCATCCATGAGAAGACAG 
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XIAPfw2 52.9 17 49.4 ACACCATATACCCGAGG 
XIAPrv2 56.3 16 51.2 CCAGGCACGATCACAA 
 
 
2.1.6 siRNAs 
Gene Supplier Name Number Target 
No target Qiagen AllStars SI1027281 No target 
BIRC2 Qiagen Hs_BIRC2_7 SI02654435 AACATAGTAGCTTGTTCAGTG 
BIRC2 Qiagen Hs_BIRC2_8 SI02654442 CTAGGAGACAGTCCTATTCAA 
BIRC3 Qiagen Hs_BIRC3_5 SI00299439 AATTGGGAACCGAAGGATAAT 
BIRC3 Qiagen Hs_BIRC3_8 SI02661918 CAAGAACATGATGTTATTAAA 
BIRC5 Qiagen Hs_BIRC5_5 SI00299453 AAGCATTCGTCCGGTTGCGCT 
BIRC5 Qiagen Hs_BIRC5_6 SI00299460 TGCACCACTTCCAGGGTTTAT 
BIRC7 Qiagen Hs_BIRC7_2 SI02645111 TTGGATGCTTCTGAATAGAAA 
BIRC7 Qiagen Hs_BIRC7_3 SI02645118 ATGGCTTAACTGTACCTGTTT 
BIRC8 Qiagen Hs_BIRC8_2 SI00146202 CACGAGGTGCTCACTGCGCAA 
BIRC8 Qiagen Hs_BIRC8_4 SI00146216 AACGTTAATATTCGAGGTGAA 
BMPR-2 Qiagen Hs_BMPR-2_5 SI00604996 AAGCACCGAAGCGAAACTTAA 
BMPR-2 Qiagen Hs_BMPR-2_6 SI00605003 CTCGTAAGTATGTAAAGAAA 
NOD1 Qiagen Hs_CARD4_4 SI00084483 CACCCTGAGTCTTGCGTCCAA 
NOD2 Qiagen Hs_CARD15_3 SI00133049 CTGCCACATGCAAGAAGTATA 
RELA Qiagen RELA SI1027020 AAGATCAATGGCTACACAGGA 
RIP2 Qiagen Hs_RIPK2_5 SI0263200 ACGTATGATCTCTCTAATAGA 
XIAP Qiagen XIAP custom  GGAAUAAAUUGUUCCAUGC 
 
For the pilot screen, the Apoptosis siRNA set V1 (Qiagen) consisting of  418 apoptosis-related 
genes was used. For the main screening project, the Human Druggable Genome siRNA Set 
V2.0 (Qiagen) was used. This pre-designed siRNA library includes siRNAs designed against 
6992 potentially druggable targets of  the human genome. An individual library for hit validation 
containing 535 genes was purchased from Qiagen and spotted on 384 well plates. 
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2.1.7 Antibodies 
 
Primary antibodies 
Antigen Type Clone Dilution Reference 
GAPDH Rabbit pc FL-355 1:1000 Santa Cruz Biotechnology  (sc-25778) 
NF-B p65 Mouse mc F-6 1:500 Santa Cruz Biotechnology (sc-8008) 
phospho-p42/44 Rabbit mc 137F5 1:1000 Cell Signaling (#4695) 
p42/44 Mouse mc E10 1:2000 Cell Signaling (#9106) 
XIAP Mouse mc 48 1:500 BD Biosciences (#610763) 
 
 
Secondary antibodies 
Antigen Type Enzyme Dilution Reference 
Mouse IgG Goat HRP 1:4000 Bio-Rad Laboratories (170-6516) 
Rabbit IgG Goat HRP 1:4000 Bio-Rad Laboratories (170-6515) 
 
 
2.1.8 Instruments 
Instrument Manufacturer 
384 well pipetting head Beckman Coulter 
Biomek FXP laboratory automation workstation Beckman Coulter 
Centrifuge 5415R Eppendorf 
Centrifuge 5418 Eppendorf 
Centro XS3 LB960 Luminometer Berthold Technologies 
Cytomat Microplate Hotel and Incubator Thermo Electron Corporation 
Envision plate reader Perkin Elmer 
Incubator Heraeus 
Gel electrophoresis system Bio-Rad Laboratories 
iQ5TM cycler (qRT-PCR) Bio-Rad Laboratories 
LAS-4000 Luminescent Image Analyser  Fujifilm 
Micro Centrifuge Roth 
MicroDrop MD combi Thermo Electron Corporation 
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MicroDrop MD micro Thermo Electron Corporation 
Micropipettes Gilson, Finnzymes 
Multifuge 4KR Heraeus 
Multipette plus dispenser Eppendorf 
Nano Photometer Implen GmBH 
Neubauer counting chamber Labor Optik 
Nunc-Immuno Wash 12 Nunc 
OD600 DiluPhotometer Implen GmBH 
ORCA robot arm Beckman Coulter 
Pipetboy acu Integra Biosciences 
Primus Thermocycler MWG Biotech 
PS-M3D Orbital Shaker Grant-bio 
Research pro multichannel pipettes Eppendorf 
Steri-Cycle CO2 Incubator, Model 381 Thermo Forma 
Sterile bench Heraeus 
Thermomixer comfort Eppendorf 
TRANS BLOT SD, Semi-Dry Transfer Cell Bio-Rad Laboratories 
 
 
2.1.9 Software 
Software Company/Source 
Adobe Acrobat 9 professional Adobe Systems Incorporated 
Adobe Illustrator CS5 Adobe Systems Incorporated 
Adobe Photoshop CS5 Adobe Systems Incorporated 
Bioconductor Open source (www.bioconductor.org) 
Biomek Workstation Software Beckmann Coulter 
Bio-Rad iQ5 version 2.0 Bio-Rad Laboratories 
CellHTS2 (Boutros et al., 2006) 
Endnote X Thomson Reuters 
GOrilla (Eden et al., 2009; Eden et al., 2007) 
GraphPad Prism 5 GraphPad Software Inc. 
Imagereader LAS-4000 Fujifilm 
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Ingenuity Pathway Analysis Ingenuity Systems 
Microwin 2000 Berthold Technologies 
Microsoft Office 2003 Microsoft 
Microsoft Excel 2007 Microsoft 
SAMI EX Workstation Editor Beckmann Coulter 
STRING 9.0 www.string.embl.de 
 
 
2.2 Methods 
 
2.2.1 Cell biological methods 
 
Tissue culture 
HEK293T cells were grown at 37 °C with 5 % CO2 in Dulbecco’s MEM (with 3.7 g/l NaHCO3, 
4.5 g/l D-Glucose and stable glutamine, without Na-Pyruvate, low endotoxin) (in the following 
referred to as DMEM) containing 10 % heat-inactivated fetal calf  serum (FCS) and penicillin-
streptomycin (100 IU/ml and 100 mg/ml, respectively) (P/S). HeLa cells were cultured at 37 °C 
with 5 % CO2 in DMEM (containing FCS and P/S). THP-1 cells were cultured in very low en-
dotoxin RPMI1640 (containing FCS and P/S). THP1-Blue cells were maintained in very low 
endotoxin RPMI 1640 (containing FCS and P/S) and 100 μg/ml zeocin. Cells were continu-
ously tested for mycoplasma contamination using PCR (see below). 
 
 
Luciferase reportergene assays 
Activation of  NF-B and IL-8 was measured using a luciferase reportergene assay as described 
previously (Kufer et al., 2006). HEK293T cells were trypsinised, counted using a Neubauer 
chamber and adjusted to 3x105 cells per ml in DMEM (containing FCS and P/S). Subsequently, 
100 µl of  the cell suspension was seeded in 96 well plates and transfected using FuGENE6. Per 
well, 8.6 ng β-galactosidase-plasmid, 13 ng luciferase-reporter plasmid (NF-B or IL-8) and 0.5 
ng NOD1 or 0.1 ng NOD2 expression plasmid were used, the DNA content was adjusted with 
pcDNA to 51 ng DNA total. The contents were diluted in 20 µl DMEM, 0.2 µl FuGENE6 was 
added and the mixture was incubated at RT for 20 min prior to transfection. Subsequently, cells 
were stimulated with 500 nM Tr-iDAP, 50 nM MDP or 0.01 µg/ml TNF-α. After 16 h of  incu-
bation, the growth medium was removed and cells were lysed in 100 µl lysis buffer.; 50 µl of  the 
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lysates was used to measure the luciferase activity, the remaining lysates were mixed with 100 µl 
ONPG-development buffer to determine the -galactosidase expression. Luciferase activity was 
normalised as a ratio to β-galactosidase activity, the mean and standard deviations were calcu-
lated from triplicates.  
 
 
siRNA in HEK293T cells 
Gene silencing with small interfering RNA (siRNA) was performed by transfection of  siRNA 
using HiPerFect. HEK293T cell solution was adjusted to 2x104 cells/ml in DMEM (containing 
FCS and P/S). Subsequently, 100 µl of  the cell solution was seeded in a 96 well cell culture plate. 
Cells were transfected with transfection mixes containing 20 nM siRNA, 0.8 µl HiPerFect and 
20 µl DMEM that were incubated for 10 min at RT prior to transfection. After 16 h, the growth 
medium was removed and replaced with 100 µl fresh medium. 72 hours after siRNA transfec-
tion, cells were transfected with the NF-B luciferase reporter system and NOD1 or NOD2 
expression plasmids, as described above. Subsequently, cells were stimulated with 500 nM Tri-
DAP, 50 nM MDP or 10 ng/ml TNF-α. After 16 h incubation, the luciferase and -
galactosidase read-outs were performed as described above.  
   To monitor knock-down efficiency, cells were treated as indicated above. After 48 h to 72 h 
incubation, cells were lysed in 2xLaemmli buffer. For each sample, 6 wells were pooled. Samples 
were boiled for 10 min at 95 °C and subsequently subjected to Western blotting. 
 
Reagents 
Lysis buffer: 25 mM Tris pH 8.0, 8 mM MgCl2, 1 % Triton, 15 % Glycerol, H2O 
Reading buffer: Lysis buffer containing 0.77 μg/ml D-luciferin and 1.33 mM ATP  
ONPG-dilution buffer: 0.06 M Na2HPO4, 0.04 M NaH2PO4, 0.01 M KCl, 0.001 M MgSO4, pH 7  
ONPG-development buffer: 4:1 ONPG-dilution buffer : ONPG stock solution (4 mg/ml) in ONPG-dilution 
buffer 
6xLaemmli buffer: 7 ml 0.5 M Tris pH 6.8 containing 0.4 % SDS, 3 ml glycerol, 1 g SDS, 1.2 mg brom-
phenol blue. 60 μl β-mercaptoethanol was added per ml before use  
 
 
THP1-Blue assay  
Cells were counted using a Neubauer chamber and adjusted to 1.5x106 cells/ml in RPMI1640 
(containing FCS and P/S). Subsequently, 100 µl of  the cell solution was seeded per well in a 96 
well plate. 20 µl of  the samples was added per well including appropriate controls, such as Tri-
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DAP (10 µg/ml), MDP (10 µg/ml), LPS (0.1 µg/ml) or endotoxin free water. SEAP activity was 
measured after 16 h incubation at 37 °C and 5 % CO2. For that purpose, 20 µl of  the super-
natant was added to 200 µl QUANTI-Blue SEAP-detection medium and incubated at 37 °C for 
1-2 h. SEAP activity was measured at 620 nm. All assays were performed in triplicates.  
 
Reagents 
QUANTI-Blue SEAP-detection medium: Reconstituted in ddH2O according to the manufacturer’s manual 
 
 
siRNA in THP-1 and THP1-Blue cells 
THP-1/THP1-Blue cells were counted using a Neubauer chamber and adjusted to for 4x105 
cells/ml in RPMI1640 (containing FCS and P/S). Of  this solution, 500 µl was seeded into a 24 
well plate and cells were differentiated by adding 0.1 µM PMA. After 24 h of  incubation, the 
growth medium was removed and replaced with 100 µl RPMI1640 (containing FCS and P/S). 
The transfection mixes containing 100 nM siRNA, 6 µl HiPerfect and 100 µl RPMI1640 were 
incubated for 10 min at RT and then added dropwise to the cells. After 6 h incubation at 37 °C 
and 5 % CO2, 400 µl RPMI (containing FCS and P/S) was added to the cells. Cells were incu-
bated for 48 - 72 h at 37 °C and 5 % CO2 with continuous medium changes twice a day. After 
48 - 72 h, the growth medium was replaced with 300 µl RPMI1640 (containing FCS and P/S) 
and the cells were stimulated with 10 µg/ml Tri-DAP, 10 µg/ml MDP, 0.1 µg/ml LPS or 0.01 
µg/ml TNF-α for 16 h. Subsequently, the read-out was performed as described above (only for 
THP1-Blue cells). Alternatively, cytokine secretion in the supernatants was determined by 
ELISA. Assays were performed in duplicates. In parallel, cellular RNA was extracted to deter-
mine knock-down efficiency by RT-PCR or qRT-PCR.  
 
 
siRNA in HeLa cells 
HeLa cells were counted using a Neubauer chamber and adjusted to 8x104 cells/ml in DMEM 
(containing FCS and P/S). Subsequently, 500 µl of  the cell solution was seeded in a 24 well cell 
culture plate and incubated for 5 h at 37 °C with 5 % CO2. After the incubation, cells were 
transfected with 10 nM siRNA and 4.5 µl HiPerFect in 100 µl DMEM. After 24 h, the growth 
medium was exchanged, 48 h later, cells were infected with S. flexneri BS176 afaE+ or M90T 
afaE+ (MOI=10), as indicated below. Supernatants were collected 6 h after infection and IL-8 
levels were determined by ELISA. Assays were performed in duplicates. In parallel, cellular 
RNA was extracted to determine knock-down efficiency by RT-PCR.  
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Gene knock-down in stable HeLa shRNA cell lines 
HeLa shRNA cells (HeLa shSCR or HeLa shXIAP) were counted using a Neubauer chamber 
and adjusted to 4x105 cells/ml in DMEM (containing FCS and P/S). Subsequently, 500 µl of  
the cell solution was seeded in a 24 well cell culture plate and incubated for 24 h at 37 °C with 
5 % CO2. After incubation, cells were infected with S. flexneri BS176 afaE+ or M90T afaE+ 
(MOI=37.5), as indicated below. Supernatants were collected 6 h after infection and IL-8 levels 
were determined by ELISA. Assays were performed in duplicates. 
 
 
Bacterial infection of HeLa cells with Shigella flexneri  
S. flexneri BS176 afaE+ and M90T afaE+ from glycerol stocks were plated on congo red plates 
two days prior to infection and grown at 37 °C over night. One day prior infection, pre-cultures 
in 5 ml soy bean medium with 200 µg/ml spectinomycin were inoculated with a single bacterial 
colony and grown at 37 °C over night on a shaker with 225 rpm. On the day of  infection, fresh 
Shigella cultures were prepared by diluting the overnight cultures 1:20, 1:25 and 1:30 and grown 
to an optical density at 600 nm (OD600) of  0.3 - 0.6. One millilitre of  the solution was centri-
fuged at 4000 rpm for 5 min. The pellet was resuspended in DMEM to adjust the solution to an 
OD600 of  0.3. In parallel, HeLa cells or HeLa cells stably expressing shRNA were washed with 
1 ml DMEM, then 250 µl of  DMEM was added. After 1-2 h incubation, HeLa cells were in-
fected with 13.3 µl of  the Shigella-solution (corresponds to MOI=10). Infected cells were incu-
bated for 15 min at RT to allow sedimentation of  the bacteria, then they were incubated for 30 
min at 37 °C and 5 % CO2 to allow invasion of  the cells. Subsequently, the supernatants were 
discarded and replaced by 250 µl DMEM containing 200 µg/ml gentamycin to kill extracellular 
bacteria. Cells were incubated at 37 °C and 5 % CO2 for 6 h, then supernatants were collected 
and stored at -20 °C to perform ELISA-assays. Assays were performed in duplicates. In parallel, 
cellular RNA was extracted to determine knock-down efficiency by RT-PCR.  
 
Reagents 
Soy Bean Medium: 30 g BLL Trypticase Soy Broth. Ad. 1 l ddH2O, autoclaved 
Congo Red plates: 25 µl Soy Bean Medium, 1.5 % Bacto Agar, 0.01 % Congo Red. Boiled for 15 min, after 
cooling 200 µg/ml spectinomycin was added and the solution was poured into a cell culture dish 
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Cell viability assays 
For cell viability assays, 3x104 HEK293T cells or 1.5x105 THP1-Blue cells were seeded in 96 well 
plates and treated as indicated. After 16 h of  incubation, XTT-assays (Cell Proliferation Kit II 
(XTT), Roche) were performed according to the manufacturer’s manual. Measurements were 
performed in triplicates, data are presented as percent cell viability to the control (set to 100 %). 
 
 
 
2.2.2 Screening protocols 
 
Large scale siRNA NF-B luciferase screen 
For the pilot screen, a library of  418 apoptosis-related genes (Qiagen) was used and each gene 
was targeted with two individual siRNAs. Tri-DAP and TNF-α stimulation were performed in 
parallel. The top 34 inhibiting and top 18 activating hits were subsequently validated with four 
different siRNAs. The druggable genome screen was conduced using the Qiagen druggable 
genome library consisting of  6992 genes. Each gene was targeted by four individual siRNAs. 
For validation- and TNF-α counter-screening, a subset of  the druggable genome library target-
ing the 435 inhibiting and the top 100 activating hits from the primary druggable genome screen 
was used. Each gene was targeted with two individual siRNAs. 
   For screening, uniquely HEK293T cells with a passage number of  two were used. Cells were 
thawed 6 days before use. The whole assay procedure was performed automatically using a 
Biomek FXP laboratory automation workstation equipped with a 384 well pipetting head, an 
ORCA robot arm, two Multidrop (MD) dispensing devices, a Cytomat microplate hotel and 
incubator, and an integrated Envision plate reader operated with SAMI EX and Biomek soft-
ware. 
   Four µl of  200 nM siRNAs were pre-spotted on clear 384 well cell culture plates to allow re-
verse transfection of  cells (final concentration of  20 nM). All plates contained non-targeting 
(AllStars) as well as RELA (p65), NOD1 and PLK (Polo-like kinase) siRNAs as internal controls. 
For transfection, 8 µl medium per well were mixed with 0.25 µl HiPerFect and added to the 
siRNAs. The mixtures were incubated at RT for 15 min before adding 1x103 HEK293T cells in 
30 µl RPMI1640 medium (containing FCS and P/S). 
   After 48 h of  incubation to allow establishment of  the knock down, and a medium change 
after 24 h, cells were transfected. The transfection mixtures contained 11.6 ng β-gal plasmid, 
7.03 µl NF-B-luciferase plasmid, 0.135 ng NOD1 expression plasmid, 8.78 ng pcDNA-plasmid 
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and 0.0918 µl FuGENE6. The mixture was added up to a volume of  5 µl with RPMI and incu-
bated at RT for max. 2 h. Subsequently, cells were stimulated with 0.5 µM Tri-DAP in a volume 
of  3 µl H2O. For the TNF-α-counter-screen, 5 ng/ml TNF-α in a volume of  3 µl RPMI was 
added instead. After stimulation, cells were incubated at 37 °C and 5 % CO2 for 16 h.  
   For read-out, cells were lysed by adding 30 µl 2xlysis buffer and subsequently mixed by pipet-
ting. 35 µl of  the lysate was then added to a white 384 well plate containing 35 µl reading-buffer. 
Subsequently, bioluminescence of  the samples was measured using an Envision plate reader. 
   For β-galactosidase read-out, 35 µl of  ONPG-development buffer was added to the remaining 
lysate. After 15 min incubation at 37 °C and 5 % CO2, the absorbance of  the samples at 405 nm 
was measured automatically with an Envision plate reader. Each siRNA was tested in four bio-
logical replicates. 
 
Reagents 
2xLysis buffer: 50 mM Tris pH 8.0, 16 mM MgCl2, 2 % Triton, 30 % Glycerol, H2O 
 
 
THP1-Blue siRNA screen 
For screening, uniquely THP1-Blue cells with a passage number of  three were used. Cells were 
thawed 10 days before use. The whole assay procedure was performed automatically using a 
Biomek FXP laboratory automation workstation equipped with a 384 well pipetting head, an 
ORCA robot arm, two Microdrop (MD) pipetting devices (MD combi and MD micro), a Cy-
tomat microplate hotel and an Envision plate reader operated with SAMI EX workstation editor 
and Biomek software. 
   The siRNAs (200 nM) were pre-spotted on clear 384 well cell culture plates in 4 µl volume 
and the cells were reversely transfected. All plates contained AllStars, RELA, NOD1 and PLK 
siRNAs as internal controls. For transfection, 8 µl medium were mixed with 0.25 µl HiPerFect 
and added to the microplates containing the siRNAs using a MD micro pipetting device. The 
mixtures were incubated at RT for 15 min, then 8x103 THP1-Blue cells in 10 µl RPMI1640 me-
dium (containing FCS and P/S) and 0.1 µM PMA were added using the MD micro pipetting 
device. After 6 h incubation, 20 µl medium was added.  
   The cells were incubated for 72 h, while the growth medium was exchanged twice a day. To 
prevent detachment of  the cells, only 35 µl of  the 42 µl total volume in the wells was aspirated 
and replaced with 35 µl fresh medium using the 384 well pipetting head. 
   After 72 h, 35 µl growth medium was replaced by 15 µl growth medium containing 10 µg/ml 
Tri-DAP to stimulate the cells. The cells were incubated for 16 h before read-out. For SEAP-
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detection, 10 µl supernatant per well was transferred to a fresh plate containing 50 µl QUANTI-
Blue SEAP detection medium and incubated for 5 h. 10 µl XTT reagent was added to the re-
maining 10 µl and incubated at 37 °C for 1 h. Absorption at 632 nm and 485 nm, respectively, 
were measured. 
 
 
Data analysis  
Data was processed using the CellHTS2 package (Boutros et al., 2006), Bioconductor/R, and 
Excel. The luciferase signal (relative light units; RLU) was normalised by division by the -
galactosidase signal (ABS405) (normalised RLU; RLU/ABS405 = nRLU). To exclude experi-
mental artefacts, all those plates were excluded, where the average -galactosidase signal of  the 
non-targeting controls (ABS405) was >2.5, <0.2 or had a standard deviation of  >50 %.  
   Next, all wells displaying a β-galactosidase signal of  <40 % of  the non-coding controls, sup-
posedly due to low plasmid transfection efficiency or siRNA toxicity,  were excluded from fur-
ther analysis. 
   Subsequently, the nRLUs were normalised relative to the inhibitory effect of  the RELA-
control siRNAs compared to the non-targeting controls (normalised percent inhibition; NPI) 
and median z-scores of  the 4 biological replicates were calculated using CellHTS2. 
   In the next step, the median z-scores of  individual siRNAs were used to calculate two separate 
ranked gene lists, using the redundant siRNA analysis algorithm (RSA) (Konig et al., 2007). 
These lists comprise genes leading to a decreased NF-B activity when knocked down (termed 
“inhibiting hits”), or to an increased activity (“activating hits”), respectively.  
   For validation and TNF-α-counter-screening in HEK293T cells, as well as for hit validation in 
THP1-Blue cells (only for the druggable genome screen), the top 34 (pilot screen) or 435 inhib-
iting (druggable genmome screen) as well as the 18 (pilot screen) or top 100 activating (drug-
gable genome screen) hits were selected. For each of  these genes, both siRNAs and two new 
siRNAs were re-synthesised and assembled on 384 well plates for the pilot screen. For the 
druggable genome screen, the two siRNAs showing the strongest effect in the screen were re-
synthesised and assembled on 384 well plates (“validation plates”). 
   To validate the results of  the primary screens, the experiments were repeated as above, using 
the validation plates. Data analysis using CellHTS2 was performed as described above; siRNAs 
were selected as “inhibiting Tri-DAP-hits”, if  their median Z-score exceeded the median of  
non-targeting controls by more than two standard deviations. To exclude unspecific hits, all 
siRNAs selected for validation were screened for their influence on TNF-α-induced NF-B 
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activation. Data analysis was done analogous to the Tri-DAP validation screen. “Inhibiting 
TNF-α-hit siRNAs” were excluded from further analysis.  
   Data from the THP1-blue screen consists of  two parameters (QUANTI-Blue absorption at 
632 nm for Tri-DAP response [QB], and XTT absorption at 485 nm for cell viability [XTT]) 
and was processed similar as described above: QB-signal of  each well was normalised to cell 
viability (XTT), yielding nQB (normalised QUANTI-Blue absorption; QB/XTT = nQB). After 
quality control and outlier flagging, the three best experimental replicates were NPI-normalised 
to non-targeting and NOD1-control siRNAs using CellHTS2, and median Z-scores were used 
for hit identification. All genes with two siRNAs displaying a decrease of  > 1.5 fold standard 
deviation compared to the non-targeting control were regarded as validated inhibiting hits. 
 
 
 
2.2.3 Molecular biological methods 
 
Production of competent bacteria 
Approximately 10 µl of  DH5α or XL01-Blue bacteria was taken from glycerol stocks, plated on 
LB agar plates and incubated at 37 °C over night. A single colony was inoculated in 5 ml liquid 
LB medium and incubated at 37 °C over night on a shaker with 100 rpm. Of  this culture, 1.5 ml 
was inoculated in 500 ml LB medium and incubated at 20 °C at 225 rpm until the culture 
reached  an OD600 of  0.3 – 0.6. The culture was chilled on ice for 10 min and centrifuged for 
15 min at 4000 rpm and 2 °C. The supernatant was discarded and the pellet was washed with 
150 ml cold transformation buffer. The culture was centrifuged again for 15 min at 4000 rpm 
and 2 °C, the pellet was re-suspended in 40 ml transformation buffer and 3 ml DMSO and 500 
µl aliquots were frozen in liquid nitrogen and stored at -80 °C.  
 
Reagents 
LB medium: For 1 l medium, 10 g tryptone, 10 g NaCl and 5 g yeast extract were dissolved in H2O and 
adjusted to 1 l volume. The solution was sterilised by autoclaving. 
LB agar plates: LB medium was prepared as described above, 15 g agar powder was added per litre. After 
autoclaving, antibiotics were added and the liquid was poured in 10 cm petri dishes.  
Transformation buffer : 15 mM CaCl2, 250 mM KCl, 10 mM PIPES, 55 mM, MnCl2x4 H2O, pH 6.7; sterile 
filtrated. 
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Heat-shock transformation of E. coli 
Chemical competent DH5α or XL01-Blue E. coli cells were thawed on ice. One microlitre plas-
mid DNA was added to 50 µl cell suspension and incubated on ice for 30 min. Subsequently, 
bacteria were subjected to a heat-shock at 42 °C for 1 min. For transformation of  bacteria with 
plasmids containing an ampicillin resistance marker, bacteria were subsequently diluted in 1 ml 
LB medium and 200 µl of  the solution was directly plated on LB agar plates supplemented with 
100 µg/ml ampicillin. For transformation of  plasmids containing a kanamycin resistance marker, 
bacteria were diluted in 1 ml LB medium and incubated for 45 min at 37°C. After incubation, 
200 µl of  the solution was plated on LB agar plates supplemented with 50 µg/ml kanamycin. 
Bacteria were grown overnight at 37 °C.  
 
 
Isolation of DNA from E. coli 
A single transformed E. coli clone picked from the appropriate LB agar plate was inoculated in 2 
ml LB medium containing 100 µg/ml ampicillin or 50 µg/ml kanamycin and incubated at 37 °C 
while shaking at 225 rpm for 6 h. 100 µl of  the starter culture was then inoculated in 100 ml LB 
medium (for Maxi preps) or 500 ml LB medium (for Giga preps) containing the appropriate 
antibiotics and cultivated over night under the aforementioned conditions. Cultures were pel-
leted by centrifugation at 6000 x g for 15 min and plasmid DNA was isolated using the Nu-
cleoBond PC500 Maxi prep kit (for Maxi preps) or the Plasmid Giga kit (for Giga preps) ac-
cording to the manufacturer’s manuals. DNA was eluted in 100-200 µl (Maxi prep) or 500 µl 
(Giga prep) 10 mM TE buffer (pH 8.0) and DNA concentration was determined using a Nano 
Photometer.  
 
 
Isolation of RNA from human cells 
RNA was isolated from human cells using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s manual. Concentration and purity of  the RNA was determined at 260 and 280 
nm using a Nano Photometer.  
 
 
Reverse transcription of RNA 
Reverse transcription of  isolated RNA was performed using the First Strand cDNA Synthesis 
Kit with oligo-dT18 primers according to the manufacturer’s manual. In each reaction 1 µg 
RNA was transcribed. 
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End-point RT-PCR 
Polymerase chain reaction (PCR) of  cDNA templates was performed according to the following 
protocol: 
 
Reagent Volume [μl] 
Buffer (+KCl, -MgCl2) 5  
MgCl2 4  
dNTPs 2  
Taq DNA polymerase 0.5  
ddH2O 35.5  
Fwd primer 1 [1:10] 
Rev primer 1 [1:10] 
cDNA 1 – 2 
 
Reaction mixes were prepared on ice and drops were collected by brief  centrifugation before 
starting the reaction. The reaction was performed in a Primus Thermo-cycler using the follow-
ing programme: 
 
PCR step Temperature [°C] Time  
Denaturation 94 1 min 1x 
Melting 94 30 sec 
Annaealing 54 - 55, as indicated 30 sec 
Elongation 72 1 min 
30-35x 
Final elongation 72 5 min 1x 
Storage 4   
 
PCR products were analysed by gel electrophoresis on a 2 % agarose gel. 
 
 
PCR for Mycoplasma detection  
For Mycoplasma testing, cells were cultured over night in the appropriate medium without antibi-
otics. Aliquots of  the supernatant were boiled at 100 °C for 5 min and briefly centrifuged. PCR 
mixes were prepared according to the following protocol: 
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Reagent Amount / Volume [μl] 
PuReTaq Ready-To-Go beads 1 bead  
Myco fwd primer 0.8 
Myco rev primer 0.8 
Boiled supernatant (template) 1 
ddH2O 22.4 
 
Reaction mixes were prepared on ice and drops were collected by brief  centrifugation before 
starting the reaction. The reaction was performed in a Primus Thermo-cycler using the follow-
ing programme: 
 
Temperature [°C] Time   
94 2 min 1x 
57 2 min 1x 
72 2 min 
92 30 sec 
57 1 min 
34x 
72 1 min 1x 
72 4 min 1x 
4   
 
PCR products were analysed by gel-electrophoresis on a 2 % agarose gel. 
 
 
Agarose gel electrophoresis 
PCR products were analysed by gel electrophoresis on 2 % agarose gels. Agarose was dissolved 
in 1xTBE buffer, boiled for 1 ½ min and poured in a gel tray. After letting the gel cool down to 
~50 °C, 0.5 µl/ml Ethidiumbromide was added. Samples were diluted in DNA loading buffer 
and 10 µl of  the dilution was applied to the gel. Four µl GeneRuler DNA ladder or GeneRuler 
DNA ladder low range were applied to the gel as standard. Samples were subjected to electro-
phoresis for 35 min at 80 V. PCR products were detected under UV light in a LAS4000 device. 
 
Reagents 
TBE (Tris-borate EDTA): Prepared as 10x solution. 0.89 M (108 g) Tris Base and 0.89 M (55 g) of  boric 
acid were dissolved in 900 ml H2O. 20 mM (40 ml 0.5 M) Na2EDTA (pH 8.0) was added and the volume 
was adjusted to 1 l with ddH2O. The solution was sterilised by autoclaving. 
6xDNA loading buffer : 2 % glycerol in ddH2O, bromephenol blue powder was added using a pipette tip. 
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Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was performed using a Bio-Rad iQ cycler and the 
iQ SYBR Green Supermix. For each reaction, 5 ng/µl cDNA in a volume of  5 µl was used. 
The reaction was prepared as follows: 
 
Reagent Volume / Conc. 
iQ SYBR Green Supermix 12.5 μl  
Fwd primer 0.188 μl / 7.5 pmol 
Rev. primer 0.188 μl / 7.5 pmol 
H2O ad. 20 μl 
 
5 µl cDNA (corresponding to 5 ng/ml) was added to each reaction. Reaction mixes were pre-
pared on ice and drops were collected by brief  centrifugation before starting the reaction. The 
PCR was performed in 96 well PCR plates according to the following settings: 
 
Temperature [°C] Time   
95 3 min 1x 
95 15 sec 
60 1 min 
40x 
55 30 sec 81x 
25  1x 
 
Reactions were performed in triplicates. Data was processed according to the ΔΔCt method 
with GAPDH as reference gene using the Bio-Rad software package iQ5 version 2.0. 
 
 
 
2.2.4 Biochemical methods 
 
Measurement of protein concentrations 
Protein concentrations of  samples were determined using the Dc Protein Assay according to 
the manufacturer’s manual.  
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SDS polyacrylamide electrophoresis 
Proteins from cell lysates were separated by SDS-polyacrylamide gelelectrophoresis (SDS-
PAGE) (Laemmli, 1970). A discontinuous gel system consisting of  a lower separation gel (10 %) 
and an upper stacking gel (4 %) was used. Samples were diluted in 2xLaemmli buffer and boiled 
at 95 °C for 10 min. 10 µl of  the samples was loaded in the gel pockets. Electrophoresis was 
performed in SDS-PAGE running buffer at 195 V for 45 min.  
 
Reagents 
Separating gel: 2.1 ml ddH2O, 2.5 ml acrylamide (40 %), 5 ml 0.5 M Tris/0.4 % SDS pH 8.8, 25 μl TEMED, 
50 μl APS (10 %)  
Stacking gel: 4.5 ml ddH2O, 650 μl acrylamide (40 %), 1.25 ml 0.5 M Tris/0.4 % SDS, pH 6.8, 25 μl 
TEMED, 50 μl APS (10 %)  
6xLaemmli buffer: 7 ml 0.5 M Tris pH 6.8 containing 0.4 % SDS, 3 ml glycerol, 1 g SDS, 1.2 mg brom-
phenol blue. 60 μl β-mercaptoethanol was added per ml before use  
SDS-PAGE running buffer: 250 mM Tris, 1.92 M glycine, 34.67 mM SDS, add up to 1 l with ddH2O  
 
 
Western Blot 
Proteins were transferred to a nitrocellulose membrane by semidry Western transfer at 15 V for 
30 min. Blotting efficiency was controlled by Ponçeau-S staining. Membranes were blocked for 
20 min at RT in PBS containing 5 % milk. Proteins were detected by over night incubation at 
4 °C of  the membrane in PBS containing 5 % milk and a primary antibody. Subsequently, 
membranes were washed three times in PBST and then incubated for 1 h at RT with the secon-
dary antibody in PBS containing 5 % milk. After washing again three times in PBST, mem-
branes were finally incubated with Pico substrate or Femto maximum sensitivity substrate, de-
pending on the strength of  the signal. Chemiluminescence was detected using a LAS4000 device. 
For detection of  phospho-specific antibodies, TBS containing 5 % milk was used for blocking 
and incubation and TBST was used for washing.  
 
Reagents 
Transfer buffer: Prepared as 10x solution. 250 mM Tris and 1.92 M glycine were adjusted to 1 l with H2O. 
Working solution was prepared by 1:10 dilution in H2O and addition of  20 % methanol. 
PBST: Prepared as a 10x solution. 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4 x 2 H2O and 2.4 g KH2PO4 in 1 l 
H2O, pH adjusted to 7.4 using HCl. Working solution was prepared by 1:10 dilution in H2O and 0.5 ml  
tween 20 was added per litre 
TBST: Prepared as 10x solution. 50 mM TRIS, 150 mM NaCl, pH 7.5. Working solution was prepared by  
1:10 dilution in H2O and 0.5 ml tween 20 was added per litre 
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Ponçeau-S solution:  0.2 % Ponçeau S, 3 % acetic acid in 100 ml ddH2O  
 
 
Protein stability assay 
To determine XIAP protein stability, 2x105 THP1-Blue cells were seeded in 24 well plates in 500 
µl RPMI1640 (containing FCS and P/S). Cells were differentiated over night with 0.1 µM PMA. 
After 24 h, the growth medium was discarded and replaced with 200 µl RPMI1640 (containing 
FCS and P/S). Cells were treated with 0.5 µg/ml cycloheximide (diluted in DMSO) and/or 0.5 
µg/ml BMP-2 (diluted in 4 mM HCl). Untreated control cells were treated with DMSO and/or 
4 mM HCl to ensure equal conditions. After 3 h and 6 h, the medium was discarded and sam-
ples were lysed in 50 µl 2xLaemmli buffer, boiled for 10 min at 95 °C and then subjected to 
SDS-PAGE and Western-blotting to detect XIAP and GAPDH protein levels.  
 
 
Detection of p44/42 activation 
To determine p44/42 MAPK activation in response to BMP-2 treatment, 2x105 THP1-Blue 
cells were seeded in 24 well plates in 500 µl RPMI1640 (containing FCS and P/S). Cells were 
differentiated over night with 0.1 µM PMA. After 24 h, the growth medium was discarded and 
replaced with 200 µl RPMI1640 (containing FCS and P/S). Cells were treated with 0.5 µg/ml 
BMP-2 (diluted in 4 mM HCl) for the indicated time points. Untreated control cells were treated 
with 4 mM HCl to ensure equal conditions. After incubation, the medium was discarded and 
samples were lysed in 50 µl 2xLaemmli buffer, boiled for 10 min at 95 °C and then subjected to 
SDS-PAGE and Western-blotting to detect phospho-p44/42  and total p44/42 protein levels.  
 
 
ELISA 
Secretion of  interleukin 8 (IL-8, CXCL-8) from human cells was measured using enzyme-linked 
immuno absorbent assays (ELISAs) purchased from BD and R&D Systems according to the 
manufacturer’s manuals. Assays were performed in duplicates or triplicates, as indicated. 
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3 Results 
 
3.1 High-throughput siRNA screen to identify factors involved in NOD1 sig-
nalling 
 
To identify factors involved in NOD1-mediated NF-B activation, we conducted a high-
throughput (HT) siRNA screen in human embryonic kidney (HEK293T) cells. HT reverse ge-
netic screens, such as siRNA screens, have the advantage over other screening techniques that 
factors that do not necessarily physically interact with each other can be identified. Typically, the 
first step in a HT siRNA screen is to build a library of  genes of  interest that are to be targeted 
by siRNA. Often, the whole genome of  an organism is targeted, but there are also libraries tar-
geting sub-sets of  genes that are related to certain biological processes or enzymatic functions. 
It should be considered that each gene is targeted by more than one siRNA, as RNAi-based 
methods are prone to off-target effects (reviewed in Singh et al., 2011; Svoboda, 2007). Next, a 
suitable read-out system that allows monitoring of  the phenotypic effect(s) of  siRNA-mediated 
gene-silencing has to be established. This system has to be easy to handle, applicable to auto-
mated procedures and yield highly reproducible results. Typically, more than one biological rep-
licate is conducted, to ensure statistical significance of  the obtained results. For final hit-list gen-
eration, several methods for ranking are available that include simple mean- or median-based 
cutoff  methods and probability-based algorithms (reviewed in Birmingham et al., 2009). Ideally, 
hits are validated in an additional read-out or cell system (reviewed in Moffat and Sabatini, 2006). 
The screening procedure, statistical methods and data handling should be fixed beforehand to 
avoid introduction of  a bias during the data generation and analysis. 
 
First, the well accepted cell-based reportersystem for NOD1 activation in HEK293T cells 
(Girardin et al., 2003c; Inohara et al., 1999) was adapted for siRNA-mediated gene-silencing. To 
test if  the system was suited for HTS approaches, a pilot screen with a smaller sub-library con-
sisting of  418 apoptosis-related genes was conducted (Fig. 5A). In the next step, the human drug-
gable genome library was screened on NOD1-mediated NF-B activation (“primary screen”). 
The druggable genome consists of  6992 genes that are regarded as potential drug targets, based 
on their encoded protein domain structure. A subset of  this library containing hits showing 
effects on NOD1 signalling (“hit library”) was subsequently re-screened on NOD1-mediated 
NF-B activation to validate the hits, and in parallel used for a counter-screen on TNF-α-
mediated NF-B activation to identify factors that are specifically involved in NOD1 signalling. 
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Finally, the hit library was screened for NOD1 activation in the myeloid cell line THP1-Blue. 
Data from all the screening steps was merged to generate a double validated, NOD1-specific 
hit-list (Fig. 5B). 
 
HEK293T screen (druggable genome, 6992 genes)
Preliminary gene-based hit-list (RSA)
TNF-α stimulationTri-DAP stimulation
Selective hit-lists: Tri-DAP + TNF-α specific siRNAs
HEK293T Tri-DAP validation screen and TNF-α
counter-screen (535 hits from screen)
THP1-Blue validation screen (535 hits from screen)
Final validated gene-based NOD1-specific hitlist
n=4, 4 siRNAs/gene
Tri-DAP stimulation
n=4, 2 siRNAs/genen=4, 2 siRNAs/gene
n=4, 2 siRNAs/gene
Tri-DAP stimulation
HEK293T Tri-DAP pilot screen, parallel 
TNF-α counter-screen
(apoptosis library, 418 genes)
TNF-α stimulationTri-DAP stimulation
Selective hit-lists: Tri-DAP + TNF-α specific genes (RSA)
n=3, 2 siRNAs/genen=3, 2 siRNAs/gene
Pilot screen Druggable genome screenA B
HEK293T Tri-DAP validation
(34 inhibiting, 18 activating  genes)
n=4, 4 siRNAs/gene
Tri-DAP stimulation
Final validated gene-based NOD1-specific hit-list
 
 
Figure 5. Schematic overview of the screening projects. A The pilot screen was conducted using the Apop-
tosis V1.0 set siRNA library, each gene was targeted by two siRNAs. The whole library was screened on Tri-
DAP- and TNF-α-mediated NF-B activation and data was merged to generate Tri-DAP/NOD1- and TNF-α-
specific hit-lists. The top 34 NOD1-specific inhibiting and top 18 activating hits were subsequently validated 
using 4 siRNAs per gene. B The druggable genome screen was conducted using the Human Druggable 
Genome set V2.0 siRNA library. The library was first screened on Tri-DAP-mediated NF-B activation and 
gene-based hit-lists were generated by applying the RSA algortithm. The 435 inhibiting and top 100 activat-
ing hits were subsequently validated with two siRNAs that were newly synthesised based on the siRNAs 
that showed the strongest effects in the primary screen. In parallel, a counter-screen on TNF-α-mediated 
NF-B activation was conducted using the same hit-library. Next, the same hit-library was validated in THP1-
Blue cells stimulated with Tri-DAP. Finally, data was merged to generate a validated, NOD1-specific hit-list. 
 
 
 
 
3.1.1 Establishment of the assay system in HEK293T cells 
 
3.1.1.1 Establishment of the reporter system 
In order to quantify the phenotypic effects of  siRNA-mediated knock-down of  a certain gene 
on NOD1-mediated NF-B activation, a reliable and easy-to-perform read-out system was 
needed. We decided to use a cell-based luciferase reportergene assay specific for NF-B activa-
tion. This assay is a modification of  the original luciferase assay (Kain and Ganguly, 2001), and 
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is widely used to decipher basic functions of  the NOD1 and NOD2 signalling cascades 
(Girardin et al., 2003c; Inohara et al., 1999). We recently showed that this system can be used to 
elucidate the function of  candidate NOD regulatory proteins and can be combined with siRNA 
(Bielig et al., 2009; Kufer et al., 2006). The human embryonic kidney cell line HEK293T was 
used, as these cells are quickly growing, easy to culture and can be transfected with very high 
efficiency. Furthermore, HEK293T cells do not have functional TLR signalling that might inter-
fere with the read-out (Kurt-Jones et al., 2004; Brightbill et al., 1999). The cells were transiently 
transfected with the NF-B luciferase reporter plasmid together with a β-galactosidase plasmid 
containing a constitutive promoter, which served for normalisation of  the assay (in the follow-
ing referred to as “reporter system”). As HEK293T cells do not express high levels of  NOD1, 
low amounts of  a NOD1-expression plasmid were co-transfected with the reporter system to 
obtain a higher reactivity towards NOD1 elicitors. We have chosen to specifically activate 
NOD1 using the chemically synthesised minimal NOD1 elicitor Tri-DAP. Using this defined 
compound instead of  living bacteria, such as Shigella flexneri, that naturally trigger NOD1 signal-
ling (Girardin et al., 2001) has the advantage that conditions can be better controlled, leading to 
a higher reproducibility of  the results. Most importantly, this also prevents that pathogen-
specific host factors, such as proteins involved in the invasion process of  S. flexneri, are found as 
hits. To facilitate uptake of  Tri-DAP into the cells, the cells were stimulated directly following 
transfection of  the reporter system, taking advantage of  the transfection reagent for delivery of  
Tri-DAP into the cells, as recenlty described (Girardin et al., 2003c). In order to allow for accu-
mulation of  sufficient amounts of  luciferase enzyme for detection, cells were incubated over 
night (~ 16 h), as the activation ratio was higher than after shorter incubation periods (data not 
shown). 
   The original assay (Girardin et al., 2003c), described for 24 well plates, was scaled down to 96 
well plates and optimised for NOD1 and NOD2 activation. Activation of  the NOD1 reporter 
system with Tri-DAP and of  the NOD2 reporter system with the NOD2-specific elicitor MDP 
induced a strong NF-B activation, dependent on the amounts of  the expression plasmids (Fig. 
6A). The best ratio of  NF-B activation between stimulated cells and non-stimulated cells (spe-
cific activation vs. background caused by auto-activation of  the proteins) was obtained with 0.5 
ng NOD1 plasmid (ratio stimulated/non-stimulated ~40), for the NOD2 plasmid, 0.1 ng per 
well were optimal (ratio stimulated/non-stimulated ~20). With increasing amounts of  trans-
fected plasmids, the ratio decreased due to the tendency of  the NOD proteins to auto-activate. 
Thus, standard conditions for further experiments were defined as 0.5 ng NOD1 plasmid and 
0.1 ng NOD2 plasmid per well.  
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Figure 6. Establishment of the NF-B-luciferase reporter system as read-out for siRNA experiments in 
HEK293T cells. A Titration of the NOD1 and NOD2 expression plasmids. HEK293T cells were transiently 
transfected with a reporter system consisting of a NF-B-luciferase plasmid, a -galactosidase plasmid and 
different amounts of NOD1 or NOD2 expression plasmids. Subsequently, cells were stimulated with 0.5 μl 
Tri-DAP or 50 nM MDP, respectively. After 16 h, cells were lysed and luciferase activation was determined 
and normalised with the -galactosidase values (nRLU). Values are mean +SD (n=3). B-C Establishment of 
the knock-down conditions. 4000 or 3000 HEK293T cells were transfected with 10 or 20 nM CTRL or RELA 
siRNA using 0.6 or 1 μl HiPerFect and incubated for 48 – 72 h. Subsequently, cells were transfected with the 
NF-B luciferase RPS 0.5 ng NOD1 expression plasmid (B), the RPS containing 0.1 ng NOD2 expression 
plasmid (C, upper panel) or the RPS alone (C, lower panel) and stimulated with Tri-DAP (0.5 μM) , MDP (50 
nM) or TNF-α (10 ng/ml), respectively. After 16 h, cells were lysed and luciferase activation was determined 
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and normalised with the -galactosidase values (nRLU). Values are mean +SD (n=3). D Determination of 
knock-down conditions by Western blot. 5000 HEK293T cells were transfected with 20 nM CTRL siRNA or 5, 
10 or 20 nM RELA siRNA using 0.6 or 1 μl HiPerFect. After 72 h, cells were lysed and RELA protein levels were 
determined by Western blot using a RELA-specific antibody. Detection of GAPDH served as loading control. 
RPS: reporter system, nRLU: normalised relative light units 
 
 
 
3.1.1.2 Establishment of the siRNA knock-down conditions 
Next, the siRNA knock-down protocol was established and the parameters cell number, incuba-
tion times and concentrations of  transfection reagent and siRNA were optimised. Again, opti-
mal conditions were established for the NOD1- and for the NOD2-reporter system, as well as 
for stimulation with TNF-α. A siRNA targeting the essential NF-B subunit RELA (v-rel re-
ticuloendotheliosis viral oncogene homolog A; also termed p65) was used as positive control, as 
depletion of  RELA is known to abrogate canonical NF-B signalling regardless of  the triggered 
pathway (reviewed in Hayden and Ghosh, 2008). HEK293T cells were transfected with different 
concentrations of  CTRL or RELA siRNA using 0.6 or 1 µl HiPerFect per well. 24 h after 
siRNA transfection, the growth medium was exchanged in order to minimise toxic effects of  
the transfection reagent. Cells were incubated for 48 h or 72 h prior to transfection of  the re-
porter system, and subsequently stimulated with Tri-DAP, MDP or TNF-α over night. In assays 
using the NOD1 reporter system, a higher knock-down efficiency was achieved using 1 µl 
HiPerFect compared to 0.6 µl HiPerFect. The knock-down efficiency with 20 nM RELA siRNA 
was higher compared to 10 nM siRNA. The 48 h knock-down displayed comparable results to 
the 72 h knock-down (Fig. 6B). For the NOD2 and TNF assay systems, again 20 nM RELA 
siRNA showed a slightly stronger reduction of  NF-B activation compared to 10 nM siRNA. 
In this case, the knock-down efficiency after 48h was clearly higher than after 72h (Fig. 6C).  
   Having demonstrated the phenotypic effect of  the RELA knock-down and the functionality 
of  the combined siRNA and NF-B reportergene assay system, we next validated the effect of  
the RELA knock-down as well on protein level by transfecting HEK293T with different 
amounts of  RELA siRNA using 0.6 or 1 µl HiPerfect per well. Higher cell numbers were used 
to facilitate detection of  RELA on protein level. After 48 or 72 h, cells were lysed and RELA 
protein levels were determined by Western blotting. Knock-down was visible starting at 5 nM 
siRNA, and 1 µl HiPerFect per well induced to a stronger knock-down than 0.6 µl HiPerFect 
(Fig. 6D and data not shown).  
   Taking these results into account, standard operating procedures (SOPs) for the siRNA NF-
B luciferase reportergene assay were defined as follows: 4000 cells per well, 20 nM siRNA, an 
intermediate value of  0.8 µl HiPerFect per well and a knock-down time of  48 h.  
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3.1.1.3 Proof of principle for the differential read-out 
We used TNF-α-stimulation as differential read-out to identify NOD1-specific genes. The TNF 
signalling pathway also leads to activation of  the canonical NF-B pathway, but through a dif-
ferent signalling cascade than NOD1. Stimulation of  cells with TNF-α activates NF-B through 
a cascade involving the TNF receptor TNFR1, the factors TRADD, RIP1 and others. This path-
way converges with the NOD1 signalling cascade at the level of  TAK1 (Fig. 7A) (reviewed in  
Hayden and Ghosh, 2008). To prove the principle of  the differential read-out in our assay sys-
tem, the essential NF-B subunit RELA and the kinase RIP2, which is specific and essential for 
NOD1/2-mediated NF-B activation (Inohara et al., 2000; Bertin et al., 1999; Inohara et al., 
1999; McCarthy et al., 1998) were targeted by siRNA and cells were subsequently transfected 
with the NOD1 NF-B-luciferase reportersystem and stimulated with Tri-DAP or TNF-α. As 
expected, silencing of  RIP2 strongly impaired NF-B activation in response to NOD1 stimula-
tion (Fig. 7B, lower panel), but did not exert a significant effect on TNF-α-mediated NF-B activa-
tion (Fig. 7B, upper panel), whereas knock-down of  RELA strongly inhibited both signalling path-
ways (Fig. 7B). This proved that our assay system was suited to attribute siRNA targets to the 
NOD1 or to the TNF-α signalling pathway. 
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Figure 7. Proof-of-principle for the differential read-out. A Simplified overview of the NOD1 and TNF signal-
ling pathways. The different cascades merge at the stage of TAK1 and induce the canonical NF-B pathway 
(for details see text). B HEK293T cells were transfected with 20 nM CTRL, RELA or RIP2 siRNA and incubated 
for 48 h. Subsequently, cells were transfected with the NF-B luciferase RPS alone (upper panel) or the RPS 
together with 0.5 ng NOD1 expression plasmid (lower panel) and stimulated with TNF-α (10 ng/ml) or Tri-
DAP (0.5 μM), respectively. After 16 h, cells were lysed and luciferase activation was determined and normal-
ised with the -galactosidase values (nRLU). Values are mean +SD (n=3). RPS: reporter system, nRLU: nor-
malised relative light units 
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3.1.1.4 Validation of the assay principle 
In order to get a statistical size that is large enough to draw conclusions on the quality of  the 
assay system, NOD1 NF-B-luciferase reportergene assays were performed with two sets of  
three 96 well plates containing untreated cells (n=30), mock-transfected cells (n=30), cells trans-
fected with non-targeting control siRNA (CTRL) (n=60) and RELA siRNA transfected cells 
(n=30). The first set of  three plates was prepared using the same master mixes (cell suspension, 
siRNA mixes and plasmid mixes) for each plate, for the second set each plate was prepared in-
dependently. The data of  the three plates of  each set was subjected to statistical analyses. First, 
the p-values of  each sample in comparison to the values of  CTRL siRNA-transfected cells were 
calculated using the two-sided student’s T-test. Analysis of  the three dependent plates revealed 
that the values of  non-treated cells and mock-transfected cells did not significantly differ from 
cells treated with CTRL siRNA. In contrast, treatment of  cells with RELA siRNA caused a 
highly significant reduction in NF-B activation (p=1.69x10-31) (Fig. 8A). Next, the Z’-factor was 
calculated. This method is widely used for quality assessment of  assay systems in HTS. The Z’-
factor reflects the assay signal dynamic range as well as the data variation associated with the 
signal measurements (Zhang et al., 1999). It indicates the separation between the positive (c+; 
here: RELA siRNA) and negative controls (c-; here: non-targeting CTRL siRNA). The Z’-factor 
is calculated according to the following formula: 
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The Z’-factor for CTRL vs. RELA was 0.19, which indicated that the assay system was fairly 
stable and suited for high-throughput applications (Birmingham et al., 2009).  
   For the set of  three independent plates, the overall variations in the RELA and non-targeting 
CTRL containing wells were higher, but nevertheless the effect of  the knock-down of  RELA 
compared to CTRL siRNA-treated cells was still highly significant (p=2.5x10-28) (Fig. 8B). The Z’-
factor for CTRL vs. RELA of  -0.09 was lower than for the three dependent plates. Of  note, the 
assay design provided that each single plate was normalised to internal controls during the 
screening. Thus only well-to-well variations were of  crucial importance, plate-to-plate variations 
were aligned during the normalisation process.  
   Taken together, the obtained results indicated that the HEK293T NF-B reporter system was 
suited for HTS. 
 
RESULTS 
 48
A B
N
F-
κB
 [n
RL
U
]
N
F-
κB
 [n
RL
U
]
0
250
500
750
1000
1250
1500
0
250
500
750
1000
1250
1500
1750
2000
n.t. mock siCTRL siRELA n.t. mock siCTRL siRELA
p=0,007
p=0,15
p=2,5E-28
p=0,96 p=0,95
p=1.69E-31
Z’=0.19
Z’=-0.089
 
 
Figure 8. Validation of the NF-B luciferase assay as read-out for siRNA-mediated knock-down in HEK293T 
cells. Cells in three 96 well plates were transfected with CTRL (n=60) or RELA siRNA (n=30), mock-
transfected (n=30) or left untreated (n=30) according to the SOPs using the same master mixes (A) or using 
independent master mixes (B). After 48 h, cells were transfected with the NOD1 RPS and stimulated with Tri-
DAP (0.5 μM). After 16 h, cells were lysed and luciferase activation was determined and normalised with the 
-galactosidase values (nRLU). Data was subjected to statistical analyses. The indicated p-values were calcu-
lated using the two-sided student’s T-test, assay quality was assessed by calculating the Z’-factor. n.t.: non-
treated; RPS: reporter system; nRLU: normalised relative light units 
 
 
 
3.1.1.5 Downscaling and automation of the protocol 
In order to apply the established assay protocol to an automated high-throughput screen, first 
the assay procedure had to be scaled down to the 384 well format. The critical factors (most 
importantly cell number, amount of  NOD1-plasmid and amount of  transfection reagent) were 
re-optimised and some major modifications had to be done in order to match the requirements 
of  the automated screening platform. Thorough testing (data not shown) indicated that 1x103 
cells in 30 µl medium, transfected with 20 nM siRNA in 8 µl medium with 0.25 µl HiPerFect 
were the optimal conditions, and thus used for the whole following screening procedures with 
HEK293T cells (Fig. 9). To enhance reproducibility of  the results, we decided to use exclusively 
cells with a defined passage number of  3 (downscaling was accomplished with the help of  Dr. 
Peter Braun and co-workers, MPIIB Berlin).  
   Furthermore, the protocols for the automated liquid handling and plate processing were de-
signed and optimised (data not shown) (automation of  the procedure was established by Dr. Peter 
Braun and co-workers, MPIIB Berlin).  
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Figure 9: Schematic overview of the NF-B luciferase assay as read-out for siRNA-mediated knock-down in 
HEK293T cells as used for screening. In brief, pre-spotted siRNAs were incubated with medium containing 
HiPerFect. Subsequently, HEK293T cells were reversely transfected by seeding onto the siRNA mixes. 48 h 
later, cells were transfected with the NOD1 reporter system and stimulated with Tri-DAP (0.5 μM) or TNF-α 
(10 ng/ml).  After 16 h, cells were lysed and luciferase activation was determined in parallel to measurement 
of -galactosidase activation. All steps were performed automatically. 
 
 
 
3.1.2 Pilot screen with an apoptosis library 
To test if  the established and optimised automated system was suited for our aimed HTS, a pilot 
screen was performed. We have chosen the apoptosis siRNA set V1 (Qiagen) consisting of  418 
apoptosis-related genes, as there were several recent reports indicating that factors involved in 
the control of  apoptosis also act in inflammatory pathways (Bauler et al., 2008; Bertrand et al., 
2008; Conte et al., 2006). First, the NOD1/Tri-DAP screen was carried out in 384 well plates 
with pre-spotted siRNAs according to the established conditions (screening was performed by 
Dr. Peter Braun and co-workers, MPIIB Berlin). Each gene was covered by two different 
siRNAs and four independent biological replicates were performed in order to increase statisti-
cal validity of  the data. Data was normalised to plate-internal controls. On each plate, RELA 
siRNA served as positive control and non-targeting siRNA as negative control. Furthermore, 
PLK (Polo-like kinase) siRNA was included as control to monitor transfection efficiency, as 
knock-down of  PLK induces cell death in cancer cells (Liu et al., 2006; Liu and Erikson, 2003), 
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which can be monitored by microscopy. Mock-transfected controls were also included. Statisti-
cal analyses confirmed robustness of  the RELA and non-tageting CTRL assay controls and the 
reproducibility of  the results. 
   For plates that met the quality requirements (described in the methods section), first the nor-
malised percent inhibition (NPI) for each sample in relation to the RELA controls was calcu-
lated plate internally (RELA control siRNA: NPI=100, non-targeting CTRL siRNA: NPI=0). 
Then data was normalised by Z-transformation to the overall screen data and individual Z-
scores were calculated for each replicate according to the following formula: 
 

 xz  
 
Toxic samples were removed from the data pool. Definition for toxicity was <60 % -
galactosidase signal compared to the screen-average. Only genes that were covered by at least 
two non-toxic siRNAs were further processed (bioinformatics performed by Dr. Peter Braun, 
MPIIB Berlin).  
   In order to determine if  identified siRNAs were specific to the NOD1 pathway, a counter-
screen with TNF-α-stimulation of  the cells was performed in parallel. The counter-screen also 
covered the whole apoptosis-library and was conducted analogous to the NOD1/Tri-DAP 
screen. Data was processed as described above. Samples differing at least 2 standard deviations 
(SD) of  the CTRL siRNAs from the median of  the CTRL siRNAs (+2 SD: “inhibiting hit 
siRNA”; -2 SD: “activating hit siRNA”) in the respective screen were defined as significant for 
the Tri-DAP/NOD1 or the TNF-α/TNFR1 pathways (Fig. 10A). 
   Final ranking and generation of  gene-based hit-lists was performed using the RSA (redundant 
siRNA activity) algorithm. This method is based on an iterative hypergeometric distribution 
formula and assigns probability (p) values to each gene, based on the behaviour of  the different 
corresponding siRNAs. Thus it accounts for differences in the effects of  multiple siRNAs for 
the same gene: i.e. genes with multiple moderately active wells are weighed more heavily than 
genes with fewer, but highly active wells, minimising the contribution of  off-target effects 
(Konig et al., 2007). By applying the RSA-algorithm to the normalised data sets from the Tri-
DAP/NOD1 screen and the TNF-α counter-screen, gene-based hit-lists were generated. Genes 
with p-values lower than 0.05, according to the RSA analysis, were considered as strong hits. 
Among the inhibiting hits, 24 genes from the Tri-DAP/NOD1 screen and 25 genes from the 
TNF-α counter-screen fulfilled these criteria. The hit-lists were merged and NOD1- and TNF-
α-specific hit-lists were generated by excluding factors appearing in both lists (12 factors in total) 
(Fig. 10B). Furthermore, a hit-list containing genes that were found in both of  the screening steps 
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was generated (NF-B associated hits) (Fig. 10B). In total, out of  24 hits from the Tri-
DAP/NOD1 screen, 12 were also positive in the TNF-α counter-screen. Of  note, we were able 
to identify many genes that are well established to be critically involved in the canonical NF-B 
and the NOD1 signalling cascades, such as RELA, p50, CUL1, RIP2, TAK1 or TNFR1, among 
the inhibiting hits (Fig. 10B).  
 
Rank Gene p value
1 RIPK2 2,60E-05
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Figure 10. Results of the pilot screen. A Data from the Tri-DAP-screen was merged with data from the TNF-
α counter-screen to identify factors that are specifically involved in NOD1-signalling. Each dot represents 
the median Z-scores after NPI-normalisation (Normalised Percent Inhibition) to the plate-internal RELA-
controls for the single siRNAs, Tri-DAP/NOD1 activation is plotted on the x-axis, the corresponding TNF-
α/TNFR1 values are plotted on the y-axis. A positive value represents an inhibitory effect of the respective 
siRNA on NF-B activation, siRNAs activating NF-B activation are represented by negative values. Samples 
differing at least 2 SD of CTRL from the median of the CTRL siRNAs of the respective screen were defined as 
significant for Tri-DAP or TNF-α. B Gene-based hit-lists displaying strong (p <0.05) Tri-DAP-specific, TNF-α-
specific and non-specific hits according to the RSA algorithm. Bold: Hits that could be validated C STRING 
database analysis of the validated Tri-DAP-specific and NF-B-associated hits. Genes, where the NPI values 
of at least two out of four siRNAs exceeded 2 SD of CTRL from the median of CTRL were regarded as vali-
dated. Genes were clustered according to the Marcov cluster (MCL) algorithm. Stronger associations are 
represented by thicker blue lines. 
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   The same procedure was applied to the activating hits as well. In total, out of  34 activating 
hits from the Tri-DAP/NOD1 screen, 16 were also positive in the TNF-α counter-screen (data 
not shown).  
   Finally, the top NF-B inhibiting hits from the Tri-DAP/NOD1 screen, including the 24 
genes with p-values below 0.05, and the next 10 genes with less significant RSA scores from this 
list were validated with a set of four different siRNAs, consisting of the two sequences already 
used in the screen and two new sequences, to knock down gene function individually. The assay 
procedure was repeated four times individually, Z-scores were calculated and genes were ranked 
according to the RSA algorithm. Genes, where NPI values of at least two out of the four 
siRNAs exceeded 2 SD of CTRL from the median of CTRL were regarded as validated. In total, 
25 out of the 34 NF-B inhibiting genes from the Tri-DAP/NOD1 screen could be validated. 
Among those, 14 genes were specific for the NOD1 pathway, as compared with the TNF-
specific RSA list. STRING database analysis revealed that there are several known and predicted 
functional and physical interactions between the identified non-specific and NOD1-specific 
factors (Fig. 10C). 
   Moreover, the top 18 NF-B activating hits were validated according to the same procedure. 
However, out of the 18 hits, only three could be validated with at least 2 siRNAs below -2 SD 
of CTRL from the median of CTRL (data not shown). For that reason we decided to focus on the 
inhibiting hits in the further screening steps. 
 
 
3.1.3 Druggable genome screen 
 
3.1.3.1 Primary druggable genome screen 
In the next step, we conducted the HT screen with the druggable genome siRNA set V2.0 li-
brary (Qiagen) consisting of  6992 genes, each represented by four individual siRNAs. The li-
brary was screened for NOD1-mediated NF-B activation induced by Tri-DAP in four inde-
pendent biological replicates (Fig. 5B). Normalisation, quality control and data processing were 
conducted as described for the pilot screen (screening and bioinformatics performed by Dr. 
Peter Braun and co-workers, MPIIB Berlin). Statistical analyses confirmed robustness of  our 
assay controls (RELA and the non-targeting AllStars siRNA) and reproducibility of  the results 
(average correlation of  the four replicates: 0.65). siRNAs with at least 2 functional biological 
replicates were subjected to the RSA algorithm to generate a gene-based hit-list. In total, 435 
genes where silencing inhibited NF-B activation were identified as hits by fulfilling two criteria: 
RESULTS 
 53
(I) a minimum of  2 siRNAs per gene were identified as hits by the RSA algorithm (“preliminary 
hit siRNAs”) and (II) the gene-specific p-value was below 0.06. According to the same parame-
ters, 379 genes were identified that activated NF-B activation upon siRNA-mediated knock-
down (Fig. 11A). 
   Of  note, the RSA-based ranking identified many factors that are known to be involved in the 
NOD1 pathway or canonical NF-B signalling, such as RIP2, RNF31, IKKα, IKK, p50 and 
RELA. Furthermore, the known general negative regulators of  canonical NF-B signalling A20 
and CYLD were identified as activating hits. The gene-based hit-lists were then used to compile 
an siRNA library consisting of  the 435 inhibiting and the top 100 activating hits from the RSA 
ranking for subsequent validation and TNF-α counter-screening. To create this library, the two 
siRNAs from the primary screen that displayed the strongest effects were re-synthesised and 
spotted on 384 well plates. 
 
 
3.1.3.2 Validation and TNF-α counter-screen 
To validate the hit-lists generated from the druggable genome screen, and to allow for identifi-
cation of  NOD1-specific factors, a validation- and counter-screen was performed. The hit li-
brary consisting of  the 435 inhibiting and the top 100 activating hits identified in the druggable 
genome screen was screened according to the previously used conditions in four independent 
biological replicates. Cells were stimulated with Tri-DAP to validate the hits from the druggable 
genome screen. In parallel, the same library was screened in cells stimulated with TNF-α.  
   Aligning the data from the Tri-DAP-stimulated cells with the data from the TNF-α-stimulated 
cells allowed extraction of  hits specific for either the NOD1- or the TNFR-signalling cascade, i.e. 
factors that act upstream of  TAK1 in the corresponding pathway (Fig. 11B). Of  note, the Tri-
DAP results of  the counter-screen showed a high reproducibility of  the primary screen (correla-
tion coefficient 0.77). The overall hit-list comprised 173 genes inhibiting NF-B activation when 
silenced (1-2 siRNAs >2 SD in Tri-DAP validation), among those, 66 genes were specific for 
Tri-DAP/NOD1 (1-2 siRNAs <2 SD in TNF-α counter-screen). All of  the hit-lists contained 
factors with known functions in the NOD1 pathway or directly linked to NF-B signalling. Top 
NOD1-specific hits comprised RIP2, GALK2, XIAP, KLK8, MSH3 and KIF22 (2 siRNAs >2 
SD in Tri-DAP validation, no TNF-α hit).  
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Figure 11. Results of the druggable genome screen in HEK293T cells. A Distribution of the siRNAs in the 
primary druggable genome screen. Each dot represents the median Z-score of the experimental replicates 
after NPI-normalisation (Normalised Percent Inhibition) to the plate-internal RELA-controls. A positive value 
represents an inhibitory effect of the respective siRNA on NF-B activation. Preliminary hit-siRNAs are de-
fined by the RSA (redundant siRNA activity) algorithm. B Data from the Tri-DAP-validation screen was 
merged with data from the TNF-α counter-screen to identify factors that are specifically involved in NOD1-
signalling. The graph displays the Z-scores for the single siRNAs, Tri-DAP/NOD1 activation is plotted on the 
x-axis, corresponding TNF-α values are plotted on the y-axis. Samples differing at least 2 SD of CTRL from 
the median of the CTRL siRNAs of the respective screen were defined as significant for Tri-DAP or TNF-α. 
CTRL: non-targeting control siRNAs. 
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3.1.4 THP1-Blue validation screen 
 
3.1.4.1 Assay setup, downscaling and automation 
In order to validate the hits in a more physiological system, we conducted a final validation 
screen on endogenous NOD1 activation in myeloid THP1-Blue cells. THP1-Blue cells are de-
rivatives of  the human monocytic cell line THP-1 that contain a NF-B-inducible secreted alka-
line phosphatase (SEAP) reportergene. In contrast to HEK293T cells, THP1 cells express func-
tional endogenous NOD1 and are reactive towards Tri-DAP (Uehara et al., 2005). THP-1 and 
THP1-Blue cells can be differentiated into adherent macrophage-like cells by stimulation with 
phorbol 12-myristate 13-acetate (PMA).  
 
In order to apply the THP1-Blue assay for HTS using our pre-spotted siRNA plates, a suitable 
protocol had to be established. To this end, a previously described THP1-Blue siRNA assay 
(Bielig et al., 2011b) was first performed in 96 well plates to test if  down-scaling is possible with 
this system, as this assay is typically performed in 24 well plates. This required re-adjustment of  
the cell number and the volume of  medium in which the transfection was performed. For that 
purpose, different cell numbers were transfected with CTRL or RELA siRNA in the presence 
of  PMA. Growth medium was exchanged twice a day to remove excess SEAP induced by 
stimulation with PMA. After 72 h, cells were stimulated with LPS over night, as LPS induces a 
stronger SEAP-secretion than NOD1-elicitors. The best knock-down effect of  the RELA 
siRNA was observed with 1x104 cells, but the measured SEAP-induction was rather low. With 
2x104 cells, the read-out was more robust and the knock-down effect of  the RELA siRNA was 
still very pronounced, albeit lower than with 1x104 cells (Fig. 12A).  
   Next, it was tested if  reverse transfections, which were required for the automated platform, 
were possible in this system, and which elicitor was suited best to stimulate NOD1. To this end, 
cells were reversely transfected with CTRL, RELA or NOD1 siRNA. After 72 h, cells were 
stimulated with Tri-DAP or C12-ieDAP over night. C12-ieDAP consists of  the minimal motif  
required for NOD1 stimulation that additionally contains a lipophilic group that facilitates entry 
into cells and was tested in this setting, because it induces a stronger NOD1 activation in THP1 
cells (data not shown). To normalise the obtained data for cell death induced by toxic side effects 
of  siRNAs, we decided to include cell viability assays using the XTT system as additional read-
out system. The SEAP read-out indicated that stimulation with C12-ieDAP induced a stronger 
NF-B activation than stimulation with Tri-DAP, as expected (Fig. 12B, upper panel). Of  note, a 
robust SEAP secretion was only observed with 2x104 cells per well, SEAP-levels measured with 
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1x104 cells per well were hardly above the background level (Fig. 12B, upper panel), correlating 
with the XTT read-out (Fig. 12B, lower panel). 
   Collectively, these results indicated that downscaling of  the siRNA THP1-Blue assay proce-
dure and reverse transfections were possible, the next step was to scale the assay further down 
based on these optimised parameters. 
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Figure 12. Downscaling to 96 well and re-optimisation of the THP1-Blue siRNA assay. A Titration of the cell 
numbers. Either 1x104, 2x104 or 3x104 THP1-Blue cells were seeded in 20 μl medium, or 2x104 cells were 
seeded in 40 μl medium in 96 well plates and transfected with 20 nM CTRL or RELA siRNA. Cells were differ-
entiated with 0.1 μM PMA 10 min after transfection. After 72 h, cells were stimulated with LPS (100 ng/ml), 
16 h later, NF-B activation was determined by measurement of SEAP activation from the supernatants at 
OD620. Values are OD620, mean +SD (n=3). B Assessment of different elicitors to stimulate NOD1-mediated  
NF-B activation. Either 1x104 or 2x104 THP1-Blue cells in 20 μl medium containing 0.1 μM PMA were re-
versely transfected with 20 nM CTRL, RELA or NOD1 siRNA in 96 well plates. After 72 h, cells were stimulated 
with Tri-DAP or C12-ieDAP (10 μg/ml each), 16 h later, NF-B activation was determined by measurement of 
SEAP activity in the supernatants. (upper panel). Values are OD600, mean +SD (n=3). In parallel, cell viability 
was determined by XTT assays (lower panel). Values are OD450, mean +SD (n=3). 
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   For downscaling to the 384 well format, the same automated workstation was used as for 
screening, and cell number and amount of  transfection reagent were optimised. Cells were in 
parallel stimulated with C12-ieDAP and Tri-DAP. Aditionally, cell viability was measured after 16 
h using the XTT assay to normalise the data. Data was subjected to statistical analysis using the 
Z’-method. The results indicated that stimulation with C12-ieDAP induced a ~3 fold higher 
SEAP activation than stimulation with Tri-DAP. But the effect of  the RELA and NOD1 knock-
downs were much less pronounced with C12-ieDAP stimulation compared to stimulation with 
Tri-DAP. The best results were obtained using 6.5x103 cells per well, as lower cell numbers dis-
played a weak signal-to-noise ratio (data not shown).  
   In order to decide which stimulus to use in the screen, we performed further test assays. Also 
the optimal amount of  HiPerFect was titrated. In all cases, C12-ieDAP induced a much stronger 
NF-B activation, but the observed knock-down effects were less pronounced compared to Tri-
DAP as stimulus. Moreover, standard deviations were much higher when using C12-ieDAP 
compared to Tri-DAP. Thus we decided to use Tri-DAP as stimulus for further testing and for 
the screen (Fig. 13A). 
   As Tri-DAP is a weaker inducer of  SEAP compared to C12-ieDAP, the cell number was re-
adjusted to yield a more robust read-out. For that purpose, different cell numbers were trans-
fected using 0.2 or 0.25 µl HiPerFect per well and stimulated with Tri-DAP after 72 h. The re-
sults indicated that 8x103 cells per well, transfected using 0.25 µl HiPerFect, were optimal among 
the tested conditions, showing the best knock-down effects for the RELA and NOD1 siRNAs, 
the highest signal-to-noise ratio, the lowest standard deviations and the best Z’-factor 
(CTRL/NOD1: 0.14) (Fig. 13B). 
   In the final pilot experiment, the read-out conditions and the cell culture volume for the Tri-
DAP stimulation were optimised. Optimal results were obtained using a volume of  15 µl, of  
which 10 µl were used for the QUANTI-Blue measurement. The optimal incubation time for 
the QUANTI-Blue assay was 6 h, for the XTT assay 2 h proved to be optimal (data not shown).  
   According to these experiments, SOPs were defined as indicated in the materials and methods 
section (Fig. 14) (down-scaling to 384 well was accomplished with the help of  Dr. Peter Braun 
and co-workers at the MPIIB Berlin).  
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Figure 13: Downscaling to 384 well and re-establishment of the THP1-Blue siRNA assay. A Assessment of 
different elicitors to stimulate NOD1-mediated NF-B activation. 6500 cells were reversely transfected with 
20 nM CTRL, RELA or NOD1 siRNA using 0.1, 0.2 or 0.3 μl HiPerFect. Cells were incubated for 72 h and subse-
quently stimulated with C12-ieDAP or Tri-DAP (10 μg/ml each), 16 h later, NF-B activation was determined 
by measurement of SEAP activation from the supernatants at OD600. In parallel, cell viability was assessed 
by XTT assays. Values are OD600 normalised with XTT values, mean +SD (n=16). B Titration of the cell num-
bers. 5000, 6500, 8000 or 10000 cells were reversely transfected with 20 nM CTRL, RELA or NOD1 siRNA 
using 0.2 or 0.25 μl HiPerFect. Cells were incubated for 72 h and subsequently stimulated with Tri-DAP (10 
μg/ml), 16 h later, NF-B activation was determined by measurement of SEAP activity in the supernatants. In 
parallel, cell viability was assessed by XTT assays. Values are OD600 normalised with XTT values [nQB], mean 
+SD (n=16). 
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Figure 14: Schematic overview of the THP1-Blue assay as read-out for siRNA-mediated knock-down as used 
for the validation screen. In brief, pre-spotted siRNAs were incubated with medium containing HiPerFect. 
Subsequently, THP1-Blue cells were reversely transfected by seeding onto the siRNA mixes. Cells were 
washed twice a day for 72 h and subsequently stimulated with Tri-DAP (10 μg/ml).  After 16 h, NF-B activa-
tion was determined by measurement of SEAP activity in the supernatants. In parallel, cell viability was as-
sessed by XTT assays.  
 
 
3.1.4.2 THP1 screen and results 
For the validation in THP1-Blue cells, our hit-library consisting of  the 435 inhibiting and the 
top 100 activating hits identified in the primary screen was screened in four independent bio-
logical replicates. In brief, 8x103 THP1-Blue cells were seeded onto the pre-spotted siRNAs 
(final concentration of  20 nM) in the presence of  0.25 µl HiPerFect transfection reagent in 384-
well plates and treated with PMA. Cells were washed twice a day to get rid of  excess SEAP in-
duced by stimulation of  the cells with PMA. After 72 h, cells were stimulated with Tri-DAP and 
NF-B activation was measured 16 h later by SEAP-detection from the supernatants. To nor-
malise for toxic effects, XTT cell viability assays were performed in parallel (Fig. 14). In this 
screen we used siRNAs directed against NOD1 as positive controls (set to 100% NF-B inhibi-
tion), as the effect of  a knock-down of  RELA in these cells was not as pronounced compared 
to the effect in HEK293T cells (Fig. 12 and 13). Data was normalised by Z-transformation to the 
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overall screen data, individual Z-scores were calculated for each replicate (Fig. 15) (screening was 
performed by Dr. Peter Braun and co-workers, MPIIB Berlin). In total, 28 genes with two 
siRNAs inhibiting Tri-DAP-induced NF-B activation (> 1.5 SD) could be identified (Fig. 22D). 
Among those, RIP2, NOD1, RELA, XIAP, DTX4, CALR, OR12D2 and RNF31 were the 
strongest hits (> 3 S.D).  
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Figure 15. Distribution of the siRNAs in the THP1-Blue validation screen. Each dot represents the median Z-
score of the experimental replicates after NPI-normalisation (Normalised Percent Inhibition) to the plate-
internal NOD1-controls. A positive value represents an inhibitory effect of the respective siRNA on NF-B 
activation. THP1 hit-siRNAs are defined as exceeding 1.5 SD of CTRL from the median of the CTRL siRNAs. 
CTRL: non-targeting controls. 
 
 
3.1.5 Final hitlist generation 
The primary druggable genome screen yielded 435 preliminary inhibiting hits with p-values be-
low 0.06, according to the RSA analysis. These preliminary hits were subsequently validated in 
HEK293T cells using two different siRNAs to target each gene. In total, 173 genes inhibiting 
NF-B activation when silenced could be validated (1-2 siRNAs per gene >2 SD), among them 
66 genes were specific for Tri-DAP/NOD1 (1-2 siRNAs per gene <2 SD in TNF-α counter-
screen) (Fig. 16A).  
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Primary screen: HEK293T +Tri-DAP
druggable genome library: 6992 genes
435 preliminary hits (knock-down
reduces NF-κB activation)
Validation screen: HEK293T
  +Tri-DAP 
Counter screen: HEK293T
+ TNF-α 
Validation screen: THP1-Blue
+Tri-DAP
173 Tri-DAP  hits
(HEK293T)
168 TNF-α hits
(HEK293T)
28 Tri-DAP hits
(THP1)
66 NOD1-specific hits
in HEK293T 
18 NOD1-specific hits
in THP1
n=4, 4 siRNAs/gene
n=4, 2 siRNAs/gene
A
B
6 overlapping
genes
Rank Gene Best Mean Best Mean Best Mean Best Mean
CTRL -0.13 -0.13 -0.621 -0.621 -0.64 -0.64 -0.71 -0.71
1 RIPK2 2.11 2.11 2.44 2.40 0.02 -0.14 2.59 2.33
2 XIAP 1.67 1.65 1.56 1.56 -1.17 -1.17 2.03 1.81
3 DTX4 1.74 1.40 -0.59 -0.59 -0.35 -0.35 1.95 1.29
4 PFKFB2 1.33 1.17 0.5 -0.50 -1.06 -0.77 1.76 1.23
5 ARID1A 1.77 1.43 -0.26 -0.26 0.51 0.51 1.63 1.46
6 GPR17 1.32 1.30 1.18 1.18 0.63 0.63 1.52 1.28
7 ANAPC1 1.30 1.20 n.d. n.d. n.d. n.d. 1.49 1.19
8 CUBN 1.53 1.39 0.27 0.27 0.44 0.44 1.24 1.02
9 SSH1 1.27 1.14 0.87 0.87 0.51 0.51 1.03 0.90
10 SNAI1 1.46 1.31 1.4 -0.16 -1.58 -1.58 1.01 0.82
11 GCLM 1.20 1.16 -0.57 -0.66 0.48 0.08 0.88 0.84
12 DDI2 1.43 1.26 0.37 -0.25 0.09 0.04 0.85 0.85
13 SETD1A 1.58 1.32 0.29 0.04 0.39 0.13 0.85 0.74
14 PATE1 1.37 1.23 0.47 0.41 0.24 0.19 0.83 0.83
15 EXT2 1.77 1.48 0.64 -0.80 0.44 -0.49 0.79 0.74
16 CHUK 1.20 1.11 0.83 0.71 0.36 0.19 0.78 0.70
17 OPRL1 1.54 1.47 0 0 0.58 0.58 0.78 0.74
18 FNTB 1.15 1.07 -1.07 -1.94 -1.20 -1.20 0.72 0.69
Druggable genome screen HEK validation Counter-screen THP1 validation
(Tri-DAP) (Tri-DAP) (Tri-DAP)(TNF-α )
 
 
Figure 16. Final ranking of the inhibiting screen hits. A Schematic representation of the siRNA screening 
procedure including the numbers of identified hit genes for the respective screening steps. 435 preliminary 
hit genes from the primary druggable genome screen were re-tested in three different settings. After differ-
ential analysis of the validation screens and the counter-screen, 66 and 18 genes could be validated as 
NOD1-specific in HEK293T or THP1 cells, respectively. Of those, 6 were involved in NOD1-specific signaling 
in both cell lines.  B Final hit-list of genes specifically involved in NOD1-dependent NF-B activation. Ranked 
to the results of the THP1 screen (best score). Bold: NOD1-specific genes also validated in the HEK293T Tri-
DAP validation screen. 
 
 
   To rule out the possibility that the obtained hits were cell-type specific regulators, the same 
library was subsequently used for a validation screen in THP1 cells. In this screen, 28 genes 
were regarded as significant hits (2 siRNAs per gene >1.5 SD), among those, 18 were specific 
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for NOD1 signalling, as compared with the results of the TNF-α screen (Fig. 16A, B). Although 
the hit-list achieved in THP1 cells differed from the one from HEK293T cells, the genes RIP2, 
XIAP, GPR17, SSH1, SNAI1, and CHUK could be confirmed as hits in all screening rounds in 
both cell lines and did not show an inhibiting effect in the TNF-α counter screen (Fig. 16B).  
 
 
3.1.6 Hit validation: XIAP 
Beside RIP2, XIAP was the top hit in the final ranking that takes into account all steps of  the 
screening procedure (Fig. 17A). XIAP (X-linked inhibitor of  apoptosis, also termed BIRC4) is a 
protein belonging to the BIRC family that is known to exert strong anti-apoptotic functions. 
Beside its important role in counter-acting apoptosis, it has also been attributed to other func-
tions. Of  note, there are recent reports linking XIAP to functions in innate immunity (Krieg et 
al., 2009; Bauler et al., 2008). 
   In order to validate the predicted role of  XIAP in NOD1 signalling, we first performed 
knock-down experiments in HEK293T cells using a different siRNA than in the screen. To this 
end, cells were transfected with XIAP-specific siRNA or non-targeting CTRL siRNA in 96 well 
plates for 48 h, then the NF-B-luciferase reporter system containing NOD1 or NOD2 expres-
sion plasmids was transfected and cells were stimulated with Tri-DAP or MDP, respectively.  In 
line with the data obtained in the screen, knock-down of  XIAP strongly reduced NOD1-
mediated NF-B-luciferase activation (Fig. 17B, left panel). Of  note, also NOD2-mediated NF-B 
activation was strongly impaired by knock-down of  XIAP, indicating a role for XIAP as well in 
NOD2 signalling (Fig. 17B, right panel). Importantly, this siRNA largely reduced XIAP protein 
levels, as judged by Western blot analysis, confirming the functionality of  this siRNA (Fig. 17C).  
   To expand the analysis to another cell type, additional siRNA experiments were performed in 
human myeloid THP1-Blue cells. THP1-Blue cells differentiated with PMA were transfected 
with CTRL, NOD1, NOD2 or XIAP siRNA and stimulated with Tri-DAP or MDP, or left un-
treated. The NOD1 and NOD2 positive controls clearly reflect the functionality of  the assay 
system: Knock-down of  NOD1 selectively impaired Tri-DAP-mediated NF-B activation, 
whereas knock-down of  NOD2 selectively impaired MDP-mediated NF-B activation. In con-
trast, knock-down of  XIAP reduced both Tri-DAP- and MDP-induced NF-B activation to 
background levels, supporting the essential role for XIAP in both of  the pathways and confirm-
ing the results from the screen (Fig. 17D). Measurement of  IL-8 (CXCL-8) in the supernatants of  
the same cells revealed that IL-8 secretion in response to Tri-DAP and MDP stimulation was 
also strongly impaired by knock-down of  XIAP (Fig.17E).  
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   In order to validate the effect of  XIAP knock-down on NOD1 signalling in a more physio-
logical system, we performed infection experiments with epithelial HeLa cells stably expressing 
short hairpin RNA (shRNA) targeting XIAP. For that purpose, HeLaWT, HeLashSCR cells (ex-
pressing a non-targeting control shRNA) and HeLashXIAP cells were infected with the invasive 
Gram-negative pathogen Shigella flexneri (strain M90T afaE). This strain is known to induce 
NOD1-specific NF-B and cytokine responses (Girardin et al., 2001). As control, cells were 
infected with the non-invasive (virulence plasmid cured) S. flexneri strain BS176. Infection of  
HeLaWT and HeLashSCR cells with M90T induced a strong IL-8 secretion. IL-8 secretion in re-
sponse to M90T was strongly impaired in HeLashXIAP cells compared to HeLaWT and HeLashSCR 
cells. Moreover, over-expression of  Myc-XIAP in HeLashXIAP cells fully restored M90T-induced 
IL-8 secretion, clearly confirming an essential role for XIAP in NOD1 signalling (Fig. 17F). In-
fection with the non-invasive strain BS176, in contrast, did not induce IL-8 secretion in any of  
the cell lines (experiments with shRNA cell lines were performed by Maureen Menning, Univer-
sity of  Cologne). 
   The mitochondrial protein SMAC is known to inhibit XIAP by direct binding (reviewed in 
Riedl and Salvesen, 2007). Of  note, expression of  a truncated version of  SMAC that localises to 
the cytoplasm (SMACMTS) potently inhibited NOD1-mediated NF-B activation in a dose-
dependent manner in the HEK293T reporter system. In this setting, also NF-B activation trig-
gered by over-expression of  RIP2 was inhibited by expression of  SMACMTS (Fig. 17 G), pro-
viding further evidence that XIAP is essential for NOD1 signalling. In contrast, NF-B activa-
tion triggered by over-expression of  IKK was not inhibited by expression of  SMACMTS, 
indicating that XIAP acts upstream of  the IKK complex in the NOD1 signalling cascade (Fig. 
17G). 
   Collectively, these findings confirmed the results obtained in the screen and revealed that 
XIAP is essentially involved in NOD1-mediated NF-B activation and IL-8 secretion in epithe-
lial and myeloid-like cells. Furthermore, we provide evidence for an important role for XIAP 
also in NOD2 signalling. 
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Figure 17. Validation of the role of XIAP in NOD1 signalling. A Screening results for XIAP in the different 
screening steps. B HEK293T cells were transfected with CTRL or XIAP siRNA and incubated for 48 h. Subse-
quently, cells were transfected with the NF-B luciferase RPS containing NOD1 (left panel) or NOD2 (right 
panel) expression plasmids and stimulated with Tri-DAP (0.5 μM) or MDP (50 nM), respectively. After 16 h, 
cells were lysed, luciferase activation was determined and normalised with the -galactosidase values 
(nRLU). Values are mean +SD (n=3). C Confirmation of the XIAP knock-down on protein level. HEK293T cells 
were transfected with CTRL or XIAP siRNA. After 72 h, cells were lysed and XIAP protein levels were deter-
mined by Western blot using a XIAP-specific antibody. Detection of GAPDH served as loading control. D 
Differentiated THP1-Blue cells were transfected with CTRL, NOD1, NOD2 or XIAP siRNA. Cells were incu-
bated for 72 h and subsequently stimulated with Tri-DAP or MDP (10 μg/ml each), 16 h later, NF-B activa-
tion was determined by measurement of SEAP activity in the supernatants. In parallel, IL-8 secretion was 
determined by ELISA (E). Values are NF-B activation [OD620] or IL-8 secretion [pg/ml], respectively, mean 
+SD (CTRL, XIAP: n=3; NOD1, NOD2: n=2). Data is representative for at least 3 idependent experiments. F 
HeLaWT, HeLashSCR or HeLashXIAP were incubated for 24 h and subsequently infected with Shigella flexneri 
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BS176 or M90T for 6 h. IL-8 secretion was determined by ELISA. Values are IL-8 secretion [pg/ml], mean +SD 
(n=2). G HEK293T were transfected with the NF-B luciferase RPS containing NOD1 (left panel), RIP2 (5 ng) 
(middle panel) or IKK (5 ng) (right panel) expression plasmids. The indicated amounts of SMACMTS were 
co-expressed. NOD1 transfected cells were subsequently stimulated with Tri-DAP (0.5 μM). After 16 h, cells 
were lysed and luciferase activation was determined and normalised with the -galactosidase values (nRLU). 
Values are mean +SD (n=3). Data is representative for 3 independent experiments. nRLU: normalised rela-
tive light units 
 
 
 
3.1.7 Hit validation: BMPR-2 
The bone morphogenetic receptor 2 (BMPR-2) is a receptor for growth factors of  the trans-
forming growth factor  (TGF-) superfamily (reviewed in Miyazono et al., 2005). Intriguingly, 
it has been shown that BMPR-2 interacts with XIAP and stabilises XIAP protein levels under 
serum starvation conditions (Liu et al., 2009). For that reason we decided to validate the role for 
BMPR-2 in NOD1 signalling clearly indicated by our screen data, even though BMPR-2 was not 
among the top inhibiting hits. Still, in the druggable genome screen, most siRNAs targeting 
BMPR-2 stably displayed clear inhibiting effects on NOD1-mediated NF-B-luciferase activa-
tion, and this was confirmed in the HEK293T validation screen. In contrast, depletion of  
BMPR-2 did not exert any effect in the TNF-α counter-screen, indicating that BMPR-2 specifi-
cally acts on the NOD1 signalling pathway. In the THP1 validation screen, again one of  the 
siRNAs (BMPR2_6) inhibited NOD1-mediated NF-B activation. Surprisingly, another siRNA 
(BMPR2_4) induced a slight increase in NF-B activation in these cells (Fig. 18A). Although this 
was likely an off-target effect, owing to the strict parameters for ranking this led to exclusion of  
BMPR-2 from the final hit-list. 
   As it has been described that BMPR-2 might be expressed cell type specifically (Liu et al., 
2009), expression of  BMPR-2 in several myeloid and non-myeloid cell lines was assessed by RT-
PCR. This revealed that BMPR-2 is expressed in HEK293T and HeLa cells, in myeloid THP1 
and Jurkat cells and also in the colon epithelial cell line TC-7/CaCo2 (Fig. 18B). Next, siRNA 
knock-down experiments in HeLa cells were performed to confirm the data obtained in the 
screen. Treatment of  HeLa cells with two different siRNAs targeting BMPR-2 strongly impaired 
IL-8 secretion induced by infection with invasive S. flexneri M90T (Fig. 18C, upper panel). Infection 
of  cells with the non-invasive S. flexneri strain BS176, in contrast, did not lead to secretion of  
detectable amounts of  IL-8 (data not shown). Knock-down of  the validated screen hit XIAP was 
used as positive control. RT-PCR using cDNA transcribed from RNA isolated from cells of  the 
same experiment confirmed that both siRNAs targeting BMPR-2 efficiently reduced BMPR-2 
mRNA levels (Fig. 18C, lower panel).   
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Figure 18. Validation and characterisation of the role of BMPR-2 in NOD1 signalling. A Screening results for 
BMPR-2 in the different screening steps. B Expression of BMPR-2 in different cell lines, determined by RT-
PCR with BMPR-2-specific primers. GAPDH expression levels served as loading control. C Knock-down of 
BMPR-2 in HeLa cells. Cells were transfected with CTRL, XIAP or BMPR-2 siRNA and incubated for 72 h. Sub-
sequently, cells were infected with Shigella flexneri M90T and IL-8 secretion was determined 6 h after infec-
tion by ELISA (upper panel). Values are mean +SD (n=2). Knock-down efficiency was determined by RT-PCR 
using BMPR-2-specific primers and cDNA transcribed from RNA isolated from cells of the same experiment. 
RT-PCR with GAPDH-specific primers served as control (lower panel). D Knock-down of BMPR-2 in THP1-Blue 
cells. Differentiated THP1-Blue cells were transfected with CTRL, XIAP or BMPR-2 siRNA and incubated for 72 
h. Subsequently, cells were stimulated with Tri-DAP (10 μg/ml) and IL-8 secretion was determined after 16 h 
incubation by ELISA (left panel). Values are mean +SD (n=2). Data is representative for two independent 
RESULTS 
 67
experiments. Knock-down efficiency was determined by qRT-PCR using BMPR-2-specific primers and cDNA 
transcribed from RNA isolated from cells of the same experiment. Data was normalised to GAPDH-levels 
(right panel). Data is representative for two independent experiments. E Differentiated THP1-Blue cells were 
treated with 0.5 μg/ml cycloheximide and/or 0.5 μg/ml recombinant BMP-2 for 3 h or 6 h. Cells were lysed 
and XIAP protein levels were determined by Western blot using a XIAP-specific antibody. Detection of 
GAPDH served as loading control (upper panels). Densitometric quantification of two independent experi-
ments (XIAP/GAPDH, +SD) (lower panels). F Differentiated THP1-Blue cells were treated 0.5 μg/ml recombi-
nant BMP-2 for the indicated time points. Cells were lysed and phospho-p44/42 protein levels were deter-
mined by Western blot using a phospho-p44/42-specific antibody. Detection of total p44/42 levels served 
as loading control. Data is representative for 2 independent experiments. 
 
 
   In order to further confirm the involvement of  BMPR-2 in NOD1 signalling in another set-
ting, knock-down experiments in myeloid THP1-Blue cells were performed. Knock-down of  
BMPR-2 with two different siRNAs impaired Tri-DAP induced IL-8 secretion in THP1-Blue 
cells (Fig. 18D, left panel). Quantitative PCR using cDNA transcribed from RNA isolated from 
cells of  the same experiment confirmed that both siRNAs highly efficiently reduced BMPR-2 
mRNA levels in THP1-Blue cells (Fig. 18D, right panel). Collectively, these results strongly support 
a role for BMPR-2 in NOD1 signalling. Preliminary data from knock-down experiments in 
THP1-Blue cells indicated that BMPR-2 might also be involved in NOD2 signalling (data not 
shown).  
   Recently, it has been described that treatment of  mouse embryonic fibroblasts (MEFs) with 
the BMPR-2 ligands BMP-2 and GDF-5 (growth differentiation factor 5) counter-acted apop-
tosis induced by serum starvation by stabilising XIAP protein levels and preventing its protea-
somal degradation (Liu et al., 2009). Strikingly, we observed that administration of  recombinant 
BMP-2 to differentiated THP1-Blue cells, cultured in medium containing FCS, also stabilised 
XIAP protein levels when protein neo-synthesis was blocked with cycloheximide (CHX), as 
monitored by Western blot analysis using a XIAP-specific antibody. This effect was observed 3 
h and still 6 h after treatment with CHX and BMP-2, whereas GAPDH protein levels remained 
unchanged (Fig. 18E). In order to assure the functionality of  the recombinant BMP-2 used for 
these experiments, BMP-2 induced p42/p44 phosphorylation was monitored by Western blot 
analysis using an antibody that specifically detects phosphorylated p42/44. As described for 
MEFs (Liu et al., 2009), BMP-2 induced a strong p42/44 phosphorylation as well in the differ-
entiated THP1-Blue cells 15 min after treatment (Fig. 18F). This revealed that THP1 cells have a 
functional BMP-2 signalling pathway and demonstrated the functionality of  the recombinant 
BMP-2. 
   Taken together, these results reveal BMPR-2 as interesting novel regulator of  the NOD1 
pathway, that likely acts by stabilising XIAP.  
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3.1.8 Analysis of the roles of BIRC proteins in NOD1 signalling 
The finding that XIAP is essentially involved in NOD1 and NOD2 signalling and recent reports 
linking the closely related proteins BIRC2 and BIRC3 to innate immunity (Tseng et al., 2010; 
Bertrand et al., 2008; Conte et al., 2006) and NOD signalling (Bertrand et al., 2009), raised the 
question if  also other members of  the BIRC family might contribute to NOD1 signalling. The 
data obtained in our screen was not very conclusive on this point, as among the BIRC family 
members only XIAP was identified as a robust hit (Fig. 17A). The other BIRC family members 
did not achieve high ranks in the RSA-based hit-lists, mostly due to heterogeneity in the effects 
of  different siRNAs (data not shown). As siRNA screens are prone to off-target effects (reviewed 
in Singh et al., 2011; Svoboda, 2007), and as the raw data for some of  the BIRCs, for example 
for BIRC5 (data not shown) indicated that there might be effects on NOD1 signalling caused by 
some of  the siRNAs, we investigated the possible roles for the BIRC proteins in NOD1 signal-
ling in more detail. To this end, BIRC2, BIRC3, BIRC5, BIRC7 and BIRC8 were targeted with 
two different siRNAs each in HeLa cells. Cells were then infected with invasive S. flexneri M90T 
or non-invasive S. flexneri BS176. Knock-down of  the validated screen hit XIAP thereby served 
as positive control. Measurement of  IL-8 secretion in response to S. flexneri infection indicated 
that knock-down of  BIRC2, BIRC5 and BIRC8 impaired S. flexneri M90T induced IL-8 secre-
tion, whereas knock-down of  BIRC3 enhanced IL-8 secretion in response to S. flexneri M90T 
infection. Infection with S. flexneri BS176, in contrast, did not induce secretion of  detectable 
amounts of  IL-8 (Fig. 19 A, upper panel and data not shown).  
   The experiment was subsequently repeated with the siRNAs that showed the strongest effect 
on IL-8 secretion to validate the findings from the first experiment. The results were qualita-
tively comparable to the results from the first experiment, albeit the effects were not as pro-
nounced. Again, knock-down of  BIRC2, BIRC5 and BIRC8 impaired S. flexneri M90T induced 
IL-8 secretion, knock-down of  BIRC3 enhanced IL-8 secretion (Fig. 19A, lower panel). RT-PCRs 
performed with cDNA generated from RNA isolated from cells in the same experiment con-
firmed reduction of  the corresponding mRNA levels (Fig. 19B). However, we failed to detect 
BIRC7 mRNA using RT-PCR (data not shown).  
   To expand this analysis to another cell system, differentiated THP1 cells were transfected with 
our BIRC-specific siRNAs. Subsequently, IL-8 secretion induced by stimulation of  NOD1 with 
Tri-DAP was measured. In line with the observations made in HeLa cells, knock-down of  XIAP, 
BIRC2, BIRC5 and BIRC8 impaired NOD1-mediated IL-8 secretion. In contrast to the obser-
vations made in HeLa cells, knock-down of  BIRC3 did not exert any effect on NOD1-mediated 
IL-8 secretion in THP1 cells, indicating that effects of  BIRC3 on NOD1 signalling are cell-type 
specific (Fig. 19C).  
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Figure 19. Analysis of the roles of BIRC proteins in NOD1 signalling. A Knock-down of BIRC2, 3, 5 and 8 in 
HeLa cells. Cells were transfected with CTRL, XIAP, BIRC2, BIRC3, BIRC5 or BIRC8 siRNA and incubated for 72 
h. Subsequently, cells were infected with Shigella flexneri M90T and IL-8 secretion was determined 6 h after 
infection by ELISA. The experiment was repeated twice (upper panel / lower panel). Values are mean +SD 
(n=2). B Knock-down efficiency was determined by RT-PCR using primers specific for the respective BIRC 
gene and cDNA transcribed from RNA isolated from cells of the same experiment. RT-PCR with GAPDH-
specific primers served as control. C Knock-down of BIRC2, 3, 5 and 8 in THP1-Blue cells. Differentiated 
THP1-Blue cells were transfected with CTRL, XIAP, BIRC2, BIRC3, BIRC5 or BIRC8 siRNA and incubated for 72 
h. Subsequently, cells were stimulated with Tri-DAP (10 μg/ml) and IL-8 secretion was determined after 16 h 
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incubation by ELISA. Values are mean +SD (n=2). Data is representative for at least two independent ex-
periments. D Assessment of the specificity of the BIRC8 siRNA. THP1-Blue cells were transfected with siRNA 
targeting CTRL, XIAP or BIRC8. After 72 h incubation, cells were lysed and XIAP protein levels were deter-
mined by Western blot analysis using a XIAP-specific antibody. Detection of GAPDH levels served as loading 
control. 
 
 
   To exclude that the effects observed for the knock-down of  BIRC8 were caused by a simulta-
neous knock-down of  XIAP induced by the BIRC8 siRNA due to the high sequence similarity 
of  BIRC8 with XIAP (Richter et al., 2001), THP1 cells were transfected with CTRL, XIAP- or 
BIRC8-specific siRNAs and XIAP protein levels were determined by Western blot analysis. Of  
note, treatment of  cells with BIRC8 siRNA did not affect XIAP protein levels, whereas treat-
ment with XIAP siRNA strongly reduced XIAP protein levels, confirming the specificity of  the 
BIRC8 siRNA (Fig. 19D). 
   Collectively, these results indicate that beside XIAP (BIRC4) also BIRC2, BIRC3, BIRC5 and 
BIRC8 are implicated in NOD1 signalling. However, the molecular functions and physiological 
relevances of  these findings still remain to be established.  
 
 
3.2 Bacterial outer-membrane vesicles trigger NOD-mediated inflammatory 
responses in a quorum sensing-dependent manner 
Even though it is well established that NOD1 and NOD2 detect PGN fragments derived from 
bacteria, it is not fully understood how PGN from extracellular bacteria is translocated to the 
cytoplasm of  host cells. Recent publications indicate that different host cell mechanisms, such as 
peptide transporters (Swaan et al., 2008; Ismair et al., 2006; Vavricka et al., 2004) and endocytic 
pathways (Lee et al., 2009; Marina-Garcia et al., 2009), but also bacterial mechanisms, such as 
secretion systems (Viala et al., 2004) and pore-forming toxins (Ratner et al., 2007), contribute to 
this process. In this part of  the project we aimed at elucidating if  outer-membrane vesicles 
(OMVs) derived from the Gram-negative non-invasive pathogen Vibrio cholerae might serve as 
mechanism for delivery of  NOD1/2 active PGN to the cytoplasm of  human cells.  
 
 
3.2.1 Activation of NOD1 and NOD2 by extracellular bacteria 
OMVs are spherical membrane fragments consisting of  bacterial outer-membrane material that 
are produced during normal growth of  many Gram-negative bacteria (reviewed in Kulp and 
Kuehn, 2010). They enclose a variety of  outer-membrane and periplasmic constituents, includ-
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ing proteins, phospholipids, DNA, bacterial toxins and LPS (Deatherage et al., 2009; Lindmark et 
al., 2009; Renelli et al., 2004; Wai et al., 2003; Kolling and Matthews, 1999). Consistently, it has 
been shown that OMVs derived from Pseudomonas aeruginosa induce IL-8 secretion in epithelial 
cells (Bauman and Kuehn, 2006). 
   Vibrio cholerae is an inhabitant of  aquatic systems and one of  the causative agents of  severe 
dehydrating diarrhea in humans. V. cholerae bacteria belonging to the O1 and O139 serogroups 
cause cholera epidemics in many developing countries, whereas strains belonging to non-O1 
non-O139 V. cholerae (NOVC) serogroups have been associated with endemic gastroenteritis 
and extraintestinal infections in humans (Faruque et al., 1998; Kaper et al., 1995). Unlike the case 
for the O1 and O139 strains of  V. cholerae, little is known about the virulence and pathogenicity 
of  NOVC strains.  
   Of  note, we could show that several V. cholerae strains, including V:5/04, produce OMVs (data 
not shown) (Bielig et al., 2011b). As OMVs very likely contain physiologically relevant PAMPs, we 
wanted to elucidate if  V. cholerae OMVs trigger inflammatory responses in human cells. 
   To assess if  V. cholerae OMVs can activate NOD1 and/or NOD2, HEK293T cells were trans-
fected with a NF-B reportersystem and NOD1 or NOD2 expression plasmids and treated 
with OMVs isolated from the V. cholerae NOVC strain V:5/04 or the V. cholerae O1 El Tor Inaba 
strain P27459. OMV preparations were adjusted to equal protein concentrations. Stimulation of  
cells with the NOD1 or NOD2 elicitors Tri-DAP or MDP, respectively, served as positive con-
trols. The results clearly revealed that OMVs from both strains induced a robust NOD1- and 
NOD2-dependent NF-B activation in HEK293T cells, but failed to activate the reporter in the 
absence of  NOD1 or NOD2. Of  note, OMVs isolated from V. cholerae V:5/04 induced a 
stronger  NF-B activation compared to OMVs from V. cholerae P27459 (Fig. 20A). These find-
ings were affirmed by experiments using an IL-8-luciferase reportersystem that yielded qualita-
tively similar results (data not shown). Importantly, the OMVs did not induce cell death in the 
cells at the concentrations used and during the incubation time used, as monitored by cell viabil-
ity assays (XTT) in the same experiments (data not shown). 
   In line with the previous findings, treatment of  HeLa cells with OMVs isolated from V:5/04 
induced a strong IL-8 secretion (Bielig et al., 2011b) (performed by Prof. Dr. Sun Nyunt Wai and 
co-workers, Umeå University, Sweden). Furthermore, stimulation of  THP1-Blue cells with 
V:5/04 OMVs induced a very pronounced NF-B activation (Fig. 20B). The OMV preparations 
contained LPS (Bielig et al., 2011b), which likely contributed to the observed inflammatory re-
sponses by activating TLR4 in HeLa and THP1 cells. To address whether V:5/04 OMVs also 
elicit TLR4-independent responses in THP1 cells, we quenched the activity of  the LPS by incu-
bation of  the vesicles and cells with the LPS-sequestering drug polymyxin B. This revealed that 
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a great fraction of  the inflammatory activity was induced by LPS. However, a highly significant 
response was still seen in the presence of  polymyxin B, indicating that the inflammatory re-
sponse towards OMVs in THP1 cells was partly mediated by other receptors than TLR4 
(Fig.20B). 
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Figure 20. Activation of NOD1 and NOD2 by V. cholerae OMVs. A HEK293T cells were transfected with the 
NF-B luciferase RPS containing NOD1 (left panel) or NOD2 (right panel) expression plasmids and treated 
with Tri-DAP (0.5 μM) or MDP (50 nM), respectively, or with P27459 or V:5/04 OMVs (0.5 μg/ml each). After 
16 h, cells were lysed and luciferase activation was determined and normalised with the -galactosidase 
values (nRLU). Values are mean +SD (n=3). Data is representative for at least two independent experiments. 
B Differentiated THP1-Blue cells were treated with Tri-DAP (10 μg/ml), LPS (100 ng/ml) or V:5/04 OMVs (0.5 
μg/ml). OMVs were either pre-treated with Polymyxin B (25 μg/ml) or left untreated. After 16 h incubation, 
NF-B activation was determined by measurement of SEAP activation from the supernatants. Activity is 
given as fold over background, mean +SD (n=3). C Knock-down of NOD1 impairs NF-B activation in re-
sponse to V:5/04 OMVs. THP1-Blue cells were transfected with CTRL, NOD1 or NOD2 siRNA and incubated 
for 72 h. Subsequently, cells were treated with Tri-DAP or MDP (10 μg/ml each) or with V:5/04 OMVs (1 
μg/ml). After 16 h incubation, NF-B activation was determined by measurement of SEAP activity in the 
supernatants. Activity is given as fold over background, mean +SD (n=4), data represents two independent 
experiments. n.t.: non-treated; nRLU: normalised relative light units. Differences were regarded as signifi-
cant (*), when the p value was <0.05 or as highly significant (***) when the p value was <0.0005, as assessed 
by the two-sided Student’s T-Test. 
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   To gain evidence that NOD1 and NOD2 are involved in inflammatory responses towards 
OMVs in THP1-Blue cells, NOD1 or NOD2 expression was silenced by treatment with specific 
siRNAs. Silencing of  NOD1 significantly reduced NF-B activation in response to V:5/04 
OMVs compared to cells treated with non-targeting control siRNA. However, silencing of  
NOD2 seemed to exert no effect on NF-B activation in response to V:5/04 OMVs (Fig. 20C). 
Knock-down efficiency was assessed by qRT-PCR using cDNA generated from RNA isolated 
from cells from the same experiment (Bielig et al., 2011b).  
   In order to gain insight into the mode of  interaction of  V. cholerae OMVs with mammalian 
cells, HeLa cells were incubated for 8 h with OMVs isolated from V:5/04. OMVs were visual-
ised by indirect immunofluorescence analysis with an antibody specific for the outer membrane 
protein (Omp) U. This revealed a specific localisation pattern for the OMVs, which appeared to 
accumulate in the vicinity of  the nucleus, whereas the antibody did not stain untreated cells 
(Bielig et al., 2011b) (Microscopy performed by Birte Zurek, University of  Cologne). 
   Collectively, these results provide evidence that V. cholerae OMVs are taken up into human 
epithelial cells and that NOD1 and NOD2 are at least partially involved in their detection.  
 
 
3.2.2 The role of quorum sensing in subverting host-detection by NODs 
Quorum sensing is well known to control the expression of  virulence factors in O1 serotypes 
of  V. cholerae (Raychaudhuri et al., 2006; Vaitkevicius et al., 2006; Vance et al., 2003; Miller et al., 
2002; Zhu et al., 2002). The protein HapR (hemagglutinin/protease regulatory protein) is 
thought to act as major regulator of  quorum sensing, as it represses virulence gene expression 
under conditions where the density of  bacterial cells is high (reviewed in Sanchez and Holmgren, 
2008). However, the role of  HapR in virulence gene regulation in NOVC is currently not well 
established. In order to investigate a putative function of  quorum sensing in the regulation of  
OMV-mediated responses, a mutant of  V:5/04 with an in-frame deletion of  the hapR gene was 
constructed and analysed in comparison to wild-type (WT) NOVC V:5/04. OMVs from both 
strains were isolated and the composition and structure of  the OMVs were analysed by SDS-
PAGE, Western blot analysis, and electron microscopic (EM) examination. Although deletion 
of  HapR led to slight changes in the appearance of  the vesicles in EM analysis, yielding a more 
uniform size, the protein compositions of  OMVs from V:5/04 hapR and the parent WT strain 
were highly similar. The amounts of  vesicles released from these two strains also were compara-
ble as shown by Western blot analysis detecting a major outer membrane protein, OmpU, as a 
marker protein for Vibrio OMVs. Silverstained SDS-PAGE of  preparations of  these OMVs also 
revealed similar amounts and patterns of  lipopolysaccharide (LPS) in both samples (Bielig et al., 
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2011b) (bacterial genetics, OMV purification, biochemistry and EM microscopy were per-
fromed by Prof. Dr. Sun Nyunt Wai and co-workers, Umeå University, Sweden). In conclusion, 
both NOVC V:5/04 strains produced OMVs, whereas the amounts of  OMVs and the overall 
protein and LPS compositions in V:5/04 WT cells and V:5/04 hapR mutant cells, which are 
locked in a “virulence-like” state, were similar. 
   To assess whether there were differences in the immunogenicity of  OMVs isolated from WT 
and hapR bacteria, HeLa cells were treated with OMV preparations of  either of  the two strains. 
As observed before, treatment of  cells with WT OMVs induced a robust IL-8 secretion. Strik-
ingly, OMVs isolated from the hapR strain induced significantly less IL-8 secretion compared 
to WT OMVs (Fig. 21A). In line with that, OMVs isolated from the hapR strain also induced 
significantly less IL-8 secretion than WT OMVs in THP1 cells (Fig. 21B). Qualitatively similar 
results were observed in HEK293T cells, where OMVs isolated from either the WT or hapR 
strain induced NOD1- and NOD2-dependent NF-B activation. However, again hapR OMVs 
were significantly less active than WT OMVs (Fig. 21C). The same was observed when using an 
IL-8 reporter plasmid (Bielig et al., 2011b). Taken together, these findings indicated that OMVs 
derived from V:5/04 hapR were less immunogenic compared to OMVs derived from WT 
V:5/04 bacteria. As NOD1 and NOD2 specifically detect PGN fragments, we concluded that 
this effect might be caused by PGN contained in the OMVs and that hapR OMVs might con-
tain less PGN than WT OMVs. Indeed, X-ray photoelectron spectroscopy (XPS) confirmed 
that V:5/04 OMVs contained PGN and that hapR OMVs contained lower amounts of  PGN 
than WT OMVs (Bielig et al., 2011b) (XPS was performed by Dr. M. Ramstedt, Umeå University, 
Sweden).  
   Next, we tested whether the inflammatory activity of  whole bacterial lysates, generated by 
boiling of  the bacteria, might also be differently affected by HapR compared to OMVs. That is, 
does Vibrio change the overall PGN/PAMP composition or selectively omit PGN or PAMPs 
from OMVs during infection? To this end, the inflammatory potentials of  equal amounts of  
lysates from WT V:5/04 and V:5/04 hapR bacteria were tested. Cell lysates induced a NF-B 
response in THP1-Blue cells (Fig. 21D), as well as NOD2 activation in HEK293T cells (Bielig et 
al., 2011b). Strikingly, in contrast to the observations obtained with the OMVs, lysates from 
V:5/04 bacteria lacking HapR did not show a diminished potential to activate NF-B (Fig. 21D) 
(Bielig et al., 2011b). In contrast, lysates from V:5/04 hapR bacteria induced even slightly 
stronger responses (Fig. 21D) (Bielig et al., 2011b). Similar results were obtained when measuring 
IL-8 release from HeLa cells by ELISA (Bielig et al., 2011b).  
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   Taken together, these results displayed that PGN can be delivered by bacterial OMV to host 
cells where it is sensed by intracellular NOD1 and in some cases NOD2. Furthermore, we re-
vealed a novel mechanism of  how bacteria can escape NOD1 detection by actively influencing 
NOD1/2 immunogenicity of  shed OMVs by a pathway involving the quorum-sensing system.  
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Figure 21. Differential NOD1/2 responses to OMVs and bacterial cell lysates. A HeLa cells were treated for 8 
h with V:5/04 or V:5/04 hapR OMVs (1 μg/ml). Stimulation with LPS (0.1 μg/ml) served as control for the 
reactivity of the cells. Subsequently, IL-8 secretion was determined by ELISA. Values are mean +SD (n=3). B 
THP1 cells were treated for 16 h with V:5/04 or V:5/04 hapR OMVs  (0.05 μg/ml). Stimulation with MDP (10 
μM) or LPS (0.1 μg/ml) severd as controls. Subsequently, IL-8 secretion was determined by ELISA. Values are 
mean +SD (n=3) C HEK293T cells were transfected with the NF-B luciferase RPS containing NOD1 (left 
panel) or NOD2 (right panel) expression plasmids and treated with V:5/04 or V:5/04 hapR OMVs (0.5 μg/ml). 
Stimulation with Tri-DAP (0.5 μM) or MDP (50 nM) served as controls. After 16 h, cells were lysed and 
luciferase activation was determined and normalised with the -galactosidase values (nRLU). Values are 
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mean +SD (n=3). D THP1-Blue cells were treated for 16 h with bacterial lysates from V:5/04 or V:5/04 hapR 
OMVs (0.5 μg/ml each). Stimulation with MDP (10 μg/ml) or LPS (0.1 μg/ml) served as controls.  NF-B activ-
ity was determined by measuring SEAP activity in the supernatant.  Activity is given as fold over back-
ground, mean +SD (n=3). n.t.: non-treated; nRLU: normalised relative light units; RPS: reporter system. Dif-
ferences were regarded as highly significant (**) when the p value was <0.005. A p value <0.0005 is indi-
cated by ***, as assessed by the two-sided Student’s T-Test. 
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4 Discussion 
 
4.1 Screen results 
In this project we aimed to further elucidate the regulation of  the NOD1 innate immune signal-
ling cascade by conducting a high-throughput siRNA screen based on NF-B activation in 
HEK293T cells. In the first step, a pilot screen using a smaller sub-library consisting of  apop-
tosis-related genes was performed. After analysis and validation of  the obtained data, we used 
the established protocols to conduct a high-throughput screen using the human druggable ge-
nome library. Subsequent validation and counter-screening, in combination with validation in an 
additional cell system, yielded a list of  NOD1-specific candidates. The quality of  this procedure 
was reflected by the fact that many factors that are known to be involved in the regulation of  
NOD1 signalling were identified. Detailed characterisation confirmed XIAP (BIRC4) and 
BMPR-2 as novel components of  the NOD1-mediated NF-B cascade. Additional analyses 
indicated that also other BIRC family members are implicated in the regulation of  NOD1-
mediated inflammatory responses.  
 
 
4.1.1 Pilot screen 
To evaluate and optimise the automated assay protocols and data pipelines, we first screened a 
sub-library consisting of  apoptosis-related genes in 384 well plates. The whole library was 
screened both for Tri-DAP- and for TNF-α-mediated NF-B activation. In the subsequent vali-
dation, we were able to validate 73.5 % of  the identified inhibiting hits with four different 
siRNAs targeting each gene, underscoring the reproducibility of  the results and the robustness 
of  the assay system. In contrast, only 16.7 % of  the activating hits could be validated. This is in 
line with observations made in other siRNA screens condcuted at the same platform, suggesting 
that false-positives appear to be overrepresented over false negative results (Dr. Peter Braun, 
personal communication). Therefore we focused our efforts on the inhibiting hits in the follow-
ing druggable genome screen. 
   Of  note, we were able to identify many factors that are known to be involved in NF-B 
pathways among the inhibiting hits of  the pilot screen. Strikingly, the strongest hit in the Tri-
DAP/NOD1-specific hit-list was RIP2, a kinase that is well established to be essentially and 
specifically involved in NOD1-mediated NF-B activation (reviewed in Kufer, 2008). Another 
factor contained in the NOD1-specific hit-list that is known to be involved in NOD1-mediated 
NF-B activation was CARD6. CARD6 has been shown to positively modulate NOD-mediated 
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NF-B activation by interaction with RIP2 (Dufner et al., 2006). Beside these established factors, 
the screen also identified a number of  factors that have so far not been linked to NOD1 signal-
ling, such as PRF1 (perforin 1), CTNNB1 (-catenin) or NOS3 (nitric oxide synthase 3) (Fig. 10B, 
left panel). Follow-up work is required to validate these and other candidates in other cell systems 
and to characterise their putative functions in the NOD1 cascade. 
   The strongest TNF-α-specific hit was the TNF-receptor itself, TNFR1 (TNFRSF1A). TNFR1 
is a transmembrane receptor of  the TNFR-superfamily crucially involved in NF-B activation 
following TNF-α stimulation (reviewed in Chen and Goeddel, 2002) (Fig. 10B, middle panel). 
   Notably, we were also able to identify factors that are generally involved in the regulation of  
canonical NF-B signalling, i.e. which inhibited both NOD1- and TNF-α-mediated NF-B acti-
vation. The strongest NF-B-associated hit was the NF-B subunit RELA. RELA forms het-
erodimers with other Rel-family members. The canonical NF-B heterodimer consists of  
RELA and p50 (NFKB1, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) 
(reviewed in Hayden and Ghosh, 2008). Strikingly, also p50 was found in the screen as a strong 
NF-B-associated hit. Moreover, cullin1 (CUL1), a subunit of  the SCF (Skp, Cullin, F-box con-
taining) E3 ubiquitin ligase complex, was contained in this hit-list. The SCF complex is essential 
for the canonical NF-B pathway, as it mediates the phosphorylation-dependent degradation of  
IB-α (reviewed in Maniatis, 1999). Furthermore, the NF-B-associated hit-list contained TAK1 
(MAP3K7), a kinase that is essential both the NOD1 and the TNFR1 signalling cascades (re-
viewed in Hayden and Ghosh, 2008) (Fig. 10B, right panel). 
   Taken together, these results clearly demonstrated that the HEK293T NF-B reporter assay 
system and the establsihed conditions were well suited to identify novel components of  the 
NOD1 signalling pathway. 
 
 
4.1.2 Druggable genome screen 
In the subsequent primary druggable genome screen, again a number of  factors that are estab-
lished to be involved in canonical NF-B and/or NOD1 signalling could be identified. Most 
importantly, however, the hit list contained several factors that have not been associated with 
NOD1 signalling. Ingenuity pathway analysis revealed that 56 out of the 435 preliminary screen 
hits (12.9 %) are known components of  NF-B signalling. Among these 56 preliminary hits, 28 
could be validated in the HEK validation screen, of  which 14 were not influencing TNF-α-
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induced NF-B activation (Ingenuity pathway analysis was performed by Dr. Peter Braun, 
MPIIB Berlin) (Fig. 22A). 
   Same as in the pilot screen, RIP2, p50 and RELA were identified as preliminary inhibiting hits. 
Furthermore, also IKKα and IKK were identified as significant hits. IKK mediates the phos-
phorylation and subsequent targeting for degradation of  IB-α in the canonical NF-B pathway 
(reviewed in Hayden and Ghosh, 2008). Of  note, IKKα has recently been linked to NOD1 sig-
nalling in response to S. flexneri infection (Kim et al., 2010). Furthermore, the TAB/TAK com-
plex component TAB2 was identified in the screen. TAB2 mediates activation of  the IKK com-
plex through TAK1 by binding to K63-linked ubiquitin chains on upstream proteins and is in-
dispensable for canonical NF-B activation (reviewed in Chiu et al., 2009). This process is also 
critical for NOD1 signalling (Hasegawa et al., 2008; Abbott et al., 2007). Another gene identified 
with high confidence was RNF31 (ring finger protein 31). RNF31 is part of  the LUBAC E3 
ligase complex that mediates M1-linked linear ubiquitination of  IKK and is required for ca-
nonical NF-B signalling (reviewed in Bianchi and Meier, 2009). Of  note, also the activating hit-
list obtained in the druggable genome screen identified known NF-B regulatory factors. The 
de-ubiquitinating enzymes A20 and CYLD, which are known to negatively regulate canonical 
NF-B signalling, as well as the NOD1 pathway (reviewed in Liu and Chen, 2011), were identi-
fied with strong probability values (Fig. 22B). Collectively, these findings prove that the primary 
druggable genome screen effectively identified anticipated factors involved in the regulation of  
canonical NF-B activation and NOD1 signalling. 
   To gain insight in which biological processes the identified 435 candidates are involved, gene-
ontology (GO) enrichment was performed using the GOrilla (Gene Ontology enRIchment 
anaLysis and visuaLizAtion) tool. Clustering of the primary hits according to their GO terms 
revealed that genes linked to immunity and in particular to immune receptors, among others, 
were significantly enriched in comparison to the druggable genome library used as background. 
Moreover, genes involved in the regulation of NLR signalling were also significantly over-
represented among the preliminary hits (Fig.22C).  
As we aimed to identify general regulators of  NOD1 signalling, we next validated the 535 pre-
liminary hits (the 435 inhibiting and the top 100 activating) in another cell system, to exclude 
cell-type specific regulators. For that purpose, we used the monocytic cell line THP1. THP1 
cells are accessible with siRNA and have the advantage that they are competent for endogenous 
NOD and TLR signalling and thus provide a more physiological system than the previously 
used HEK293T cells (Uehara et al., 2005).  
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Figure 22. In-depth analyses of the screen results. A Known regulators of NF-B retrieved by the screens. 
Shown are 56 (out of 435) preliminary inhibiting screen hits already known to be involved in NF-B regula-
tion (Ingenuity Pathway Analysis). Among them, 28 could be validated in the HEK validation screen (dark 
red: strong hit; light red: weaker hit; white: not validated). A sub group of 14 were not influencing TNF-α-
induced NF-B activation (blue borders). B Schematic representation of the NOD signalling cascade. Known 
positive regulators retrieved by the primary screen are highlighted in green, known negative regulators in 
red. The corresponding p-values (RSA-based) are indicated. C Gene ontology (GO) enrichment of the 435 
preliminary hit genes retrieved by the primary screen compared to the druggable genome library (back-
ground). Number of hit genes associated with enriched terms according to the GO of biological processes. 
Enrichment factors and negative log(P-values) are indicated in brackets. D STRING database analysis of the 
28 hits from the THP1 screen. Genes, where the NPI values of both siRNAs exceeded 1.5 SD of CTRL from the 
median of CTRL were regarded as validated. Stronger associations are represented by thicker blue lines. 
Genes were clustered according to the Marcov cluster (MCL) algorithm.  
 
 
Although the hit-list obtained in THP1 cells differed markedly from the one obtained in 
HEK293T cells, a number of  factors known to be involved in NF-B signalling, such as RELA 
and RNF31, and factors known to be involved in NOD1 signalling, such as NOD1, RIP2 and 
IKKα, were identified in these cells as well (Fig. 22D). Of  note, again XIAP was found in this hit-
list in a very prominent position. Among the hits identified in THP1 cells, the genes RIP2, XIAP, 
GPR17, SSH1, SNAI1, and CHUK could be confirmed as hits in all screening rounds in both 
cell lines and did not show inhibiting effects in the TNF-α counter-screen (Fig. 16B). RIP2 is well 
known to be critically involved in the NOD1 signalling cascade (discussed above); CHUK/ 
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IKKα was recently also linked to NOD1 signalling (discussed above). SSH1 (slingshot homolog 
1 (Drosophila)) was also contained in the hit-list of  a recently published NOD1 screen (discussed 
below). GPR17 (G protein-coupled receptor 17) and SNAI1 (snail homolog 1 (Drosophila)) were 
so far not linked to any events in innate immunity; follow-up work is required to validate the 
observed effects and to characterise their putative roles in NOD1 signalling. The top NOD1-
specific hit XIAP was subsequently extensively characterised in this study (Fig. 17).  
 
 
4.1.3 Comparison with published screens 
During our screening project, two other siRNA screening projects aiming at identifying NOD1 
regulatory factors were published. Kim et al. screened a small siRNA library targeting 132 genes 
of  the signalling proteome in HeLa cells by monitoring p65 translocation to the nucleus follow-
ing Shigella flexneri infection. In this process, CHUK (conserved helix-loop-helix ubiquitous 
kinase, also termed IKKα) was identified as primary hit and subsequently validated. Consistently, 
the authors could demonstrate that IKKα was required for S. flexneri and PGN-induced NOD1-
mediated NF-B activation and IL-8 secretion in HeLa cells (Kim et al., 2010). Strikingly, we 
also identified IKKα as NOD1-specific hit, albeit at a lower position in the final ranking (Fig. 
16B). This prompted us to compare our screening results with the published results to find out 
if  there were more common factors. Out of  the 132 genes screened by Kim et al., 105 were also 
contained in our druggable genome library (Fig. 23A, left panel). Among those, 10 genes were clas-
sified as preliminary hits in our primary druggable genome screen. In total, Kim et al. identified 
13 genes from their library as significant hits; three of  those (NOD1, RIP2 and IKKα) were 
likewise identified as hits in our primary druggable genome screen. Of  note, exactly these three 
genes could also be validated in the THP1 screen, whereas the remaining 7 genes displayed re-
sults differing from the druggable genome screen and were not regarded as validated (Fig. 23A, 
right panel). Taken together, the identification of  IKKα in our screen supports the findings of  
Kim et al., as it has previously been presumed that only IKK is required for NOD1-mediated 
NF-B activation. We further add to this by showing that IKKα acts NOD1-specific, as we did 
not observe effects on TNF-α-mediated NF-B activation. Moreover, the identification of  
IKKα provides further evidence that our screening project effectively identified NOD1-specific 
regulators. 
 
During the finalisation of  this project, another siRNA screen on NOD1 activation was pub-
lished. The authors screened the same druggable genome library in human HT29 colonocytes, 
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making this screen in principle comparable to our data. Measurement of  IL-8 secretion in re-
sponse to stimulation with Tri-DAP served as read-out for the primary screen. In total they 
identified 227 inhibiting and 198 activating hits. Among those, they could validate a total num-
ber of  200 genes by measuring IL-8 expression by qRT-PCR. In a secondary screen, cells were 
stimulated with TNF. Altogether, they could identify 114 genes as non-specific common regula-
tors of  both pathways; among those, 60 were found to be specifically involved in NOD1 signal-
ling. Surprisingly, the authors then characterised the non-specific hit BID (BH3 interacting do-
main death agonist), despite the rather low position in their hit-list (position 74 in the primary 
screen, position 5 in the secondary TNF screen). They revealed that BID interacts with NOD1, 
NOD2 and the IKK complex and that human and murine cells deficient for BID are defective 
in inflammatory responses to NOD agonists. (Yeretssian et al., 2011).  
   However, we could not identify BID in our screening approach and none of  the siRNAs tar-
geting BID displayed any significant effect on NF-B activation induced by Tri-DAP in our 
primary screen (data not shown). The overlap of  the hits identified by Yeretssian et al. and the hits 
identified in our screen was rather small, even though the same druggable genome library and a 
similar screen set-up was used. In total, there was an overlap of  10 inhibiting hits between the 
published primary screen and our primary screen. The established factors RELA and RIP2 were 
identified in both of  the screens, however, most other factors were either not validated, or not 
NOD1-specific in at least one of  the screens (Fig. 23B). Interestingly, the only validated and 
NOD1-specific factors found in both of  the screening projects are RIP2 and SSH1 (Fig. 23B). 
This strongly suggests that SSH1 might play a pivotal role in the NOD1 signalling pathway. In-
deed, preliminary data obtained by knock-down of  SSH1 in THP1 cells and subsequent meas-
urements of  Tri-DAP-induced IL-8 secretion indicated that SSH1 is necessary for NOD1 sig-
nalling (data not shown). SSH1 belongs to the SSH family of  phosphatases, which is crucially 
implicated in the regulation of  actin filament dynamics (reviewed in Huang et al., 2006). Intrigu-
ingly, there are reports linking actin dynamics to NOD signalling. It has been shown that NOD2 
is present at the plasma membrane (Kufer et al., 2006; Barnich et al., 2005a; McDonald et al., 
2005) and that disruption of  the actin cytoskeleton increases NOD2-mediated NF-B activa-
tion (Legrand-Poels et al., 2007). Furthermore, there is evidence that NOD1 activation in re-
sponse to S. flexneri infection is dependent on a membrane-localisation of  NOD1, which in turn 
is dependent on an intact actin cytoskeleton (Kufer et al., 2008). However, so far it is not under-
stood how NOD1 and NOD2 are recruited to the plasma membrane. The small RhoGTPase 
RAC1 (ras-related C3 botulinum toxin substrate 1), a factor that is involved in the regulation of  
the actin cytoskeleton, has been shown to interact with NOD2 at the plasma membrane (Eitel et 
al., 2008; Legrand-Poels et al., 2007). The regulation of  this process remains to be elucidated, 
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but there is evidence that RAC1 is also essential for the membrane localisation of  NOD1 
(Regueiro et al., 2011). In addition, the cytoskeleton-associated factor GEF-H1 (guanine nucleo-
tide exchange factor H1) has been shown to be required for NOD1-activation in response to S. 
flexneri infection (Fukazawa et al., 2008). It might well be that also SSH1 is somehow involved in 
the regulation of  the membrane recruitment of  NOD1. Further experiments are required to 
validate the observed effect of  SSH1 knock-down on NOD1-mediated IL-8 secretion and to 
characterise the putative role of  SSH1 in NOD signalling.  
   Taken together, the comparison with the published screen and preliminary validation data 
revealed SSH1 as promising candidate for further characterisation.     
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Figure 23. Meta-analysis comparing the screening results with published NOD1 siRNA screens. A Compari-
son with the screen from Kim et al.. In this approach, 132 genes were screened in HeLa cells by monitoring 
p65 translocation to the nucleus following Shigella flexneri infection. Out of the 132 genes targeted in this 
screen, 105 were also contained in the druggable genome library (left panel). Among those, 10 genes were 
classified as preliminary hits in the primary druggable genome screen and three (NOD1, RIP2, IKKα) were 
also classified as hits by Kim et al. (right panel). B Comparison with the screen from Yeretssian et al.. In this 
approach, the human druggable genome library was screened in HT29 cells. IL-8 secretion following Tri-
DAP stimulation served as read-out. Hits were subsequently validated using qRT-PCR to monitor IL-8 gene 
expression. NOD1-specific hits were obtained by using a secondary screen with TNF stimulation. The table 
shows the primary screen data obtained by Yeretssian et al. that overlap with our preliminary hit-list in com-
parison to the HEK293T druggable genome screen and the THP1 validation screen. Note that THP1 ranks do 
not necessarily correspond to THP1 ranks in Fig. 16B, as Fig. 16B uniquely represents NOD1-specific hits. 
Bold: NOD1-specific in the respective screen; * validated in the respective screen; n.h.: no hit in THP1 valida-
tion screen 
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4.1.4 XIAP and BMPR-2 are involved in NOD1 signalling 
XIAP (X-linked inhibitor of  apoptosis, also termed BIRC4) was found as top inhibiting hit 
throughout the whole screening steps, indicating that XIAP is of  crucial importance in the 
NOD1 pathway.  
   XIAP belongs to the BIRC (baculoviral IAP repeat-containing) family, which is known to play 
important roles in counter-acting apoptosis. It has been shown that XIAP counter-acts apop-
tosis by direct inhibition of  caspases (Eckelman and Salvesen, 2006; Eckelman et al., 2006). 
However, the physiological role of  XIAP in the regulation of  apoptosis is still not clear, as mice 
deficient for XIAP did not display obvious defects in induction of  apoptosis (Harlin et al., 2001). 
   There is increasing evidence that XIAP is implicated in a variety of  other important regulatory 
cascades, such as TGF- signalling, MAPK and NF-B activation and ubiquitin pathways 
(Gyrd-Hansen and Meier, 2010; Kashkar, 2010; Srinivasula and Ashwell, 2008; Birkey Reffey et 
al., 2001). Importantly, there is also evidence for crucial functions of  XIAP in innate immune 
responses. For instance, mutations in XIAP caused a primary immunodeficiency in patients with 
X-linked lymphoproliferative syndrome (XLP) (Rigaud et al., 2006). Strikingly, it has been shown 
that macrophages from mice deficient for XIAP displayed reduced NF-B activation and cyto-
kine secretion in response to a combined treatment with TLR2 and NOD2 ligands and in re-
sponse to the invasive pathogen Listeria monocytogenes. Accordingly, XIAP showed to be crucial 
for protection of  mice against L. monocytogenes infection (Bauler et al., 2008). This is in line with 
our observations from the screen and with subsequent siRNA experiments indicating that XIAP 
is of  crucial importance for inflammatory responses to NOD1 and NOD2 elicitors as well as to 
the invasive pathogen S. flexneri in human cells. Of  note, during the time when we discovered 
XIAP as NOD1-specific hit in the druggable genome screen, a publication revealed that XIAP 
mediates NOD signalling via interaction with RIP2. The authors demonstrated that cells defi-
cient for XIAP display a strong reduction in NF-B activation induced by NOD-elicitors as well 
as by over-expression of  NOD1 or NOD2, strongly supporting our observations. Furthermore, 
this study revealed that the interaction of  RIP2 with XIAP is dependent on the BIR2 domain of  
XIAP. Consistently, expression of  the XIAP inhibitor SMAC disrupts the interaction of  RIP2 
and XIAP, indicating that RIP2 interacts with the SMAC-binding site of  the BIR2 domain 
(Krieg et al., 2009). This is in line with our observation that over-expression of  cytosolic SMAC 
strongly inhibited NOD1- and RIP2-mediated NF-B activation. In contrast, NF-B activation 
triggered by over-expression of  IKK was not inhibited by expression of  SMAC, indicating that 
XIAP acts upstream of  the IKK complex in NOD signalling. This is also underlined by the 
observations from the TNF-α counter-screen that indicated that silencing of  XIAP does not 
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inhibit the TNF signalling pathway. Taken together, our observations and the literature provide 
strong evidence that XIAP is critically involved in NOD signalling. However, the molecular 
mechanisms still remain to be elucidated. 
 
There are reports linking XIAP to TGF- and BMP signalling (Liu et al., 2009; Birkey Reffey et 
al., 2001; Yamaguchi et al., 1999). Strikingly, the bone morphogenetic protein receptor II 
(BMPR-2) was found as inhibiting hit throughout the screening steps, displaying moderate ef-
fects on NOD1-mediated NF-B activation in the druggable genome screen and the subse-
quent validation screen, whereas there was no effect on TNF-α signalling observed. However, 
BMPR-2 was not included in the final hit-list, as one out of  the two used siRNAs activated NF-
B signalling in THP1-Blue cells. It is likely that this was caused by an off-target effect, as the 
other siRNA targeting BMPR-2 inhibited NF-B signalling in THP1-Blue cells, and as knock-
down of  BMPR-2 clearly exerted robust inhibiting effects in the other screening steps.  
   Of  note, the involvement of  BMPR-2 in NOD1 signalling was validated in siRNA knock-
down experiments in HeLa cells as well as in THP1 cells. In both cases, silencing of  BMPR-2 
with two different siRNAs significantly reduced the BMPR-2 message and impaired NOD1-
mediated responses triggerd by infection with S. flexneri or stimulation with Tri-DAP. 
   BMPR-2 belongs to the bone morphogenetic protein (BMP) receptor family. The ligands for 
these receptors are BMPs, which belong to the transforming growth factor  (TGF-) super-
family. BMPs are multi-functional growth factors with a wide range of  biological functions, in-
cluding the regulation of  cell growth, differentiation and apoptosis. BMP signalling occurs via 
transmembrane serine/threonine receptors. There are two subtypes of  BMP receptors, type I 
and type II receptors. The type I receptors BMPR-1A and BMPR-1B form heterotetrameric 
complexes with the type II receptor BMPR-2, consisting of  two pairs of  type I and type II re-
ceptors (reviewed in Miyazono et al., 2005). BMP signalling can only occur when receptors of  
both types are present. Binding of  dimeric BMPs activates PRE-FORMED COMPLEXES (PFCs), 
(Gilboa et al., 2000) or induces the formation and activation of  BMP-INDUCED SIGNALLING 
COMPLEXES (BISCs) (Nohe et al., 2002). The kinase of  BMPR-2 is constitutively active and 
trans-phosphorylates the type I receptor, which in turn transmits intracellular signals to down-
stream targets. Complexes consisting of  BMPR-2 and the type I receptors BMPR-1A or BMPR-
1B have high affinities for BMP-2 and BMP-4, however, both type I receptors have higher af-
finities for BMP-2/4 than BMPR-2 (Knaus and Sebald, 2001; Koenig et al., 1994). Interestingly, 
stimulation of  PFCs induces different signalling cascades than BISCs. Activation of  PFCs trig-
gers Smad signalling, whereas BISCs activate MAPK pathways (Nohe et al., 2002).  
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   Strikingly, it has been shown that BMP triggers TAK1 activation in early Xenopus embryos in 
vivo by recruitment of  the TAB1/TAK1 complex to BMPR-1 and that XIAP is essentially in-
volved in this process. The same study revealed that XIAP interacts with TAB1 via its BIR do-
main and with the cytoplasmic region of  BMPR-1A via its RING domain in mammalian cells. 
The authors propose that XIAP serves as an adaptor molecule to link BMP signalling to the 
TAB1/TAK1 complex (Yamaguchi et al., 1999). Moreover, a role for XIAP as co-factor in TGF-
 signalling has been described. It has been shown that XIAP co-localises and interacts with the 
TGF- type I receptor (TRI), potentiates TGF- signalling and activates JNK and NF-B 
(Birkey Reffey et al., 2001). 
   The implications of  XIAP in BMP signalling have been further investigated by Liu et al.. The 
authors revealed that anti-apoptotic effects exerted by BMP-2 and GDF-5 are mediated by an 
interaction between BMPR-2 and XIAP. This interaction enhanced protein stability of  XIAP by 
reducing its ubiquitination and proteasomal degradation. The enhanced concentration of  XIAP 
in turn counter-acts apoptosis caused by serum starvation. Of  note, stabilisation of  XIAP by 
BMPR-2 seemed to be independent of  BMP downstream signalling, as inhibition of  Smads and 
MAPKs did not affect XIAP protein levels. This effect, however, is likely cell-type specific, as 
BMP-induced stabilisation of  XIAP was observed in MEFs, but not in human umbilical vein 
smoth muscle cells (HUVSMCs) (Liu et al., 2009). 
   To investigate if  BMPR-2 also stabilises XIAP in our assay system, we stimulated cyclo-
heximide-treated THP1 cells with recombinant BMP-2. Blocking of  protein neo-synthesis with 
cycloheximide markedly reduced XIAP protein levels. Strikingly, this effect was reversed by 
stimulation of  the cells with BMP-2, indicating that stabilisation of  XIAP by BMPR-2 does not 
only occur under apoptotic conditions. Thus, it is plausible that the positive effect of  BMPR-2 
in NOD1 signalling is caused indirectly by stabilisation of  XIAP, as we and others found that 
XIAP is essentially involved in NOD1-mediated responses (Krieg et al., 2009). 
   Liu et al. observed that siRNA-mediated knock-down of  BMPR-2 inhibited the anti-apoptotic 
effects of  BMP-2 and prevented stabilisation of  XIAP. As knock-down of  BMPR-2 promoted 
apoptosis, the authors concluded that BMPR-2 might have a basic activity that stabilised XIAP 
even without exogenously added ligands (Liu et al., 2009). This is in line with our findings that 
siRNA-mediated knock-down of  BMPR-2 inhibits NOD1-mediated signalling. The basic activ-
ity of  BMPR-2 without exogenously added ligands might be sufficient to contribute to NOD1-
mediated signalling through stabilisation of  XIAP. Consistently, it has been shown that BMP 
receptor complexes consisting of  homo- and heterotetramers of  BMPR-1A, BMPR-1B and 
BMPR-2 also exist in the absence of  ligands (Gilboa et al., 2000).  
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   Interactions of  the NOD1/RIP2/XIAP signalling complex with BMPR-2 would possibly 
require recruitment of  the complex to the plasma membrane, as BMPR-2 is a transmembrane 
receptor. Of  note, it has been shown that active NOD1 is recruited to the plasma membrane 
(Zurek et al., 2012; Kufer et al., 2008), suggesting that a mechanism involving recruitment of  
NOD1 and XIAP to BMPR-2 at the plasma membrane is possible.  
   As functional BMP signalling requires complexes consisting of  type I and type II receptors, 
and as it has been shown that BMPR-1B also interacted with XIAP (Liu et al., 2009), it is likely 
that BMPR-1B might also be implicated in NOD1 signalling. Interestingly, two out of  three 
siRNAs with sufficient replicates targeting the type I receptor BMPR-1B also exerted moderate 
inhibiting effects (~1 SD of  CTRL from median CTRL) on NOD1-mediated NF-B activation 
in the druggable genome screen (data not shown). However, as the effects were not very strong, 
and as one siRNA targeting BMPR-1B caused enhanced NF-B activation (data not shown), 
BMPR-1B was not further subjected to the validation screens.  
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Figure 24. Working model for the positive effects of BMPR-2 on NOD1 signalling.  BMPR-2 possibly contrib-
utes to NOD1 signalling by stabilising XIAP, a factor that is essential for NOD1 signalling. XIAP, in turn, is 
antagonised by mitochondrial pro-apoptotic factors, such as SMAC. Increased BMP-2 expression mediated 
by NOD1-dependent NF-B activation might constitute a positive feedback loop to sustain NOD1 signalling 
through BMPR-2. For further details please refer to the main text. 
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   Taken together, our data indicate that BMPR-2 contributes to NOD1 signalling, likely by sta-
bilising XIAP. Even though BMPR-2 likely contributes to NOD1 signalling also in the absence 
of  exogenously added ligands, it is possible that ligands can sustain this effect. Further research 
will address this question in detail. Of  note, it has been shown that inflammatory stimuli, such 
as TNF-α, positively regulate BMP-2 expression through NF-B in bone cells (Huang et al., 
2010; Feng et al., 2003; Fukui et al., 2003) and endothelial cells (Csiszar et al., 2005). This might 
also apply to other cell types, indicating that BMP-2 might promote NOD1 signalling through 
BMPR-2 in a positive feedback loop (Fig. 24). Expression of  TNF-α is also controlled by NOD 
signalling (reviewed in Fritz et al., 2006), this might further increase BMP-2 expression. However, 
this remains to be proven, and the exact mechanisms and also the role of  type I receptors in this 
process remain to be elucidated.  
 
 
4.2 Roles for BIRC proteins in NOD1 signalling 
It is well established that members of  the BIRC-family (baculovirus IAP repeat containing; also 
termed IAPs, for inhibitors of  apoptosis) are anti-apoptotic factors that counter-act apoptosis 
by direct or indirect inhibition of  caspases that mediate the proteolytic cascades leading to cell 
death (reviewed in Salvesen and Duckett, 2002). However, there is increasing evidence that 
BIRC proteins also play important roles in other cellular processes. BIRC2 (cIAP-1) and BIRC3 
(cIAP-2) have been linked to events that lead to activation of  NF-B (Tseng et al., 2010; Ber-
trand et al., 2009; Bertrand et al., 2008).   
   Intrigued by these findings, we analysed if  also other BIRC family members, exept for XIAP 
that we identified in the screen, are involved in NOD1-mediated innate immunity. Due to het-
erogeneity in the effects of  the different siRNAs, our screening data was not conclusive on this 
point. Therefore we performed siRNA-mediated knock-down of  all members of  the BIRC-
family, with exeption of  BIRC1 and BIRC6, in HeLa and THP1 cells. This revealed that silenc-
ing of  BIRC2, BIRC5 and BIRC8 reproducibly impaired Tri-DAP-mediated IL-8 secretion in 
HeLa and THP1 cells. Silencing of  BIRC3, in contrast, strongly enhanced Tri-DAP-mediated 
IL-8 secretion in HeLa cells, whereas there was only a weak and not reproducible enhancement 
observed in THP1 cells. This indicated that BIRC3 might act cell-type specifically. 
   This idea is underlined by a recent publication, where the authors observed that siRNA-
mediated knock-down of  BIRC2 in HT29 colon cells displayed no effect on DAP-mediated IL-
8 secretion, whereas secretion of  the cytokines TNF-α and MCP-1 (CCL2) was strongly im-
paired. Furthermore, depletion of  BIRC2 was shown to reduce DAP-mediated NF-B and 
JNK activation in HT29 cells. Silencing of  BIRC3 in HT29 cells, in contrast, was shown to im-
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pair DAP-mediated IL-8 secretion, as well as secretion of  TNF-α and MCP-1; in addition, DAP-
mediated NF-B activation as well as JNK and p38 phosphorylation was inhibited. Furthermore, 
the authors demonstrated that murine macrophages deficient for BIRC2 or BIRC3 were defec-
tive in MDP-induced production of  the cytokines IL-6, IL-1, IL-10 and TNF-α. Moreover, the 
authors showed that BIRC2 and BIRC3 co-precipitate with RIP2 and that their E3 ligase activity 
is required for ubiquitination of  RIP2. Consistently, DAP-mediated release of  the chemokines 
KC and MCP-1 was shown to be impaired in BIRC2-/- and BIRC3-/- mice (Bertrand et al., 2009). 
   Collectively, these findings and our results strongly indicate that BIRC2 and BIRC3 are cru-
cially implicated in NOD1 signalling. However, the exact regulatory meachnisms remain elusive. 
It is likely that there are cell type-specific differences in their contributions to NOD signalling, 
reflected by the different effects of  knock-down of  BIRC2 and BIRC3 on cytokine secretion in 
different cell types. It is also possible that the strong increase in Tri-DAP-induced IL-8 secretion 
that we observed in HeLa cells treated with BIRC3 siRNA was caused by excessive activation of  
BIRC2 caused by the knock-down of  BIRC3, as it has been shown that these proteins can 
cross-control each other. For example, elevated levels of  BIRC3 have been observed in BIRC2 
null cells (Conze et al., 2005). To address this question, further experiments with simultaneous 
silencing of  BIRC2 and BIRC3 have to be conducted and protein levels should be monitored.  
   Furthermore, BIRC2 and BIRC3 also seem to contribute to TLR signalling, as they have been 
shown to positively regulate MyD88-dependent TLR signalling by mediating K48-linked ubiq-
uitination of  TRAF3 in RAW264.7 mouse macrophages and bone marrow-derived macro-
phages (BMDMs) (Tseng et al., 2010). However, conflicting data has been reported by Bertrand 
et al., where BMDMs from BIRC3 deficient mice displayed no defects in TLR4 signalling 
(Bertrand et al., 2009).  
    Of  note, also knock-down of  BIRC5 and BIRC8 impaired Tri-DAP-mediated IL-8 secretion 
in HeLa as well as in THP1 cells. To the best of  our knowledge, neither BIRC5, nor BIRC8 
have been implicated in the regulation of  events linked to innate immunity so far.  
    BIRC5 (Survivin) is the smallest of  the BIRC family members and is characterised by the 
presence of  a single BIR-domain (reviewed in Sah et al., 2006) (Fig. 3). Like most other BIRC 
family members, BIRC5 has been shown to counter-act apoptosis (Song et al., 2003; Tamm et al., 
1998), but also other functions have been reported, in particular in cell division (Skoufias et al., 
2000; Uren et al., 2000). BIRC2 and BIRC3 likely act in the NOD1 signalling pathway through 
their E3 ligase activities, which is mediated by their RING domains. BIRC5, however, does not 
contain a RING domain (reviewed in Sah et al., 2006) (Fig. 3), making it difficult to propose a 
working model for the implications of  BIRC5 in NOD1 signalling. Further experiments are 
required to validate the putative role of  BIRC5 in NOD1 signalling in other cell systems.  
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   In contrast to the other BIRCs that are evolutionary conserved, BIRC8 (ILP-2) is only con-
served in primates. BIRC8 shares 81 % sequence identity with XIAP on protein level and there 
is evidence that it is a processed gene derived by retrotransposition from ILP-1, the gene coding 
for XIAP. However, BIRC8 lacks the first two BIR domains that are present in XIAP (Richter et 
al., 2001) (Fig. 3). This renders the protein conformationally unstable. In spite of  its putative cas-
pase-9 interaction domain, it is only a weak caspase-9 inhibitor on its own (Shin et al., 2005). 
However, it has been shown that over-expression of  BIRC8 potently inhibits apoptosis induced 
by over-expression of  BAX and by co-expression of  caspase-9 and APAF-1 in vitro (Lagace et al., 
2001; Richter et al., 2001). Thus, it seems possible that BIRC8 needs co-factors to inhibit apop-
tosis in vivo. Thus far, expression of  BIRC8 had only been detected in testis and in lymphoblas-
toid cells (Lagace et al., 2001; Richter et al., 2001), however, we clearly detected BIRC8 mRNA-
expression in HeLa cells. Furthermore, we could exclude that the reduced IL-8 secretion in re-
sponse to Tri-DAP-stimulation in cells treated with siRNA against BIRC8 was caused by unspe-
cific knock-down of  XIAP. This indicates that BIRC8 is implicated in the regulation of  NOD1 
signalling. Further experiments are required to confirm this novel finding in other cell systems 
and to characterise the underlying molecular mechanisms.  
   Collectively, these results further add to the notion that BIRC2 and BIRC3 are implicated in 
NOD1 signalling and indicate novel roles for BIRC5 and BIRC8 in NOD1 signalling. Further-
more, these results reveal exiting new insights into the apparent tissue-specificity of  BIRC pro-
teins in innate immunity.  
 
 
4.3 V. cholerae OMVs trigger NOD signalling in a quorum sensing-dependent 
manner  
In the first part of  this project we identified novel factors involved in the regulation of  the 
NOD1 signalling cascade. Sensing of  PGN by NOD1 and NOD2, however, requires its trans-
location to the cytoplasmic compartment (Girardin et al., 2003c; Girardin et al., 2003b). In our 
screen this was artificially induced by transfection of  Tri-DAP with liposomoes. However, how 
PGN uptake is achieved under physiological conditions remains somewhat fragmentary. It has 
been shown for H. pylori that PGN can be introduced into the host cell by its type IV secretion 
system (Viala et al., 2004), whereas macrophages and some epithelial cell lines can directly take 
up MDP in a dynamin-dependent process (Marina-Garcia et al., 2009; Marina-Garcia et al., 2008). 
Additionally, other bacterial factors, such as pore-forming toxins, can mediate PGN uptake and 
subsequnt NOD1 and NOD2 activation (Ratner et al., 2007). Here, we analysed the possible role 
of  bacterial outer-membrane vesicles (OMVs) as carriers of  NOD1 and NOD2 active PGN. 
DISCUSSION 
 91
   We revealed that OMVs derived from V. cholerae induce NF-B-mediated innate immune re-
sponses in different human cell lines. Indeed, we observed that OMV production is a common 
feature in different V. cholerae strains. We showed that OMVs from the NOVC strain V:5/04 
induce a significant inflammatory response in the host cell that is party dependent on NOD1 
and NOD2. Activation of  NOD1 and NOD2 in selective assays by V:5/04 OMVs indirectly 
revealed that PGN is associated with OMVs, which was confirmed by physiochemical charac-
terisation of  the V. cholerae OMV preparations. Our data suggests that OMVs represent an al-
ternative route to deliver bacterial PGN to the host cell (Fig. 25). Indeed, delivery of  bacterial 
PGN was also reported for H. pylori OMVs (Ismail et al., 2003). A recent study revealed that also 
OMVs derived from Pseudomonas aeruginosa- and Neisseria gonorrhoeae contain PGN and activate 
NOD1 upon contact with host cells (Kaparakis et al., 2009). Collectively, this indicates that PGN 
delivery by OMVs is a conserved and common bacterial strategy to modulate host immune re-
sponses. Further studies are needed to understand which mechanism is relevant under different 
physiological conditions.  
   Intriguingly, we revealed that NOD1 and NOD2 activity of  Vibrio cholerae OMVs was depend-
ent on the quorum-sensing master regulator HapR, a known control switch for virulence gene 
expression in V. cholerae O1 strains (Miller et al., 2002; Zhu et al., 2002) (Fig. 25). Deletion of  
HapR significantly attenuated the NOD1/2 activation potential of  the V:5/04 OMVs, but at the 
same time did not reduce the immunogenicity of  whole bacterial lysates. However, HapR did 
not influence the amount of  OMVs produced, arguing that a natural HapR mutant might not 
show different OMV production. This indicates that genes under the control of  HapR either 
change the composition of  the PGN delivered by OMVs, or lead to the exclusion of  PGN from 
the OMVs (Fig. 25). One possible candidate gene involved in the peptidoglycan biosynthesis 
process is VCA0981, which encodes a protein with homology to the peptidoglycan-specific 
endopeptidase M23, a member of  the family of  periplasmic binding proteins (PBPs), which 
binds substrate and interacts with a membrane-bound complex. We found that the expression 
of  VCA0981 was decreased in the hapR mutant in comparison with the wild-type strain V:5/04 
(data not shown), suggesting that this gene product is involved in the observed difference be-
tween WT- and hapR-derived vesicles in activation of  NOD1 and NOD2. However, overex-
pression of  the protein in HapR-deficient bacteria did not yield complementation of  this phe-
notype, suggesting either that overexpression is not suitable for complementation, or that addi-
tional factors under the control of  HapR are involved in this process.  
   Evasion of  NOD-mediated innate immunity likely is a common scheme for pathogens, as also 
L. monocytogenes and H. pylori employ strategies to modulate NOD1 and NOD2 responses when 
colonising the host. L. monocytogenes uses N-deacetylation of  PGN by the N-deacetylase PgdA 
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(Boneca et al., 2007), whereas the coccoid form of  H. pylori escapes NOD1 detection by the 
AmiA PGN hydrolase (Chaput et al., 2006). This suggests that PGN modelling and subsequent 
coupled activation of  NOD1 and NOD2 constitute a more general theme for bacterial manipu-
lation of  the host innate immune response. However, to the best of  our knowledge, our work is 
the first to provide a role for the quorum sensing machinery in OMV-mediated activation of  
host PRRs.  
   Recently, V. cholerae OMVs were shown to be promising candidates for vaccines, as they in-
duce strong immunity in mice (Schild et al., 2008). Furthermore, NOD1 and NOD2 activation 
has been linked to the onset of  adaptive immune responses (Magalhaes et al., 2008; Fritz et al., 
2007). Thus, it is likely that PGN is one of  the active adjuvant components accounting for the 
high immunogenicity of  OMVs.  
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Figure 25. Schematic representation of the quorum sensing machinery in V. cholerae and its OMV-mediated 
interplay with epithelial cells. At low cell densities, the virulence gene-repressor HapR gets degraded in a 
process mainly dependent on the repressor protein LuxO and the autoinducer/sensor pairs AI-2/LuxQ and 
CAI-I/CqS. When HapR is not present, virulence genes are expressed, OMVs contain low amounts of pepti-
doglycan and do not induce a strong inflammatory response. At high cell densities, the repressor HapR is 
active and represses virulence gene expression. At this state, OMVs contain higher amounts of peptidogly-
can and induce strong inflammatory responses that are partially mediated by NOD1. For further details 
please refer to the main text. (From Bielig et al., 2011a). 
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6 Abstract 
Many Members of  the intracellular nucleotide binding and oligomerisation domain (NOD)-like 
receptor (NLR) family have functions in the innate immune system. The NLR NOD1 acts as 
pattern recognition receptor and confers immune responses against a broad range of  bacteria by 
triggering NF-B and MAPK signalling cascades upon detection of  bacterial peptidoglycan. 
This contributes to bacterial clearance, to the onset of  a pro-inflammatory immune response 
and the release of  anti-microbial peptides. As overwhelming inflammatory responses can be 
detrimental to the host, inflammatory signalling cascades have to be tightly controlled. Even 
though the main components of  the NOD1 signalling cascade are identified, little is known 
about the regulation and fine-tuning so far.  
 
In this project, we identified novel components of  the NOD1 signalling pathway by an auto-
mated high-throughput siRNA screen using a cell based NF-B reporter system in epithelial 
HEK293T cells. To this end, we screened the human druggable genome siRNA library for 
NOD1-mediated NF-B activation upon stimulation with the elicitor Tri-DAP. Hits specifically 
involved in NOD1-mediated NF-B activation were identified using TNF-α-stimulation as dif-
ferential read-out. Finally, these hits were validated in myeloid THP1 cells. Beside the established 
NOD1 pathway component RIP2, the combined screening steps identified the BIRC family 
member XIAP as the strongest inhibiting hit. Follow-up experiments confirmed XIAP as an 
essential component of  NOD1-mediated responses to the minimal NOD1 elicitor and to Shig-
ella flexneri. We also revealed that XIAP contributes to responses mediated by the closely related 
NOD2 protein. In line with a recent report, we provide evidence that XIAP acts upstream of  
the IKK complex in the NOD1 signalling cascade.  
   Strikingly, the screen revealed that the type II BMP receptor BMPR-2 is specifically involved 
in NOD1 signalling. Further experiments confirmed these findings and revealed that BMPR-2 
positively regulates NOD1 signalling, likely by contributing to stabilisation of  XIAP.  
   Furthermore, we analysed the contributions of  the BIRC proteins BIRC2 and BIRC3, which 
are closely related to XIAP, and of  the other human BIRC proteins to NOD1-mediated re-
sponses. By using siRNA-mediated gene knock-down, we confirmed that BIRC2 positively 
regulates NOD1 signalling. Furthermore, we provide evidence that also BIRC5 and BIRC8, 
which have not been linked to innate immunity so far, positively contribute to NOD1-mediated 
inflammatory responses. 
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Another event in NOD signalling that is still not fully understood is how bacterial peptidoglycan 
is translocated to the cytoplasm of  host cells, as extracellular bacteria are known to activate 
NOD1 as well as NOD2. In the second part of  this project, we analysed if  bacterial outer-
membrane vesicles (OMVs) might serve as carriers for peptidoglycan. We provide clear evidence 
that OMVs derived from the extracellular pathogen Vibrio cholerae are internalised by host cells, 
contain peptidoglycan and trigger NOD1- and NOD2-dependent inflammatory responses. 
OMVs derived from bacteria deficient for HapR, a master regulator of  quorum sensing that 
represses the expression of  virulence genes, induced markedly lower NOD-mediated inflamma-
tory responses than OMVs derived from WT bacteria. In contrast, the overall peptidoglycan 
composition and the inflammatory potential of  bacterial lysates derived from hapR compared 
to WT bacteria did not change. We conclude that V. cholerae uses quorum sensing to influence 
the pepdidoglycan content of  OMVs, to prevent detection by the host innate immune system 
under virulent conditions. 
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7 Zusammenfassung 
Viele Mitglieder der intrazellulären Nukleotid-binde und oligomerisierungsdomäne (NOD) ähn-
lichen Rezeptor (NLR) Familie erfüllen Funktionen im angeborenen Immunsystem. Das NLR 
Protein NOD1 fungiert als Mustererkennungs-Rezeptor und vermittelt Immunantworten gegen 
ein breites Spektrum von Bakterien durch Erkennen von bakteriellem Peptidoglykan und an-
schließender Aktivierung von NF-B und MAP-Kinase Signaltransduktionskaskaden. Dies trägt 
zur Beseitigung der Bakterien, zur Induktion einer entzündlichen Immunantwort sowie zur Ex-
pression von antimikrobiellen Peptiden bei. Da überbordende Immunantworten schädlich für 
den Wirt sein können, müssen derartige inflammatorische Signaltransduktionskaskaden strikt 
reguliert werden. Obwohl die Hauptkomponenten der NOD1 Signaltranduktionskaskade be-
kannt sind, ist wenig über die Regulation und die Feinabstimmung dieses Signalweges bekannt.  
 
In diesem Projekt haben wir mittels eines automatisierten Hochdurchsatz siRNA Screens unter 
Verwendung eines zellbasierten NF-B Reportersystems in epithelialen HEK293T Zellen neue 
Komponenten des NOD1 Signalweges identifiziert. Zu diesem Zweck wurde eine humane 
„Druggable Genome“ siRNA Bibliothek im Hinblick auf  NOD1-vermittelte NF-B Aktivie-
rung induziert durch den Elicitor Tri-DAP untersucht. Kandidaten, die spezifisch im NOD1 
Signalweg eine Rolle spielen, wurden durch ein differentielles Auslesen mittels TNF-α-
Stimulation identifiziert. Abschließend wurden diese Kandidaten in myeloiden THP1 Zellen 
bestätigt. Neben der Komponente RIP2, welche bekannt dafür ist, eine regulatorische Funktion 
im NOD1 Signalweg auszuüben, haben wir XIAP, ein Mitglied der BIRC Familie, als stärksten 
Kandidaten identifiziert. Anschließende Experimente konnten XIAP als essentielle Komponen-
te für NOD1-vermittelte Antworten auf  den minimalen NOD1-Elicitor sowie auf  Shigella flexne-
ri Infektion bestätigen. Darüber hinaus konnten wir zeigen, dass XIAP oberhalb des IKK 
Komplexes im NOD1 Signalweg agiert und dass XIAP auch in Immunantworten vermittelt 
durch das verwandte Protein NOD2 eine wichtige Rolle spielt.  
   Interessanterweise hat der Screen auch gezeigt, dass der Typ II BMP Rezeptor BMPR-2 spezi-
fisch in den NOD1 Signalweg involviert ist. Diese Hinweise wurden durch anschließende Expe-
rimente bestätigt: Es erscheint sehr wahrscheinlich, dass BMPR-2 eine positive regulatorische 
Funktion im NOD1 Signalweg ausübt, wahrscheinlich durch einen Beitrag zur Stabilisierung 
von XIAP.  
   Darüber hinaus haben wir die Einflüsse der BIRC Proteine BIRC2 und BIRC3, welche eine 
enge Verwandtschaft zu XIAP aufweisen, sowie der anderen humanen BIRC Proteine auf  
NOD1-vermittelte Antworten untersucht. Durch siRNA-vermittelte Depletion konnten wir 
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bestätigen, dass BIRC2 eine positive regulatorische Funktion auf  NOD1-vermittelte Signalwege 
ausübt. Ausserdem liefern wir Hinweise dafür, dass auch BIRC5 und BIRC8, die bisher noch 
nicht mit angeborener Immunität in Verbindung gebracht wurden, zur Positivregulation von 
NOD1-vermittelten Antworten beitragen.  
 
Ein weiterer wichtiger Prozess in NOD-vermittelten Immunantworten, der bisher nicht voll-
ständig verstanden ist, ist die Aufnahme von bakteriellem Peptidoglykan in Wirtszellen, da auch 
extrazelluläre Bakterien bekannt dafür sind, NOD1- sowie NOD2-vermittelte Immunantworten 
auszulösen. Im zweiten Teil dieses Projektes haben wir untersucht, ob bakterielle Vesikel der 
äußeren Membran („outer-membrane Vesicles“ (OMVs)) als Überträger von Peptidoglykan die-
nen können. Wir haben klare Hinweise dafür gefunden, dass OMVs, die aus dem extrazellulären 
Pathogen Vibrio cholerae gewonnen wurden, von Wirtszellen aufgenommen werden, Peptidogly-
kan enthalten sowie NOD1- und NOD2-vermittelte entzündliche Antworten auslösen. OMVs 
von V. cholerae Bakterien defizient für HapR, einen Hauptregulator des Quorum Sensings wel-
cher die Expression von Virulenzgenen unterdrückt, hingegen lösten deutlich geringere NOD-
vermittelte entzündliche Antworten aus als OMVs von Wildtyp Bakterien. Im Gegensatz dazu 
waren die gesammte Zusammensetzung des Peptidoglykans und das entzündliche Potential von 
bakteriellen Lysaten von hapR Bakterien im Vergelich zu Lysaten von Wildtyp Bakterien nicht 
verändert. Wir schließen daraus, dass Vibrio cholerae den Quorum Sensing Prozess verwendet, 
um den Peptidoglykangehalt von OMVs zu beeinflussen und damit einer Entdeckung durch das 
angeborene Immunsystem des Wirtes zu entgehen.  
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